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Abstract
Rheumatoid Arthritis (RA) is a chronic auto-immune disease that causes inflammation in the
joints. Left uncontrolled, this prolonged inflammation can lead to pain and structural damage,
resulting in erosions to the bones and total breakdown of the surrounding cartilage. Structural
joint damage, measured by plain radiographs, is an important outcome measure of RA. It pro-
vides an objective marker of disease activity to assess any improvements or failures of treatments
in controlling for the disease. Increased long-term joint damage has been linked with increased
functional disability and decreased quality of life for RA patients. While a range of studies have
looked at radiographic outcomes from observational data, they tend to be restricted to historical
cohorts, with little long-term data on how radiographic progression may have changed in line
with changes in clinical management. Additionally, these studies have not used the appropriate
statistical methods to account for non-normal data distributions and within-patient variation
over time.
As a result, the main aim of this thesis is to investigate the long-term progression of structural
joint damage in patients with early RA. The specific objectives were to; (1) investigate the
current evidence base to identify common methods in measuring and analysing radiographic
outcomes, (2) assess what statistical methods are most appropriate in modelling long-term ra-
diographic data, (3) use these models to understand the natural progression of radiographic
damage using data from two UK inception cohorts, and finally, (4) expand these models to
investigate the long-term relationship of radiographic damage with two important clinical out-
comes; disease activity and functional disability. The analysis is based on longitudinal data from
two UK prospective, multi-centre, early RA observational cohorts. These cohorts represent two
distinct eras in the management and treatment of RA, making them invaluable for investigating
how key RA outcomes have progressed in clinical practice over time.
ii
Using multi-level count models, precise rates of radiographic progression for both cohorts are
presented. The models look at how seropositive RA and increased disease activity are related to
increased radiographic progression, and what impact this has on functional disability. The re-
sults show that rates of radiological damage have declined dramatically in recent years. Possible
attributable factors to these declines include both milder disease and more effective treatment
strategies.
Analysis of the earlier cohort (1986-2001) shows how seropositive RA and increased disease
activity lead to clinically meaningful increases in radiological damage. Conversely, their impact
on patients in the more recent cohort (2002-2011) suggest that their effect on radiographic
progression is reduced, where increases in radiological damage were not larger than clinically
meaningful thresholds. This has large implications on the debate around the use of biologic
therapies in patients with less severe RA. However more data is sorely needed, particularly
long-term radiographic data from those patients on biologics treatments, before any definitive
conclusions can be made.
The possible impact of these declines on functional disability appears to be relatively small. The
analysis shows that radiographic damage is more strongly associated with functional disability
in later disease, but there is little evidence to indicate that declines in radiographic damage has
lead to large improvements in long-term functional disability. These findings are explored within
the framework of a dual-pathway model, which suggests that functional disability is caused by
two distinct mechanisms, either structural joint damage, or through increased pain. Research so
far has predominantly focused on pharmacological treatments in reducing inflammation. More
research is needed to explore the role of psychosocial factors and pain perception in order to
create a more holistic treatment programme for RA patients.
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Chapter 1
Introduction
1.1 Aims and objectives of the thesis
The overall aim of this thesis is to investigate the long-term progression of radiographic joint
damage in early Rheumatoid Arthritis (RA) using longitudinal data from two UK longitudinal
patient cohorts. The specific objectives are to; (1) investigate the current evidence base to
identify common methods in measuring and analysing radiographic outcomes, (2) assess what
statistical methods are most appropriate in modelling long-term radiographic data, (3) use these
models to understand the natural progression of radiographic damage using data from two UK
inception cohorts, and finally, (4) expand these models to investigate the long-term relationship
with two important clinical outcomes; disease activity and functional disability. The thesis is
broken down into distinct chapters, which set out to explore and address these specific aims.
These aims are explored in specific chapters as follows:
1.2 Outline of the thesis
Chapter 2 provides an overview of the epidemiology, aetiology, and pathophysiology of RA, as
well as how the clinical management developed, and how radiographic scoring methods are used
in the UK over the last three decades. The chapter will explore how Randomised Controlled
Trials (RCT) and observational studies have utilised radiographic outcomes, and how the study
designs differ in what research questions they are able to answer. Of particular interest to
this research is how observational studies have evaluated radiographic outcomes, and what
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the current prevailing theories are that involve long-term radiographic progression. To this
end, a comprehensive systematic review is conducted in Chapter 3 to evaluate all published
studies looking at observational data on radiographic damage in early RA. Through meta-
analytic techniques and narrative synthesis, the progression, and predictive factors, of long-term
radiographic damage are explored and summarised.
Chapter 4 and Chapter 5 detail the methodological aspects of this thesis. Chapter 4 introduces
the Early RA Study (ERAS) and Early RA Network (ERAN) datasets, and the radiographic
data contained within. Important aspects of the data, such as inter-reader reliability between
the two readers and missing data are explored. Finally the chapter looks at the other key
outcome measures collected as part of the ERAS and ERAN cohorts that were also examined
alongside radiographic outcomes. Chapter 5 investigates the methods commonly used to analyse
radiographic outcomes, and introduces count regression models. It explains why these methods
are most suited to the analysis of radiographic outcomes.
Chapter 6 explores the progression of radiographic damage over the first 5 years of disease in
both the ERAS and ERAN cohorts and establishes if, using the modelling techniques outlined in
Chapter 5, there have been any changes in the natural progression of radiographic damage. This
chapter also assesses whether the association of seropositive RA with radiographic progression
has been altered as a result of any secular changes. Due to the non-randomised nature of
observational data, it is difficult to explore any direct treatment cause and effects. However,
key differences in both the clinical management, and indeed any differences in the patient
populations at first presentation will be explored to ascertain the possible reasons for any secular
differences in long-term progression.
The final aim is then addressed as part of Chapter 7. The models developed in Chapter 6
are extended to provide a more in-depth evaluation of the relationship between radiographic
progression with two key clinical RA outcomes; disease activity and functional disability. Dis-
ease activity has been known to influence the extent of radiographic progression. Increased
radiographic progression is commonly considered to be the main driver of increased functional
disability, particularly in later disease. However the precise nature of how these relationships
develop over the course of the disease is not known. Currently no study has investigated this
complex relationship longitudinally, using statistical methods appropriate to the characteristics
of the radiographic data. This chapter investigates the extent of radiographic progression in
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those patients with ‘moderate’ disease. Under current UK guidelines, effective, but more expen-
sive treatments are reserved only for those patients with very severe disease. However, there is
a concern that those patients that fall just short of the threshold for these expensive treatments
suffer from similar levels of disability and structural joint damage.
Chapter 8 summarises the main findings from each chapter and discusses the implications of
these findings in relation to the current evidence base. This includes the impact that these
results may have on the treatment and management of RA. This chapter will also summarise
the strengths and limitations of using the ERAS and ERAN cohort data, as well as the methods
used to conduct the analyses. Finally, it will examine potential directions for future research
and what more is needed to improve the evidence base in this area of RA research.
Chapter 2
General Introduction
2.1 Rheumatoid Arthritis
2.1.1 Introduction
Rheumatoid Arthritis (RA) is a common and chronic inflammatory arthropathy[1]. It is an au-
toimmune disease, characterised by persistent synovitis, systemic inflammation and the presence
of auto-antibodies, such as Rheumatoid Factor (RF), and Anti-Citrullinated Peptide Antibod-
ies (ACPA), namely Anti-Cyclic Citrullinated Peptides (anti-CCP)[2]. RA is a heterogeneous
disease, ranging from mild and remitting forms, to highly active and disabling. The long-term
prognosis of RA is poor, with 80% of affected patients becoming disabled after 20 years, and
an average reduction of between 3-18 years in life expectancy[3]. RA typically occurs in the
small joints of the hands, wrists, feet and the knees and symmetry is common. Symptoms
include stiffness (usually worse in the morning), tenderness, pain, swelling and deformities of
the affected joints. Over time, if the disease is not adequately controlled, RA can have a large
impact on a patient’s quality of life. Routine daily tasks, such as the ability to button shirts,
tie shoelaces or washing hair can become severely impaired. It has a profound impact on the
patients ability to work, and a report by the National Rheumatoid Arthritis Society (NRAS)
estimated that RA as a disorder results in a loss of nearly £8 billion in the UK due to work
disability[4].
Since no medical tests are pathognomonic of RA, a range of classification criteria were developed
to assist with the diagnosis of RA in the medical community[5]. This was first brought about in
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Criterion Definition
1) Morning Stiffness Morning stiffness in and around the joints, lasting at
least 1 hour before maximal improvement
2) Arthritis of 3 or more joint areas At least 3 joint areas simultaneously have had soft tis-
sue swelling or fluid (not bony overgrowth alone) ob-
served by a physician. The 14 possible areas are right
or left PIP, MCP, wrist, elbow, knee, ankle, and MTP
joints
3) Arthritis of hand joints At least 1 area swollen (as defined above) in a wrist,
MCP, or PIP joint
4) Symmetric arthritis Simultaneous involvement of the same joint areas (as
defined in 2) on both sides of the body (bilateral in-
volvement of PIPs, MCPs, or MTPs is acceptable with-
out absolute symmetry)
5) Rheumatoid nodules Subcutaneous nodules, over bony prominences, or ex-
tensor surfaces, or in juxtaarticular regions, observed
by a physician
6) Serum rheumatoid Demonstration of abnormal amounts of serum rheuma-
toid factor by any method for which the result has been
positive in <5% of normal control subjects
7) Radiographic changes Radiographic changes typical of rheumatoid arthritis
on posteroanterior hand and wrist radiographs, which
must include erosions or unequivocal bony decalcifi-
cation localized in or most marked adjacent to the in-
volved joints (osteoarthritis changes alone do not qual-
ify)
Table 2.1: 1987 American College of Rheumatology Criteria for rheumatoid arthritis classifi-
cation
1958, when the American Rheumatism Association (ARA) developed a list of 11 criteria in an
attempt to define RA[6]. This was later revised in 1987 to improve the specificity and simplicity
of the classification criteria[7], with a major change being to remove the hierarchy of certainty
around diagnosis, which ranged from ‘possible’ to ‘classic’, as this was largely unhelpful[5]. Table
2.1 outlines the 7 major criteria for classifying RA from the 1987 ARA criteria, ranging from the
type of stiffness experienced, location of the affected joints, appearance of Rheumatoid nodules,
high levels of RF in the serum, and radiographic changes. While the latest set of criteria from the
American College of Rheumatology (ACR; renamed from the aforementioned ARA) has been
successful at distinguishing RA from other generalised rheumatic diseases, such as osteoarthritis
(OA), Systemic lupus erythematosus (SLE) and fibromyalgia[5], there are still debates about its
effectiveness in classifying patients with recent-onset polyarthritis[8]. Nevertheless, current ACR
classification criteria defines a patient’s presenting with at least 1 joint with definite synovitis,
which cannot be explained by another disease, with RA if they score 6 out of 10 based on
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the number of joints involved, serology, acute phase reactants and duration of symptoms. As
research improves our understanding of how genetics and laboratory markers are involved in
the aetiology of the disease, absolute definitions of RA that can be used in clinical practice will
become more attainable[5].
2.1.2 Epidemiology
Rheumatoid Arthritis is the most common form of chronic inflammatory arthritis[5], with es-
timated prevalence rates in the Northern European countries and Northern America estimated
at between 0.5-1.1%, with an estimated annual incidence rate of between 20 and 50 cases per
100,000 population[9]. There does appear to be geographical differences in the prevalence of
RA, with Southern European and developing countries reporting relatively lower rates of be-
tween 0.1-0.7%[10–17]. Interestingly, RA is thought to be a ‘modern disease’, with no records
of symptoms or any definite description of RA before 1800 [5]. This has led researchers to
hypothesise that urbanisation or industrialisation is likely to be a cause of RA[18], although the
exact causes are still unknown.
When studying secular trends in RA incidence over time, studies have shown evidence of a
decrease in incidence rates[5, 19, 20], particularly in women[5]. However, improvements in
healthcare and living standards continue to increase average life expectancy, resulting in an
increase in the number of elderly patients living with RA. So while the incidence of RA may
be declining, the prevalence of the disease is increasing[21], and likely to increase further in the
coming years, particularly at the higher (55+ years) age groups[22].
Patients with RA have higher premature mortality compared to the general population[23, 24]
primarily from cardiovascular disease, viral infections and cancer[25]. A recent meta-analysis
conducted by Dadoun et al. in 2013[25] assessed whether the excess risk in mortality amongst
RA patients had changed over time. The review found that the Incident Mortality Rate (IMR)
decreased from 4.7/100 person-years before 1970 to 2.0/100 person-years after 1983. In contrast,
the Standardised Mortality Ratio (SMR) did not change over time, with an estimated pooled
SMR of 2.01 from eight studies. They concluded that excess mortality had decreased amongst
RA patients over the last 5 decades, but at a slower rate compared to the general population.
This finding was substantiated further in the Norfolk Arthritis Register (NOAR), where the
SMR for all-cause mortality over the first 7 years in RA patients had not changed from 1990-
2004[24]. However, the advent of newer more effective treatments, such as methotrexate, was
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shown to reduce mortality[26]. This suggests that better treatments were having an effect on
reducing mortality rates.
2.1.3 Aetiology
While the exact causes of RA is unknown, it is widely accepted that it is a combination of
both environmental and genetic factors[9, 27, 28]. However, to date no complete hypothesis
that incorporates both these elements has been formulated[29]. The HLA-DR shared epitope
(SE) has been consistently linked with the susceptibility of RA[30], with more than 80% of RA
patients carrying the HLA-DRB1*04 epitope (often referred to as the ’Rheumatoid Epitope’)
[31]. It is thought to be a significant factor in both the onset and the severity of the disease over
the long-term[5]. Quantifying the extent to which genetic factors are involved in the onset of RA
has proved challenging for a number of reasons; including strong gene-environment interactions,
accounting for secular changes in the disease, and the specificity of identified gene alleles.
Early studies indicated a low concordance rate of around 15% between Monozygotic (MZ)
twins[17], leading to the belief that environmental factors play a significant role[30]. However,
MacGregor et al. argued that there was a need to account for changes in population prevalence
when quantifying the heritability of RA, and subsequently estimated that RA had a higher
heritability rate of approximately 60%[32], a finding validated through the use of two large twin
cohorts from the UK and Finland. The expression of the HLA-DR SE alleles in other non-RA
diseases has also questioned its specificity to RA, along with the absence of the HLA-DR SE
allele in approximately 20% of RA patients[30]. Consequently, it has been suggested that the
stronger link between HLA-DR SE in established RA indicates that its presence in patients with
RA is indicative of more severe and aggressive forms of the disease, rather than a precursor of
disease onset[5].
A range of environmental factors have been hypothesised to be involved with the onset of RA[5,
33], and smoking is thought to be a fundamental environmental risk for the development of
RA[28]. In 1996, Silman et al.[34] conducted a study in twins to investigate the effect that
smoking has on the susceptibility of RA, where an interview questionnaire was sent out to 79
identical Monozygotic (MZ) and 71 same-sex Dizygotic twins (DZ), both with and without RA.
The number of discordant pairs, that is one twin with RA that smoked and one twin without RA
that didn’t smoke, was low due to both twins being exposed to similar environmental factors.
Nevertheless, the analysis indicated a strong association between RA and smoking (Odds Ratio
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(OR) of 12 (95% Confidence Intervals (CI) 1.78-513) and 2.5 (95% CI 0.92-7.87) for MZ and
DZ twins respectively, and a OR of 3.9 (95% CI 1.64-10.5) for both MZ and DZ combined).
Subsequently, it has become clear that smoking is strongly associated with a specific sub-type
of RA referred to as seropositive RA[28, 35]. The presence of Rheumatoid Factor (RF) or
Anti-citrullinated Peptide antibodies (ACPA) have been shown to be a significant risk factor
in the development of RA[36, 37], along with being a significant predictor of increased erosive
damage[38]. The presence of ACPAs, like anti-citrullinated protein antibodies (anti-CCP), have
been found to be superior in predicting the risk of developing RA compared to RF antibodies[36,
39], with research showing that production of ACPA in the synovium can occur potentially
years before symptom onset, this provides strong evidence for its role as a biomarker in RA[40].
Interestingly, research has indicated that the presence of the HLA-DRB SE is only associated
with ACPA positive RA, leading to speculation that the production of ACPA is mediated by
the presence of the HLA-DR SE[28, 41, 42]. While direct evidence for this causal relationship is
lacking, it does highlight the need to include both genetic and ACPA information when looking
at these subsets of RA patients[28, 41]. Further still, the relationship between smoking and
ACPA positive RA suggests a interaction between the involvement of HLA-DR SE, smoking
and ACPA positive RA[29]. It is not clear how these specific genetic and environmental factors
lead to the pathophysiology seen in ACPA positive RA, but recent evidence suggests those
who have the HLA-DR SE and who also smoke have a 21-fold increase in relative risk (RR)
compared to those without the gene who do not smoke, significantly higher than either factor
in isolation[29].
Other environmental factors, such as infectious agents that trigger the auto-immune response,
have also been studied as the possible cause of RA[43]. However, no single organism has been
found in the synovial fluid or tissue to date, and there is no evidence of incidence clusters of
RA coinciding with spikes in either recorded bacterial infections or viruses in cohort data[5,
43]. Although, case studies have been documented that show RA can be caused by infections
such as the parvovirus and rubella[43]. These are limited to single cases only and therefore are
lacking in their generalisability.
The prevalence of RA is much higher in post-menopausal woman when compared to pre-
menopausal women[44], leading to speculation that hormonal factors could play a role in the
onset of RA. The incidence of RA in women who take an Oral Contraceptive Pill (OCP) was
shown to be around half that compared to women who had never taken one[45], along with
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reduced susceptibility during pregnancy[46]. What is not clear is whether there is a direct
causal link between OCP use and onset of RA, or whether OCP use is a surrogate marker of
other lifestyle choices in women who choose to take the OCP[43], e.g. smoking. Furthermore,
research has not shown any association between women during their menopause and their use
of Hormone Replacement Therapy (HRT) at the onset of RA[43], which would be expected to
decrease the risk.
2.1.4 Pathophysiology
Figure 2.1 shows a cross-section of a synovial joint. Part (A) indicates a normal joint unaffected
by RA, whilst part (B) shows the physiological changes of a joint affected by RA. Around the
joint is the synovium (or synovial membrane) that encapsulates the articular cartilage between
the two bones. Its two main purposes are to provide structure as well as nutrients to the joint.
The inner layer (intima) of the synovium is lined with fibroblast-like synoviocytes (FLS); cells
that produce unique proteins crucial for maintaining joint lubrication. This lubrication comes
in the form of synovial fluid, which allows the joint to move freely.
The immune response is the body’s natural defence against pathogens that enter the body. It
triggers an inflammatory response with the sole purpose of isolating and removing the pathogen
from the body. Initially, phagocytes, such as macrophages, will begin to consume the pathogens
in an attempt to contain it. These phagocytes send messenger cells called cytokines (e.g. Inter-
leukin and Tumour Necrosis Factor-α(TNF-α)) to warn the other immune cells of the invading
cells. T-Cells and B-Cells are major types of lymphocytes involved in the immuno-inflammatory
response. B-cells provide ‘humoral immunity’, that is the B-cells react to specific antigens by
producing antibodies that bind to them. Conversely, T-cells provide ‘cell mediated immunity’,
which in turn provides several functions to the immune response. This includes the production
of helper T-cells to mediate B-cells and macrophages, suppressor T-cells to reduce the immune
response and cytotoxic T-cells, which signal infected cells to perform apoptosis (self-destruct).
While this inflammation response is vital in maintaining good health, in auto-immune diseases
such as RA, the prolonged inflammation at the site of the joints leads to the destruction of
healthy cells. The cause of this activation and reason that the response is localised to the joint
regions is currently unknown[47]. However, T-Cells, B-Cells and pro-inflammatory cytokines
are known to play a key role in the pathophysiology of RA[27]. The first stages of RA involve
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Figure 2.1: Cross-section of a (a) a normal joint and (b) a joint affected by Rheumatoid
Arthritis
the activation of the immune response through Antigenic Presenting Cells (APCs) in the syn-
ovium[27]. APCs, including dendritic cells, macrophages and activated B cells, process unknown
antigens into peptides that are inserted into the groove of HLA-DR4, which is located on the
surface of the APCs. Attached to these APCs are class II major histocompatibility complex
(MHC) proteins, which are unique to specific B-cells. T cells with the specific T-cell receptors
are then activated by engaging with this trimolecular complex. Predominately it is CD4+ mem-
ory cells (helper T-Cells) that infiltrate the synovial membrane[47], leading to the release of the
cytokine Interleukin-2 (IL-2), which in turn leads to the expansion of T-cells and expression
of surface molecules like CD69, TNF-α and rANK ligand (RANKL)[27]. Production of soluble
mediators IL-17 and interferon-γ (IFN-γ), stimulates macrophages to produce large numbers
of pro-inflammatory cytokines IL-1, IL-6 and TNF-α[48]. The expression of these molecules
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and pro-inflammatory cytokines in the synovial fluid results in the formation of osteoclasts; the
primary mediators of bone destruction, fibroblasts and synoviocytes.
While the role of T cells in the pathogenesis of RA is well established, the precise role of B Cells is
not as well characterised [48]. It is thought that they could have a number of potentially critical
roles; including presenting as APCs to activate helper T-cells, but also in the production of
RF. B-cells with RF specificity may migrate to the synovium, creating a ’self-perpetuating’
cycle of increased B-cell activation and amplification of RF production, thereby prolonging and
exacerbating the inflammation at the joint site[48]. The role of ACPA in the inflammation
response is also of great interest, as it has been shown to be more specific to RA than RF
antibodies[41]. There is growing evidence that ACPA positive RA may represent a distinct
sub-class of RA[41]. Gaining a better understanding of the pathophysiology of RA has lead
to the development of more effective medications that are able to target specific cells in the
immuno-inflammatory response in order to modify the disease, such as anti-TNF biologics.
2.1.5 Treatment
Pharmacological treatment of RA can be broadly split into two principals; control of the under-
lying symptoms caused by RA (e.g. pain) through the use of non-steroidal anti-inflammatory
drugs (NSAIDs), or modification of the inflammation process through the use of Disease Modify-
ing Anti-rheumatic drugs (DMARDs)[47]. The treatment of RA has seen paradigmatic changes
over the last 15-years[49]. In the 1980’s, RA was treated in a pyramidal approach, where
symptoms were managed, and drugs were increased in both dose and number as the disease
progressed[50]. Given the high toxicity of steroid treatments and early DMARDs, such as Gold
and ciclosporin, the aim of this treatment method was to reduce the burden of the disease
while limiting the side-effects of these relatively potent medications[2]. With the emergence of
new generation DMARDs in the late 1990s, particularly sulphasalsine and methotrexate, data
from RCTs proved that early and more intensive treatment led to significantly better clinical
and radiological outcomes[51–53]. This then led to the realisation that RA had a ‘Window of
Opportunity’ in the early stages, when treatment was most effective [54]. From the late 2000s,
the use of Biologic DMARDs, which are highly specific in targeting specific pro-inflammatory
cytokines, has proved to be more effective than single DMARD therapy, showing increased ef-
ficacy when used in conjunction with methotrexate[55, 56]. However, given the relatively high
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cost per patient of the biologic DMARD therapies, their use in the UK is currently restricted
to only those patients with severe disease.
Treat-2-Target
Currently, RA is treated using a Treat-To-Target (T2T) approach. In 2010, findings from an
international task force were published that provided recommendations for achieving optimal
therapeutic outcomes in RA[49, 57]. Drawing parallels with other chronic illnesses, such as
hypertension and diabetes, it was highlighted how the use of treatment targets using predefined
biomarkers/markers of disease activity could greatly reduce the risk of organ damage. With
regards to the recommendations set out, the committee concluded that remission, defined as
the ‘absence of signs and symptoms of significant inflammatory disease activity’, should be the
primary goal of all RA patients[49, 57]. However, it should be noted that this recommendation
had low levels of support due to the common use of low disease activity as the primary target
in clinical trials, rather than remission. As such, it was acknowledged that while remission
should remain the ultimate goal, there might be instances where low disease activity is a viable
alternative. Recent advances in the use of DMARDs such as methotrexate, particularly in
combination with other DMARD therapies, has resulted in remission, or at the very least
low disease activity becoming a realistic goal in the majority of RA cases[58]. This therefore
became the target that all clinicians aimed to achieve with their patients. However, defining
remission or indeed low disease activity, has proven to be no easy feat. In cases where the
disease is particularly severe, and where the patient is not responding to conventional DMARD
therapies, the clinician may prescribe biologic DMARDs. These are potentially more effective,
but ultimately more expensive DMARDs, which are used to help attain remission or low disease
activity in those patients with persistent high RA.
Clinical definitions of remission
Clinical definitions of remission in RA began with the ACR definition in 1981[59]. While clini-
cally useful, its use in the setting of clinical trials was restricted by its difficulty to implement
quickly and reliably[60]. The formulation of core sets of outcomes set out by the World Health
Organisation in 1994[61] and the ACR in 1993[62] proved instrumental in quantifying disease
states in a easy, quick and standardised manner. Based on these core outcomes, the ACR devel-
oped a standardised tool of assessing response to therapies through the use of the ACR20[63].
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This defined improvement as a 20% reduction in the core outcome measures set out previously
(swollen joint count, tender joint count, patient and physician global assessments, pain, disabil-
ity, and an acute-phase reactant), which could be used across clinical trials as a standardised
primary outcome measure.
In conjunction with the ACR tool, the Disease Activity Score (DAS) was also developed as
a means of quantifying the severity of the disease using a similar set of outcomes as those
described by the ACR. Much like the ACR definition, the aim of the DAS was to enable
effective therapeutic decisions in clinical practice, as well as help standardise results across
clinical trials[64]. Van der Heijde and 5 other rheumatologists used 6 year data collected on
113 early RA patients to develop the first DAS index. Factor analysis was conducted on a
variety of laboratory and clinical markers to establish which factors could be used to devise an
index that was easy to implement in the clinical setting, while minimising any loss of critical
information. Five factors were established for the score and consisted of the Ritchie index (a
measure of Tender Joint Counts (TJC)), a 44-count for Swollen Joint Count (SJC), Erythrocyte
Sedimentation Rate (ESR; a marker of acute phase inflammation) and general health. These
separate measures, which could be obtained relatively easily in routine clinical care, were then
calculated into a single DAS index, using a pre-defined formula, to ascertain overall disease
levels[64].
The DAS was later modified by Prevoo et al.[65] to the DAS28, which included a 28-joint count
for both swollen and tender joints, rather than the Ritchie Index for tender joints and the
44-joint count for swollen joints, both of which took longer to implement[66]. Furthermore,
the formula to calculate the overall score was adjusted, where the level of ESR had a larger
impact on the overall score for the DAS28 compared to the original DAS[66]. Because of these
subtle, but key differences, it is important that these two measures of disease activity are not
used interchangeably, as direct comparisons between patient groups assessed with the two scores
will invariably lead to bias[66]. That being said, formulas have been devised to transform the
DAS-44 to the DAS28[67]. While the DAS28 has proved to be popular as a primary outcome,
modifications have been attempted to simplify the score, such as the development of the Sim-
plified Disease Activity Index (SDAI)[68]. This score has been shown to be more sensitive to
changes in disease activity, and a validated means of quantifying overall disease activity[69].
Although strictly considered as a continuous measure of disease activity, ranging from 0-9.4,
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categorisation of the DAS28 has been used widely as a means of stratifying patients into re-
mission, low, moderate and high disease activity groups[67, 70]. When compared to the ACR
remission criteria, a DAS28 score of <2.6 has been validated as a suitable cut-point in defining
remission[70]. The definition of high disease activity as a DAS28 score of >5.1 is also the basis of
the National Institute for Clinical Excellence (NICE) guidelines on the use of biologic DMARDs
in the UK[71]. Currently, NICE restricts the prescription of biologic DMARDs to those patients
that have a DAS28 score of >5.1 on two separate occasions, who have also failed to respond
to two conventional synthetic DMARDS, one of which must be methotrexate. Recent data is
questioning whether this threshold is set too high, and whether patients with moderate DAS28
(i.e. just below the threshold for biologics) are adequately controlled on conventional DMARDs
alone[72–74].
2.2 Radiographic damage
RA is characterised by persistent synovitis, and over time this leads to structural damage to
both the bone and surrounding cartilage of the affected joint. Erosive damage has been shown
to occur in early RA, and while it is a heterogeneous disease, the majority of patients show
signs of erosive arthritis after 3 years[75–77]. Radiological damage is crucial in understanding
the severity of the disease, and has been used extensively as a primary end-point in RCTs[53,
55, 56, 78–83]. A recent report by a European League Against Rheumatology (EULAR) task
force highlighted the importance of imaging techniques in the diagnosis, clinical management and
detection of joint inflammation in RA[84]. It is significantly associated with increased functional
disability[38, 85–87] and shown to significantly increase the risk of orthopaedic surgery in later
disease[88]. By taking radiographs of a patient’s hands and feet, it can provide the clinician
with an objective and accurate snap-shot of how the disease is affecting the joints at any one
time. Collected over time, these can be used to document the ability of treatments in reducing
the erosive damage over the course of the disease[89].
It is theorised that radiological damage encompasses two main components of structural joint
damage; that is erosive damage of the boney structures and narrowing of the joint space[90].
While a combination of both these components as a total score is typically the focus in RCTs
and observational studies alike[91, 92], there is evidence that both components represent related,
but ultimately distinct biological mechanisms in the disease process. Erosive joint destruction
is the product of invading synovial osteoclasts[93] and joint space narrowing (JSN) is largely
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the involvement of cartilage damage due to metalloproteinases, which are mediated by pro-
inflammatory cytokines[94]. Understanding the precise differences in disease mechanisms could
have important implications on therapeutic management, since additional therapies could be
targeted specifically at the inhibition of osteoclasts to reduce further erosions in patients with
established disease[93].
2.2.1 Measuring Radiographic Damage
Various methods have been designed and validated as a means of quantifying the extent of
radiographic joint damage[95]. The aim of the scoring methods is to evaluate the small joints of
the hands, wrists and feet (with the exception of the early Sharp scoring method[96], which only
scored the small joints of the hands and wrists) and rate the joint with respect to the severity
of the erosions and JSN. While some scoring methods provide just one score for each joint
that encompasses the severity of both the erosions and JSN, other scoring methods provide two
scores for each joint, indicating the severity of erosions and JSN individually. More often than
not, the separate erosion and JSN score are combined to provide an overall total score. Figure
2.2 shows a plain x-ray of two fingers from an RA patient. RA can be seen to be affecting the
third and fourth Proximal InterPhalangeal (PIP) joints. The red arrows in the figure highlight
erosive damage to the bones, while the blue arrow indicates reduction in JSN. The white arrow
shows evidence of soft tissue swelling.
Sharp scoring method
The Sharp scoring method was first published in 1971[96] and scored 29 areas in the hands and
wrists for erosions and 27 areas for the JSN. Each area was given a score ranging from 0 to 5
for the severity of the erosions, and 0 to 4 for the severity of the JSN. 0 indicated a normal
joint, whereas 4 indicated severe erosions and complete reduction of JSN (ankylosis). The scores
could therefore range from 0 to 290 for the erosion score, and 0 to 216 for the JSN score. This
was later modified in 1985[97], which reduced the number of assessed areas for the erosion score
from 29 to 17 and the number of areas assessed for JSN from 27 to 18. This resulted in a
reduced total score ranging from 0 to 314, with a separate maximum score of 170 and 144 for
the erosion and JSN score respectively.
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Figure 2.2: X-ray of two Proximal InterPhalangeal (PIP) joints affected by Rheumatoid
Arthritis. The white arrow indicates soft tissue swelling, the red arrows indicate erosive damage
and the blue arrow indicates joint space narrowing.
There was a further modification of the Sharp score by Fries et al.[98], which aimed to incor-
porate both the size and count of each joint, as well as an indication of the ‘global’ severity
of the affected joint. It accomplished this using a weighted score, however the additional time
needed to conduct this score was not outweighed by any significant improvements in sensitivity
or reliability[95], and therefore is not widely adopted.
The original Sharp method, including its early modifications, was the only scoring method to not
include the joints of the feet; namely the metatarsophalangeal and interphalangeal joints. The
importance of assessing the radiological damage in the small joints of the feet was highlighted
by van der Heijde in 1992[99], which demonstrated how radiographic damage was more common
in the feet than in the hands during the first 3 years in patients with early RA. This was further
substantiated by Plant et al.[100] in 1994, who demonstrated that radiographic scores in the
feet where significantly correlated with later progression[100]. As such, it is perhaps no surprise
that the final modification of the Sharp score that does include the joints of the feet is the most
widely used scoring method, being particularly popular in RCTs over recent decades. Developed
in partnership with De´sire´e van der Heijde[101], and commonly referred to as the Sharp/van der
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Heijde (SvdH) scoring method, this modification of the Sharp score rates radiographic damage
based on the severity of the erosions in 32 joints in the hands and 12 joints in the feet, and
the severity of JSN in 30 joints in the hands and 12 joints in the feet. Each joint is rated from
0-5 for both erosions and JSN (however a score of 0-10 for erosions in the joints of the feet was
used) giving a maximum score of 280 for the erosion score and 168 for the JSN score. These
scores are combined to give a total SvdH score ranging from 0 to 448 (See Appendix D).
In 1999 attempts were made by van der Heijde[102] to simplify the SvdH method by condensing
the score into a Simplified Erosion Narrowing Score, or SENS. Rather than incorporating a
grading of the severity of the joint, each joint is merely scored 1 if it has presence of erosions,
1 if it has presence of JSN or 0 if neither are present. Each joint can therefore have a score
ranging from 0 to 2. The same joints that are assessed using the SvdH method are also assessed
using the SENS, therefore a total score can range from 0 to 86. Sample data using patients
from a cohort with established RA has indicated a high level of agreement between the SENS
method and the SvdH method (84%, k=0.565)[103]. It should be noted however, that the small
sample of 25 patients and the omission of Bland and Altman plots to investigate how agreement
varies over the range of the scores (with higher variation likely towards the higher end of the
scale) makes full interpretation of these results difficult. The criticisms outlined were discussed
in a study by Klarenbeek et al.[104] that indicated, through the use of cumulative probability
plots, how the sensitivity of the SENS was reduced at the higher end of the scale. As such, they
recommended that the advantages of the SENS with respect to speed and ease of use are not
outweighed by the reduction in sensitivity, and therefore the SvdH method remains the scoring
method of choice in RCT and cohort studies[104].
Larsen scoring method
The Larsen scoring method was first developed by Avri Larsen in 1974[105]. Like the Sharp
scoring methods, it measures the severity of both the erosions and JSN but includes both compo-
nents in one score instead. A total of 30 joints of the hands and 12 joints of the feet are assessed
using the Larsen method. The wrist is considered 1 unit and the score is multiplied by 5. Each
joint is scored from 0 to 5, where 0 indicates a normal joint, 1 indicates slight abnormalities, 2
indicates definite early abnormalities, 3 indicates medium destructive abnormalities, 4 indicates
severe definite abnormalities and 5 indicates mutilating abnormalities. As with the Sharp score,
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there have been various modifications of the Larsen score, however the method most often cited
is the 1977 version[106], which has a total score ranging from 0-250 (See Appendix D).
In 1995, a significant modification was made to the Larsen score in an attempt to make it more
suitable for use in long-term studies[107]. The wrist was divided into 4 sections, rather than be-
ing treated as 1 area, and the thumb and first metatarsophalangeal (MTP) joint were omitted.
The severity of erosions was graded based on size of the erosion on the joint, rather than sub-
jective classifications of ‘severe’. As a result this Larsen score ranged from 0 to 160. Variations
on this theme were also developed further by Scott et al[108] and Rau and Herborn[109]. While
the modification detailed by Scott et al. restored the original 0 to 250 range of the Larsen score,
it changed the focus of the grading to more clinical definitions of erosive and JSN damage. Like-
wise, Rau et al. looked at employing a concept of ‘destruction of the joint surface’ (DJS), which
rated the proportion of the joint surface that was affected by erosive damage. This ranged from
<25%, 26-50%, 51-75% and >75% for grade 2, 3, 4 and 5 respectively. The Rau and Herborn
method retained the same 0 to 160 score range as the same joints were assessed.
Other scoring methods
While the Larsen and more recently the Sharp (particularly the SvdH) scoring methods are
typically the most commonly used radiographic outcomes in observational studies and RCTs,
there are other scoring methods that attempt to quantify the extent of radiographic damage in
RA patients. The Genant method was developed in 1983 by Genant et al.[110] and considered
erosive damage at 16 sites in the hand and six in the feet, and JSN in 11 sites in the hand
and six at the feet. Each site is graded from 0 to 4, however this method requires a standard
reference set of radiographs for comparison. This was modified in 1998 by Genant et al.[111] to
include 0.5 increments for the 0 to 4 gradings, and then again by Kaye et al.[112] that details
two ways of implementing the score; a similar but more detailed version of the original Genant
scoring method, and a simplified method. Both methods grade 21 joints in the hands and wrists,
however the more detailed approach grades joints from 0 to 4 for erosions and zero to five for
JSN. The total score for the detailed version ranges from 0 to 168 and 0 to 210 for erosions and
JSN respectively. The simplified method combines both erosions and JSN into one score from
between 0 to 4, but also includes a grade P for post-operative joints, and a grade X for joints
that cannot be evaluated. The simplified version ranges from 0 to 168, which is calculated based
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on the sum of the scores divided by the number of evaluated joints (i.e. not those with grade
X).
Other methods include the Ratingen score, a method derived from the Larsen scoring method
by Rau et al.[113]. This method can be seen as a natural extension from the Rau and Herborn
modified Larsen score that focuses on the proportion of the DJS on twenty joints in the hand,
four sites in the wrist and ten joints in the feet. The method restricts scoring to only those
joints with definite changes of erosion and joint destruction and grades the joints as 1 for one
or more joints with <20% DJS, 2 for a DJS of 21-40%, 3 for a DJS of 41-60%, four for a DJS
of 61-80% and finally five for a DJS of >80%. The score ranges from 0 to 190.
Finally, the Short Erosion Scale (SES) was proposed by Wolfe et al.[114] as a means of determin-
ing the minimum number of joints needed to gain a suitable estimate of the ‘global’ radiographic
damage of a RA patient. To do this, the authors used Rasch analysis on the Larsen score to
identify the minimum number of joints without compromising on specificity or accuracy of the
score in quantifying radiological damage. The analysis concluded that only twelve joints, three
of the four wrist regions and metacarpophalangeal joints (MCP) 2, 3 and 5 of the hand. Each
joint is graded from 0 to 5 using the criteria set out by Larsen in their 1995 modification of
the Larsen score[107]. However, there is little evidence of its use in the literature, making any
assessments about its reliability difficult.
Use of other imaging techniques
So far, the scoring methods outlined have been restricted to images displayed using plain ra-
diographs from X-ray. The EULAR task force[84] highlights how the use of other imaging
techniques, such as magnetic resonance imaging (MRI) and ultrasound, can also prove useful
in the diagnosis of RA, as well as predicting long-term outcomes. MRI, and to a lesser extent
ultrasound, were highlighted as particularly useful in measuring clinical features that cannot be
detected with Computerised Radiography (CR) alone, such as bone marrow oedema and syn-
ovitis, both of which have been found to be associated with increased erosions in later disease
[115–117]. However, its widespread use in clinical practice is limited due to its relatively high
cost compared to plain radiographs.
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2.2.2 Common issues with radiography
The use of radiography to measure disease is popular in both observational and clinical trials as
it provides an objective means of quantifying the extent of structural damage caused by RA[118,
119]. However, there are a range of issues that need to be considered to ensure that it remains
a ‘gold standard’ measure of disease[118]. Firstly, there are technical considerations with both
the quality of the x-ray film, and positioning of the joint to ensure that the radiographic score
can be appropriately applied. Variation in aspects such as joint rotation and film exposure has
been shown to have a marked effect on the interpretation of the erosive and JSN damage of
joints[95]. The posteroanterior view for both hand and foot radiographs has been shown to be
the most superior when compared to other angles[120], while under- and over-penetrated films
can have a marked effect on the loss of erosions[95].
For longitudinal studies assessing multiple radiographs for one patient over time, the sequence
in which the radiographs are read has been shown to have a marked impact on the measure-
ment[121]. Studies have shown that when the radiographs are read in chronological order, they
are more sensitive to changes over time, particularly in studies with a long follow-up[121]. While
this approach reduces the potential within-subject random error, it does introduce bias in that
the reader may be expecting the erosive damage to progress over time[95], thereby artificially
inflating the rate of progression. Alternatively, blinding the reader to the sequence of the ra-
diographs (referred to as ‘paired’ reading), or to both the patient and the sequence (referred to
as ‘single’ reading), has been shown to reduce bias, however the level of measurement error is
likely to increase[102]. It is not clear which method is more ‘desirable’[119], but in the context
of longitudinal analyses it is clear that chronological order in order to minimise within-reader
variability is of more importance[121].
The presence of measurement error can greatly increase the ‘noise’ during the analysis of radio-
graphic data, which in turn leads to reduced precision and biased estimations. When looking
at differences in radiographic damage between groups, or change in scores over time within
patients, it is important to be able to quantify this measurement error and distinguish between
real clinical change and random variation due to the scoring method used. Indeed, this was iden-
tified as a key objective of the Outcomes Measures in Rheumatology (OMERACT) RA Imaging
Module[122]. Often referred to as the Minimal Clinically Important Difference (MCID), clinical
panels would investigate subsets of radiographs and decide the change in units of a particular
scoring method that demonstrated a clinically meaningful change[123]. Alongside opinion based
Chapter 2. Rheumatoid Arthritis, Radiographic Outcomes and observational cohort studies 21
methods for defining this threshold, statistical methods have also been used as a means of defin-
ing the level of measurement error in any one study. The Smallest Detectable Difference (SDD)
was calculated by Lassere et al.[124], by calculating the level of agreement between two scorers.
Using Bland and Altman agreement analysis, the standard deviation (SD) of the differences
between two scorers was used to define the level of random measurement error present. Any-
thing below this SD represented random variation, whereas anything above would reflect actual
changes in radiographic damage. Using this statistical definition, Bruynesteyn et al. could
investigate how the clinical consensus of the MCID compared with the statistical quantification
of measurement error[123]. The study found that the estimated MCID and calculated SSD were
very similar for the SvdH method, however the MCID for the Larsen method was much smaller
than its SDD, perhaps indicative of the Larsen method being less sensitive to change in scores.
Since its publication, a meta-analysis was conducted by Navarro-Compan et al.[125], which
reaffirmed the use of the SDD in quantifying the measurement error was appropriate. However,
these studies mostly assume a continuous normal distribution, whereas radiographic damage
scores have been shown to be highly skewed[126]. It is therefore likely that most estimates of
the MCID are likely to be too low at low values of the scale, and too high at high values of the
scale.
The concept of measurement error also became considerably pertinent with respect to negative
progression[127]. It was often assumed that erosions and JSN could only worsen over time,
and this was reflected in the development of both the Sharp and Larsen scoring methods,
which do not directly allow for negative progression[95, 128]. Despite this, there have been
several documented clinical cases where erosive healing had occurred[128], particularly in those
patients in sustained remission with no signs of inflammation[129]. As such, the emergence
of erosive healing has become an accepted occurrence in clinical practice[130], although still
debated amongst clinical circles. Importantly, it is key to establish that any negative progression
is the reflection of true erosive healing, and not down to measurement error alone[127]. As
such, it is seen as integral that at least two scorers are used in RCTs and observational trials
that include radiographic outcomes to ensure that any random variation in the score can be
appropriately accounted for[131, 132]. It is possible that in the era of new biologics and increased
efficacy of conventional DMARDs where erosive healing is now evident, new radiographic scoring
methods that account for this are needed.
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2.3 Randomised controlled trials and observational studies
The choice of an appropriate study design for a predetermined hypothesis is paramount. Rather
than which design is better, the consideration is which study design is most suitable to facilitate
the collection of strong, robust evidence for a specific research question[133].
The current paradigm in medicine is that clinical practice should be guided and developed
through the use of high quality evidence generated from trials and studies. In the context of
treatment efficacy, RCTs are heralded as the ’gold standard’ in medical research due to their
rigorous use of methodological techniques that aim to minimise bias and reduce the effect of
human error[134]. In the absence of counterfactuals, RCTs aim to test the efficacy of a treatment
by comparing it to a group of patients, similar clinically and demographically, who do not have
the treatment. Bias from confounding effects is reduced through the use of random allocation
of patients in groups, and systematic bias is eliminated through the use of blinding both the
patients and researchers involved as to what treatment the patient group is taking, either the
drug or a placebo, as well as the statistician analysing the data. The aim is to create a vacuum,
whereby any potential associations between the treatment and unknown factors are minimised.
RCTs provide a solid framework to test the efficacy of a drug over a relatively short time-
scale. However, common criticisms of RCTs are the fact that they generally have relatively
short follow-ups, usually no more than 1 year, and that they only include very specific sub-
groups of patients, not generally representative of the patient population as a whole. In order
to investigate the natural, long-term progression of a disease, long-term observational studies
are needed[133]. The pathway from drug development to implementation includes observational
studies at phase IV, with the aim to determine long-term safety and efficacy. Furthermore, they
are useful for determining long-term prognosis where random allocation of patients is no longer
necessary, since the goal can be centred on describing and predicting, rather than estimating
treatment efficacy.
Observational cohorts follow-up a group of patients with a similar characteristic, such as a diag-
nosis of a specific disease, and the patients are either enrolled at the time of diagnosis (inception)
or anytime during their disease (prospective). The aim of observational cohorts is to examine
patterns over time from a wide range of patients, covering a wide spectrum of the disease. This
ranges from mild to severe, and patients are treated according to published guidelines at the
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time. As a result, the data collated represents a more ‘real-world’ sample of patients, and there-
fore the natural, treated progression of the disease can be analysed. Observational cohorts can
also be invaluable to health commissioners and physicians alike, since important data regard-
ing the cost and management of patients can be monitored and analysed. This is particularly
important when new therapies or treatments are introduced, where long-term data on a large
group of patients is needed to monitor adverse effects and clinical management.
Randomised control trials with radiographic outcomes
RCTs have been instrumental in demonstrating the effect of different treatment strategies on the
progression of radiographic damage. While direct comparisons between trials is difficult, since
each study recruits specific and unique patient populations[135], there has been breakthroughs
in which treatment strategies provide the best radiographic outcomes, particularly in patients
with most severe disease.
RCT for Conventional DMARD therapies
The reduction of radiographic damage in RCTs was first reported in a placebo-controlled trial
looking at intramuscular gold in the 1970s[136], followed by a number of trials in the 80s and
90s comparing sulphasalazine and methotrexate with other conventional synthetic DMARDs,
such as hydroxychloroquine[137], auranofin[138] and azathioprine[139]. All these early trials
indicated an increased efficacy of both sulphasalazine and methotrexate in reducing radiographic
progression over the comparison DMARD, thereby cementing their use as the anchor DMARDs
of choice in routine care (as detailed in the latest National Institute for Clinical Excellence
(NICE) guidelines[71]).
Following the evidence that single DMARD therapies, particularly sulphasalazine and methotrex-
ate, were superior to placebo and other conventional synthetic DMARDs, a range of RCTs were
conducted to investigate whether there were any additional benefits of combination DMARD
therapies on retarding radiographic progression. In 1997, the COBRA (Combinatietherapie Bij
Reumatoide Artritis) trial[140] investigated the efficacy of combined sulphasalazine, methotrex-
ate and prednisolone with the use of sulphasalazine alone. They found significant reductions
in disease activity over the 56-week trial period, along with reductions in the total SvdH score
at the 28, 56 and 80 week periods, for those patients on the COBRA treatment strategy (that
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is, the combination of sulphasalazine and methotrexate with concomitant prednisolone) when
compared to the patients on sulphasalazine only. Patients indicated similar baseline levels of
radiographic damage, and the difference between the groups was greater for the erosions score,
although it should be noted that the analysis was restricted to univariate rank sum testing, a
statistical method more prone to confounding bias.
Since the publication of the main trial, Landewe` et al.[141] conducted a further analysis on the
COBRA trial using 5 year follow-up data on the same patients. The longer follow-up and more
robust statistical techniques (Generalised Estimating Equation (GEE) modelling) allowed for
more precise estimation of the radiographic progression in these patient groups. Although, it is
important to note that patients were not randomised to their treatment arms beyond the first
year of the trial. From 148 patients completing follow-up measures, the combination group was
found to have significantly lower annual progression compared to the sulphasalazine only group,
with an annual unit increase of 5.6 vs. 8.6 SvdH units per year (p=0.03). Interestingly, unlike
the original analysis for the trial, this paper indicated similar reductions in both erosions scores
and JSN scores between the groups, once again highlighting the importance of using appropriate
analysis techniques when analysing radiographic data. The likelihood of patients switching to
methotrexate during the additional 4 years of follow-up was significant, showing that the use
of methotrexate after the initial 1 year trial period increased, while the use of sulphasalazine
decreased. Despite these changes between the trial arms over the subsequent 4 year follow-up,
adjusted analysis indicated that the changes in DMARD did not significantly alter the estimates
for the two groups. The results of this additional follow-up study provided evidence that the
early use of intensive DMARD therapy with the combination of prednisolone during the so-
called ‘window of opportunity’[54], has an effect on reducing radiographic progression over the
longer term.
The COBRA study was instrumental in demonstrating the efficacy of combination DMARD
therapy in early RA. However, the use of concomitant prednisolone within the combination arm
meant that it was not possible to establish whether the reduction in radiographic progression
rates was due to the combination of methotrexate and sulphasalazine, the use of predinisolone,
or the combination of all three. In 1999, Dougados et al.[142] conducted a three arm trial to
investigate the efficacy of methotrexate, sulphasalazine and the combination of the two on dis-
ease progression over 1 year. While significant declines in DAS were seen for the combination
group, a lack of difference between the groups in the ACR or EULAR response criteria, along
with increased toxicity in the combination group questioned the use of combination therapy
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in routine care. Nevertheless, there was evidence of decreased radiographic progression in the
combination group compared to both monotherapy arms. As with the COBRA trial, further
follow-up was also collected to investigate the impact of initial combination therapy on long-term
outcomes, including radiography[143]. Interestingly, this study found no perceived benefits of
early combination therapy on long-term outcomes, including disease activity, functional disabil-
ity and radiographic progression. While factors such as differences in levels of disease severity
and differences in treatment following the initial 1 year follow-up between the COBRA trial
and the trial conducted by Dougados et al. could explain the differences in results, it is likely
that the early use of corticosteroids in the COBRA study led to the significant reductions in
radiographic progression over the first 5 years in their trial.
Given that the monotherapy groups in both the COBRA trial[140] and the one conducted
by Dougados et al.[142] did not include additional prednisolone, it was also unclear whether
monotherapy with concomitant prednisolone could be as effective as combination DMARD ther-
apies, such as the COBRA strategy. The Finnish RA combination therapy trial (FIN-RACo)
trial[81] assessed the use of triple combination DMARD therapy (methotrexate, sulphasalazine,
hydroxychloroquine and prednisolone) against a single DMARD (initially sulphasalazine) with
out without prednisolone. A total of 199 patients were recruited into the trial, with 87 ran-
domised to the combination arm and 91 in the single treatment arm. Using the Larsen scoring
method, radiographic damage in the combination arm increased from a median of 2 [Inter-
quartile range (IQR) 0-4] to 4 [IQR 0-14], compared to an increase in the single therapy arm
from a median of 2 [IQR 0-8] to 12 [IQR 4-20]; indicating a statistically significant increase in
progression for the single therapy group over the first 2 years (p=0.002). Furthermore, they
found that the number of new erosions was decreased in the combination arm, and interestingly
that those patients who received prednisolone in the single treatment arm indicated higher rates
of radiographic progression over the 2-year follow-up. Although, it is likely that this increase
is a reflection of higher disease severity (thus the need for additional prednisolone along with
single DMARD), rather than the inability of prednisolone to reduce radiographic progression
when used concomitantly with single DMARDs. The data from the FIN-RACo trial was also
supplemented with additional follow-up data, which included a further two follow-ups at 5 and
11 years[144]. The study found that when adjustment for baseline Larsen score was included,
there was a statistically significant difference between the combination and single arm treat-
ment groups. The combination arm indicated a much smaller mean change from baseline to 11
years of 17 Larsen units [95% CI 12-26], compared to a mean change of 27 Larsen units [95%CI
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22-33] in the single treatment arm. It was concluded that intensive therapies using combination
DMARDs with concomitant prednisolone at the early stages, with a focus on remission as the
target, leads to tight disease control along with significant reductions in radiological damage
over the long-term.
The role of prednisolone in retarding radiographic progression over the short-term was further
supported by trials conducted by Kirwan[145] and Svensson[146], which both demonstrated
reductions in radiographic progression over the first 2 years. This was further supplemented
by a systematic review published in Cochrane, which evaluated 15 RCTs looking at the effect
of glucocorticoid steroids in combination with traditional DMARD therapies. The review con-
cluded that all but one study indicated a benefit in favour of glucocorticoids, with a pooled
standardised mean difference of 0.40 in reduction of the erosion score over the first 2 years[147].
As is often the case in medicine, standardising treatment based on the best evidence at the
time is difficult. Often different clinics will operate in different ways with regards to choice
and, more importantly, dose of a particular drug[148]. The CAMERA trial (computer assisted
management in early RA) investigated whether intensive treatment of methotrexate mediated
by a computer decision based tool could improve RA outcomes over 2 years when compared to
conventional treatment[148]. They found that higher doses of methotrexate optimised earlier in
the computer-assisted arm led to improvements in disease activity after 2 years, however there
was no difference in radiographic progression between the two arms. This is likely owing to the
very little progression in both patient groups over the first 2 years. The authors do note that of
those with radiographic damage, the progression was higher in the conventional arm compared
to the computer-assisted arm, suggestive of some beneficial effect of high dose methotrexate in
reducing long-term radiographic progression. With respect to radiographic damage, this trial
may suggest that methotrexate dose is less important in inhibiting radiographic progression,
although more long-term evidence is needed.
RCT for biologic DMARD therapies - Anti-TNF
The introduction of biologic therapies brought about the potential for a new line of RA treatment
with the potential of being more effective than conventional synthetic DMARDs, particularly
methotrexate. One of the first trials published in the New England Journal of Medicine by
Bathon et al.[78] compared the use of etanercept (belonging to a class of anti-TNF-α inhibitor
biologics) at both 10mg and 25mg doses against methotrexate. A total of 632 patients were
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randomised into the three treatment groups, with measures of disease activity and radiographic
damage reported over 12 months. The trial found that overall disease activity was reduced in
the 20mg etanercept group when compared to the methotrexate only group, along with greater
reductions in mean changes of the total SvdH and erosion score. The total SvdH and erosion
score between the methotrexate and etanercept at 10mg group were similar over the 12 months
and the rate of JSN progression was similar for all three groups.
The efficacy of etanercept and methotrexate in combination was also highlighted in the combi-
nation of methotrexate and etanercept in active early rheumatoid arthritis (COMET) trial[149].
This 2-arm RCT investigated 542 early RA patients recruited from 22 countries. Two hundred
and sixty-three were randomised to the methotrexate only arm, while 265 were randomised to
a combined treatment of etanercept and methotrexate. The trial found that those patients
randomised to the combination arm were more likely to achieve remission as defined using the
DAS28 score of <2.6 over the whole 12 month trial period. Radiographic assessment using the
SvdH score also indicated a lower rate of radiographic progression in the combination group,
progressing just 0.27 units over the 12 months, compared to 2.44 units in the methotrexate only
arm. This was largely driven by increases in erosions, rather than JSN. Furthermore, post-hoc
analysis of the COMET data[150] examined the impact of very early treatment in both the
combination and monotherapy patient sub-groups. In both trial arms patients were stratified
into very early treatment (<4 months,) or early treatment (>4 months).
In the combination arm, very early treatment resulted in better disease outcomes in 12 months,
with a higher proportion of patients in the very early group achieving low disease activity and
DAS28 remission (69.8% vs. 47.8%). In contrast, the very early treatment group within the
methotrexate only arm indicated similar proportions of patients in the low disease activity and
DAS28 remission (34.7% vs. 31.8%), although significantly different statistically. However, what
is particularly interesting is the disparity between radiographic outcomes and disease severity
in this trial. The proportion of patients with an annual increase of <0.5 SvdH was similar in
the very early and early groups within the combination arm.
Although, there was a significantly high proportion of patients treated very early in the methotrex-
ate arm with low radiographic progression compared to the early treatment group (73.9% vs.
50% respectively). No direct comparisons were made in the data analysis. The proportion of
patients in the very early methotrexate group showed similar levels of radiological progression
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when compared to both the very early and early groups within combination arm. For radio-
graphic progression outcomes, there was evidence that very early methotrexate use could be as
effective in retarding radiographic progression in the short-term as combination therapy with
biologic DMARDs. This evidence is limited by two factors; often, the precise timing of DMARD
initiation in RCTs is not recorded, and definitions of early RA can vary from 1 to 3 years from
symptom onset. Therefore, there is currently no other evidence that very early DMARD use
has such a profound effect on short-term, and indeed long-term, radiographic progression.
Other anti-TNF biologics have also shown similar results to entanercept. The PREMIER trial
conducted by Breedveld et al.[151] demonstrated the efficacy of adalimumab in a multi-centre
RCT of 799 early RA patients. They found that the early use of combination adalimumab
and methotrexate was superior to both drugs when used alone, with a greater proportion of
patients achieving the ACR90 criteria and significantly reduced radiographic progression over
the first 2 years. Using the SvdH scoring method, the mean change from baseline to year 2 was
10.4, 5.5 and 1.9 for the methotrexate, adalimumab and combination therapy arms respectively.
However, the authors do note that the methotrexate group had higher radiographic damage
at baseline, specifically a higher erosion score, partly explained by a marginally longer disease
duration compared to the other two arms.
The ASPIRE trial conducted in 2004[152] demonstrated the superiority of infliximab when used
in combination with methotrexate, again indicating better disease control over 12 months along
with a greater reductions in radiographic joint damage. In a follow-up study conducted by
Smolen et al.[153], detailed analysis of the ASPIRE data was conducted to investigate potential
prognostic markers of poor disease control and increased radiographic progression. While the
relative efficacy of methotrexate is highlighted in the report, particularly when the cost-to-
benefit ratio is considered, there are those patients that continue to progress radiographically
with poor disease outcomes. This analysis identified this sub-group in the methotrexate only
treatment arm, showing relatively higher levels of acute phase markers and swollen joint counts.
In contrast, patients receiving methotrexate in combination with infliximab had consistently
low radiographic progression, independent of increased disease markers.
RCT for biologic DMARD therapies - Rituximab, Tocilizumab and Infliximab
Along with the anti-TNF biologics outlined in trials so far, a host of other biologics, which
target other cells involved in the inflammation cascade, have also been authorised for the use in
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the treatment in RA. The IMAGE trial[154] demonstrates the improved efficacy of rituximab,
a biologic which targets CD20+B cells, when used in combination with methotrexate compared
to methotrexate alone. Those patients randomised to rituximab at 2x1000mg dose had signifi-
cantly better disease outcomes by 12 months, along with significant reductions in radiographic
progression. Methotrexate demonstrated a mean change in total SvdH score of 0.7 and 0.38
from baseline to 24-weeks and from 24-weeks to 52-weeks respectively. This compared to a
change in total SvdH score of 0.33 and 0.14 in the rituximab 2x1000mg group at baseline to
24-weeks and 24-weeks to 52-weeks respectively.
As with the other trials, the total SvdH score was largely driven by changes in the erosion
score, rather than JSN. Finally the efficacy of tocilizumab, a humanised anti-IL-6 receptor,
was investigated in the SAMURAI trial[155]. Unlike previous trials that compared the biologic
monotherapy to methotrexate monotherapy, the SAMURAI trial included patients on a range
of different conventional DMARD treatment strategies in the control arm. Having said that,
patients in the control arm were predominately on methotrexate monotherapy, however some
patients also received non-methotrexate DMARDs either in monotherapy or in combination
with methotrexate. The trial assessed disease severity and radiographic progression over 12
months in a total of 265 patients. RA duration was typically longer compared to the previous
trials, with patients having RA for up to 5 years, as opposed to 2 or 3 years. Nevertheless, the
trial demonstrated the superiority of tocilizumab monotherapy in reducing disease severity and
radiographic damage over the first year when compared to conventional DMARD therapy.
RCT comparing combination DMARDs with biologic DMARDs
With the exception of the SAMURAI trial, the sub-sample of RCTs outlined so far have demon-
strated the efficacy of biologics either alone or in combination with methotrexate against only
methotrexate monotherapy. The apparent superiority of biologics over conventional DMARD
therapies may therefore be unsurprising, as the COBRA[148] and FIN-RACo[81] have demon-
strated that early use of conventional synthetic DMARDS in combination is more effective than
DMARD monotherapy[83]. To this end, data from the Swefot trial[156] investigated the use
of add-on combination DMARDs (sulaphasalazine and hydroxychloroquine) compared to the
use of add-on biologic therapies (infliximab) on those patients receiving initial methotrexate
monotherapy who fail to respond after the first 3 to 4 months. The initial 12-month report
indicated that patients randomised to receive biologic add-on therapy had a higher proportion
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achieving the EULAR defined ‘good-response’ criteria compared to those patients receiving com-
bination conventional DMARDs. However, the report of the same trial data after 24 months
showed that the number of patients achieving EULAR defined ’good-response’ at 24 months
was similar in the two trial arms[83]. Although, there was evidence of reduced radiological
progression in the patients treated with combination methotrexate and infliximab.
The results from this extended report indicate that conventional DMARDs used in combination
early on may provide a suitable and cost-effective therapy option in the short-term, compared
to the use of add-on combination biologics. What is unclear is whether the radiographic ben-
efit of add-on biologic therapy in this patient sub-group that fail to respond to methotrexate
monotherapy is significant in the long-term, as this could still highlight the need for the use of
biologics in all but the most severe cases of RA, where radiographic retardation is difficult.
What is the optimal treatment for early RA?
The small sub-sample of RCTs described have shown that, on the whole, early intensive com-
bination DMARD therapy produces better long-term radiologic outcomes in early RA when
compared to delayed, monotherapy DMARD treatments. This has been demonstrated using a
range of different combination treatments; with combination methotrexate and sulphasalazine,
including low-dose corticosteroids in the COBRA trial[148], and triple therapy with methotrex-
ate, sulphasalazine and hydroxychloroquine, including low dose corticosteroids in the FIN-RACo
trial[81]. The use of biologic therapies, largely anti-TNF-α, have shown superiority to methotrex-
ate in monotherapy, and the potential for greater radiographic retardation when compared to
combination DMARDs in the Swefot trial[83].
The increase in treatment options for early RA has made it difficult to ascertain what the optimal
treatment strategy should be in early RA[56]. As such, the BeST trial aimed to evaluate four dif-
ferent treatment strategies in order to shed some light on which would lead to the best outcomes
in the long-term. The first group (sequential) received methotrexate monotherapy, with other
conventional DMARDs being used in sequence if response was insufficient. The second group
(add-on) were assigned to step-up combination DMARDs, with methotrexate monotherapy be-
ing used as first line, and other conventional DMARDs were added if response was insufficient.
The third group (combination DMARD) were assigned to combination DMARD therapy, with a
combination of both methotrexate and sulphasalazine, along with low-dose predinsolone being
used as first line. Finally, the fourth treatment group (combination biologics) were assigned
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to combination biologic therapy, with methotrexate and infliximab being used as first line. In
all groups, treatment was escalated over the duration of the trial from increased methotrexate
dose, switching of conventional DMARDs used, and included the use of combination DMARDs
with biologic therapies if response was lacking.
A total of 508 patients were enrolled in the study and completed the first year follow-up.
Patients in the combination DMARD and combination biologics groups had a higher proportion
of patients achieving remission by 12 months compared to the sequential and add-on group. The
proportion of patients achieving remission in the combination DMARD group was similar to
the combination biologic group (71% vs. 74%). A similar pattern was seen for functional
disability and radiographic progression, where combination therapy with either prednisone or
infliximab was superior in controlling disease when compared to monotherapy. As with the
Swefot trial[83], the results of the BeST trial do indicate that early combination DMARD
therapy with concomitant prednisolone could be as effective as combination biologic therapy in
reducing radiographic progression. Van der Broek et al.[157] argue that the common theme in
all four trial arms was the implementation of T2T principles, whereby adjustments were made
continuously when response was not being achieved. It could therefore be argued that early
combination therapy has the advantage of faster and more sustained remission in the first few
years of the disease while ensuring long-term sustainment of remission is achieved by continued
monitoring and tailored adjustments for more intensive therapies made when needed. In the
case of the BeST trial this appeared to result in sustained long-term remission in all treatment
groups over the 7 year follow-up.
Observational studies of early RA with radiographic outcomes
Early records of RA cohorts date back to the 1950s and 60s and were primarily population
based cohorts with the aim of estimating the prevalence of RA[158]. The first hospital based
RA cohort was developed in Bath, which recruited 100 early RA patients from between 1957
and 1963. The cohort collected data for over 40-years and looked at aspects of RA surrounding
disability and loss of functional capacity[159]. A similar cohort was developed in Middlesex
named the RAPS study, which also looked at serial x-rays of the hands of feet, providing some
of the first evidence about the high rate of structural joint damage in the first 5 years of RA[160].
Following these relatively small cohort studies, a host of large inception cohorts were developed
with the aim of collecting higher numbers of patients with similar lengths in follow-up.
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The Early RA study (ERAS) was formed in 1986 and aimed to collect data on 1000 early RA
patients, and follow those patients for at least 5 years[161, 162]. Recruited across 9 different
centres in the UK from the years 1986 to 2001, a total of 1465 patients were recruited with
standard clinical, radiological, laboratory and genetic data collected at baseline, six-months,
then yearly thereafter for up to 25 years; thereby exceeding its target for both patient numbers
and length of follow-up. Data collected included a range of demographic, clinical and labo-
ratory markers, the most fundamental being disease activity (DAS-44), functional disability
(Health Assessment Questionnaire (HAQ)) radiographic data (recorded using both the Larsen
and SvdH scoring methods), health survey data (Short-Form 36), genetics, surgical interven-
tions, co-morbidities and mortalities. All patients recruited were treated according to published
guidelines at the time.
The successor to ERAS, the Early RA Network (ERAN) had similar aims, design and clinical
assessments[163]. The 21st century saw a number of key developments in the management of
RA, largely due to the publication of national and international guidelines, increased activity
from patient support groups and greater access to care. The NHS as a whole was more focused
on clinical governance to advance the practice of evidence-based medicine, and governing bodies
such as NICE relied on high quality evidence to guide clinical management and evaluate current
healthcare provisions within the National Health Service (NHS). This led to higher demand
for high quality clinical data, such as those provided from observational cohorts. As a result,
ERAN, a natural extension to ERAS, was developed. It maintained many similarities with
ERAS in its core aims and design. The broad aims of the cohort were to contribute to good
clinical practice and facilitate in the decisions made by clinical governance. Importantly, ERAN
documented the clinical management of patients during the era in which biologic therapies were
introduced.
During the same time as the ERAS and ERAN cohorts, the Norfolk Arthritis Registry (NOAR)
was established to investigate the incidence of polyarthritis and RA in rural areas of East
Anglia[164]. It was one of the first studies to update UK incidence and prevalence rates on RA,
which led to the finding that age-specific prevalence was decreasing in women, but increasing
in men[5]. Patients were recruited from 1989 to 1994 with data recorded for up to 15 years,
and from 2000 to 2008 with data collected for up to 2 years. As with the ERAS and ERAN
cohorts, demographic, clinical and laboratory markers were collected. Unlike ERAS/ERAN,
patients with undifferentiated RA were also included in the cohort, which allowed the cohort
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to compare outcomes in other inflammatory arthritis sub-groups, indicating that patients with
polyarthritis experienced similar levels of worsening disability and mortality as RA[165–167].
Possibly one of the most important registries in recent years for RA is the development of
the British Society for Rheumatology Biologics Register (BSR-BR)[168]. The register was set
up to monitor all patients who were newly started on biologic DMARD therapies for safety
outcomes. While including a comparison cohort of patients on conventional synthetic DMARDs,
their primary aim is to detect any increases in risk of lymphomas owing to the use of biologic
DMARDs. To date, the register has data on several thousand RA patients on biologic DMARDs,
and is thought to represent approximately 80% of patients starting on biologics since 2002. Their
primary aim is to detect any increases in risk of lymphomas from the use of biologic DMARDs,
over and above the risk from RA itself. While no increased risk has been found for lymphoma,
but did indicate increased risk of non-melanoma skin cancers and infections[169].
Outside the UK, many cohorts have also been developed. The Leiden Early Arthritic Cohort
(EAC), started in 1993, recruited patients with early inflammatory arthritis from GP refer-
rals[170]. The aim was to detect and treat inflammatory disorders early in the disease course,
particularly early RA. Outcome measures collected included clinical measures, laboratory mea-
sures, radiographic measures and genetics. By 2003, 1,600 patients with early inflammatory
arthritis were recruited into the cohort. Also from the Netherlands, the Nijmegen cohort was
set up to monitor patients with early RA[171]. By 2005, a total of 525 patients were enrolled
into the cohort with over 10 years follow-up[172]. Of particular note is also the Danish Registry
for Biologic Therapies in Rheumatology, commonly referred to as the DANBIO registry, which
was set up in 2000 with the aim of collecting a large amount of data on patients in rheumatology
clinics. To date, it has collected data on over 10,000 patients with RA, Psoriatic Arthritis (PsA)
and Ankylosing Spondylitis (AS)[173]. What makes this cohort particularly unique is the way
in which it has integrated the collection of cohort data through the use of simple computer
software, which can be easily implemented in routine clinical care. In the early stages, the
registry was largely paper based; however in 2005, the introduction of DANBIO-online allowed
for much more efficient data collection methods. The advantages of adopting an online only
system were three-fold. Firstly, it allowed for more accurate data entry since the additional
step of entering data from paper forms was eradicated. Secondly, it also included algorithms
for checking missing data, which would prompt the user to fill in sections before submission.
This was an effective means of reducing missing data, which is not possible using paper forms.
Finally, the user-friendly interface and simple mode of data entry provided clinicians with a
Chapter 2. Rheumatoid Arthritis, Radiographic Outcomes and observational cohort studies 34
less burdensome means of enrolling patients and entering follow-up data. In fact, the online
database provided a means for clinicians to access individual patient data during consultations,
allowing them to see how both routine clinical markers and study-specific markers of disease
had changed over the course of the disease.
Other non-UK cohorts of note are the Lund cohort in Sweden[174], the Heinola and Jyva¨skyla¨
cohort in Finland[175] and the ESPOIR cohort in France[176]. To assess the radiographic
findings from these observational cohorts, the next chapter will conduct a systematic review on
all published literature concerning the progression and predictive factors of radiographic joint
damage.
2.4 Discussion
Rheumatoid arthritis is a disabling a chronic disease. It is multi-faceted and involves a number
of key outcomes, including pain, disability, quality of life, inflammation, and structural damage.
Understanding the aetiology and mechanisms of disease has helped the development of effective
treatment strategies, including the development of drugs, the optimum time to administered
these drugs, and the long-term management of the disease.
There remains a wide variety of outcome measures for quantifying the different aspects of RA,
from biomarkers of disease, to scoring systems for establishing the extent of joint damage using
plain x-rays. While these measures have their limitations, they have been important for research
into RA, as they allow for tangible assessments of objective disease outcomes for the use in RCTs
and observational studies.
RCTs have been instrumental in measuring the efficacy of different treatment strategies, and
long-term extensions of these trials are important in determining the long-term impact of these
early treatment decisions on the disease course. However, the limitations of RCTs are not to be
ignored, and their inability to answer important research questions, such as the implementation
of treatment strategies in routine clinical care and the progression of disease in patients with
less severe disease, highlights the importance of long-term observational studies.
The emergence of large observational cohorts and registries has been key in understanding
the natural course of RA, and how treatments are implemented in real-world clinics, using
patients with a wide spectrum of disease severity and co-morbidities. It has allowed a greater
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understanding of how critical changes in treatment practices have affected the progression of
key RA outcomes, such as radiographic joint damage. The use of computerised systems and
open-source software has proven to be of great assistance in the set up and maintenance of
long-term observational trials, seemingly by-passing many barriers faced when trying to set up
and run these often time-consuming and expensive studies. Implementation of these techniques
not only allows for the opportunity to collect rich and useful data for research purposes, but
can also help facilitate the clinical consultation with patients, whereby an accurate progression
of any individual patients’ disease can be easily illustrated and explained in real time.
Chapter 3
Systematic Review
3.1 Introduction
Towards the later sections of Chapter 2 a host of RCTs and observational studies that recorded
radiographic outcomes were introduced. The main focus of the RCTs were to investigate the
efficacy of different treatment regimes on radiographic progression, since restricted follow-up
periods and strict patient inclusion criteria render RCTs inappropriate for prognostic modelling
and investigation of long-term progression. In contrast, observational studies provided detailed
accounts of the natural progression radiographic damage over time, including patients covering
the wide spectrum of disease severity, treated in a natural clinical setting according to published
guidelines at the time.
The specific aim of this chapter is to expand on the observational studies detailed in Chapter 2
and conduct a systematic review on all published observational studies looking at radiographic
outcomes in early RA over the long-term. This will directly address the first aim outlined in
Chapter 1; that is to investigate the current evidence base to identify common methods in
measuring and reporting radiographic outcomes.
The first recorded systematic reviews on radiographic progression were published by Scott et al.
in 2000[85], which was later updated in 2003[38]. It reviewed the rates and clinical predictors of
radiographic progression in patients with RA. The review concluded that 39-73% of early RA
patients develop one or more erosions in the first 5 years and radiographic joint damage pro-
gresses constantly over the first 20 years of disease[38]. Two systematic reviews on radiographic
progression have been published since[86, 177]. Neither reported radiographic progression rates,
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concentrating instead on specific predictors (function and disease activity) of radiological dam-
age. To date, no review has used quantitative analysis techniques, such as meta-analysis, to
investigate radiographic progression rates from the published literature.
Despite some evidence of erosive healing[128, 129], structural damage is largely considered
irreversible[38, 178], and therefore clinicians need to identify patients at higher risk of severe
radiographic damage to tailored treatment earlier on. Predictive modelling is a useful statistical
method to identify all clinical factors that are associated with primary RA outcomes[178, 179].
Previous studies have provided contemporary accounts on the relationship between radiographic
progression with functional disability[86] and disease activity[177]. Other factors, such as anti-
CCP antibodies and genetic factors have not been fully reviewed.
The objectives of this systematic review are therefore to evaluate firstly, all published data on
baseline and annual progression rates of radiographic damage from all longitudinal observational
cohorts, and secondly, the association of standard clinical and laboratory parameters with long-
term radiographic joint damage. Where appropriate, meta-analyses were conducted on the
baseline and annual progression rates of radiographic joint damage scores, and their predictive
markers.
3.2 Methods
A systematic review protocol was developed to ensure that objectives and aims were clearly
outlined from the outset and submitted and approved by PROSPERO in February 2014 (Reg-
istration Number: CRD42014007589).
Identifying publications
Publications were identified by computerised searches of PubMed, Cochrane Library (includ-
ing CENTRAL, CDSR, DARE, HTA) and Scopus, supplemented by lateral search techniques:
checking reference lists, performing key word searches in Google Scholar and using the ‘cited
by’ option in PubMed. All databases were searched from January 1st 1975 to February 31st
2014. The search strategy used a mixture of key words and MeSH terms on the title/abstract
and full text as appropriate.
The following search strategy was used to search for all published literature in PubMed:
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((‘arthritis, rheumatoid’[MeSH Terms] AND ((((radiographic[Title/Abstract] OR X-ray [Ti-
tle/Abstract]) OR structural joint damage[Title/Abstract]) OR Larsen[Title/Abstract]) OR
Sharp [Title/Abstract])) AND ((((((((‘randomized controlled trials as topic’[MeSH Terms] OR
‘randomized controlled trials as topic’[MeSH Terms]) OR (controlled[All Fields] AND (‘clinical
trials as topic’[MeSH Terms] OR (‘clinical’[All Fields] AND ‘trials’[All Fields] AND ‘topic’[All
Fields]) OR ‘clinical trials as topic’[All Fields] OR ‘trial’[All Fields]))) OR (‘randomized con-
trolled trial’[Publication Type] OR ‘randomized controlled trials as topic’[MeSH Terms] OR
‘randomised controlled trial’[All Fields] OR ‘randomized controlled trial’[All Fields])) OR (‘clin-
ical trial’[Publication Type] OR ‘clinical trials as topic’[MeSH Terms] OR ‘clinical trial’[All
Fields])) OR observational[All Fields]) OR (‘longitudinal studies’[MeSH Terms] OR (‘longitudi-
nal’[All Fields] AND ‘studies’[All Fields]) OR ‘longitudinal studies’[All Fields] OR ‘prospec-
tive’[All Fields])) OR (‘epidemiologic studies’[MeSH Terms] OR (‘epidemiologic’[All Fields]
AND ‘studies’[All Fields]) OR ‘epidemiologic studies’[All Fields] OR (‘epidemiological’[All Fields]
AND ‘studies’[All Fields]) OR ‘epidemiological studies’[All Fields])) OR longitudinal[All Fields])).
Inclusion/exclusion criteria
The following inclusion criteria were used to select publications: (1) investigated the progression
or predictive/prognostic markers of radiographic joint damage, (2) use of validated diagnosis
criteria (.e.g European League Against Rheumatology (EULAR) and/or the American College
of Rheumatology (ACR) criteria), (3) baseline assessments occurred no later than 3 years from
symptom onset, (4) prospective cohort study design, (5) radiographic follow-up data available
for at least 5 years for progression rates, and at least 3-years for predictive markers, (6) Larsen
or Sharp van der Heijde methods (SvdH) to score radiographic damage as the primary outcome,
and (7) only publications in English.
Publication screening
One reviewer (Lewis Carpenter) screened all titles and abstracts identified by the electronic
search and applied the selection criteria to potentially relevant papers. A second reviewer (Elena
Nikiphorou) independently screened the full text of 10% to compare against agreed inclusion
criteria. Agreement was achieved in 97% and any disagreements were resolved through discus-
sion. Figure 3.1 provides a flow diagram of all publications identified, screened and included in
this review.
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Figure 3.1: PRISMA Flow Diagram
Data extraction
Two reviewers (Lewis Carpenter and Rachel Sharpe) extracted data using a pre-designed form,
piloted to ensure all data necessary for the analysis could be included: cohort study name,
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country of study population, scoring method, patients numbers, recruitment years, length of
follow-up, sex, mean age, baseline DAS and HAQ, DMARD use by 12 months, RF positivity,
number, mean/median and standard deviation/interquartile range of radiographic scores at
each follow-up, analysis method, and significant and non-significant predictors with the effect
estimate and 95% confidence intervals (95%CI). Where the raw data was not published, authors
were contacted to provide this data (n=21).
Quality Assessment
All studies were screened and rated based on the modified version of the Downs and Blacks
checklist for non-randomised studies of health care interventions[180]. Since the studies involved
were not examining effectiveness of health care interventions, all items on the checklist that
related to comparative groups (e.g. randomisation and blinding procedures) were not used. One
reviewer scored all studies using the amended checklist and a second reviewer independently
scored 10% drawn at random. All discrepancies between the two reviewers were discussed and
consensus achieved.
Analysis
Means and standard deviations of either the Larsen or Sharp score were recorded at each
follow-up for each study. Where only a median scores were obtained, the median and range was
converted into a mean score and standard deviation[181]. In order to estimate the annual rate of
change, along with standard errors, a linear regression model was conducted with follow-up year
as the independent variable. Baseline scores and annual rates of progression, with respective
standard errors, were transformed into percentage of maximum damage dependent on which
radiographic scoring method was used[182, 183]. Transformed scores were entered into random
effects meta-analysis to calculate pooled effect estimates for both baseline radiographic scores
and annual rate of change.
To assess the strength of predictive markers, the regression coefficients and odds ratios (OR),
with their respective 95%CI, were collated. Unadjusted effect estimates were primarily sought,
when not reported adjusted estimates were used. Random effects meta-analysis was used for all
models because of the likely heterogeneity between studies.
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Heterogeneity
The study entry criteria of this review included studies as homogenous as possible to allow
appropriate meta-analysis. Heterogeneity between studies was predicted a priori, mainly due to
differences in cohort start dates and scoring methods. The i-Squared statistic for each model was
found to be consistently above 80%, and therefore random effects models were used throughout.
To investigate possible sources of heterogeneity, scoring method and recruitment year were
entered into meta-regression models and were the basis of two separate stratified analyses. As
there were only ten studies for analysis, these were stratified into two recruitment periods,
1965-1989 and 1990-2000. Not only did this provide equal groupings for stratified analysis, but
around 1990 onwards signified marked changes in clinical management of RA, including early
and more intensive therapies and treat-to-target strategies.
Narrative synthesis of predictive factors
Every marker identified from each study, both significant and non-significant, was recorded and
counted. Where possible, meta-analysis was used to assess the strength of predictive markers.
However, for several predictive markers meta-analysis was not possible because too few studies
conducted or reported analyses in such a way as to make pooling of effects possible and ap-
propriate. Where a meta-analysis was not appropriate a narrative synthesis of the data was
conducted.
3.3 Results
Meta-analysis of long-term radiographic progression
Of the 28 studies identified, ten studies provided the necessary data for meta-analysis[184–192]
(See Table 3.1). Patients were recruited between 1965 and 2000, with follow-up ranging from
5-20 years. The number of patients included with baseline radiographic data ranged from 73-
1121. Four studies used Larsen; six used the SvdH scoring method. Five recruited patients from
1965-1989 and five from 1990-2000.
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Mean 
Baseline (SD)
Annual Rate 
(SE)
Post 1990
Bridges Jr., et al. CLEAR I USA Sharp (448) 357 2000 5 82.4 50 80.1 2.89 (7.65) 1.87 (0.70)
Tanaka, et al. Japan Cohort Japan Sharp (448) 130 1995 10 69 54 54 5 (10.33) 3 (0.23)
Courvoisier, et al. French Cohort France Sharp (448) 117 1993 10 80.3 50.4 78.6 5.8 (9) 3.08 (0.42)
Knevel, et al. Leiden Nether-lands Sharp (448) 678 1993 7 67.4 56.6 57.9 8.74 (10.74) 4.34 (0.11)
Viatte, et al. NOAR UK Larsen (200) 1446 1990 5 68 56 44 10.74 (13.89) 0.83 (0.61)
Pre 1990
James et al. ERAS UK Larsen (200) 1465 1986 9 66.4 55.3 62.7 4.32 (10.13) 2.44 (0.70)
Kuper, et al. Nijmegen Cohort Netherlands Sharp (448) 126 1985 6 64 50 83 1 (16.17) 8 (0.10)
Kapetanovic et al. Lund Cohort Sweden Larsen (200) 135 1985 20 62.8 52.1 83 8.13 (1.47) 3.4 (0.31)
Kaarela et al. Hienola Cohort Finland Larsen (200) 103 1973 20 68 45 100 4.3 (6.8) 4.12 (0.45)
Knevel, et al. Groningen cohort Netherlands Sharp (448) 261 1965 25 67.8 45.1 93.2 3 (56.5) 3.67 (0.50)
% Female Mean Age % RF+
Radiographic Damage
Author Cohort Country Sample Size
Recruitment 
Year
Years 
Follow-up
Scoring Method 
(Max)
Table 3.1: Summary table of studies included with long-term radiographic data
3.3.1 Baseline radiographic score
The first analysis examined baseline radiographic score across the ten studies. The overall rate
of damage at baseline was estimated at 2.02% (95%CI 1.37-2.67) of maximum damage. When
stratified by scoring method, the sub-group pooled estimate for Larsen score was 3.41% (95%CI
1.80-5.01) of maximum damage (6.82 units), and the sub-group pooled estimate for the SvdH
score was 1.20% (95%CI 0.60-1.80) of maximum damage (5.38 units). Studies recruiting patients
between 1965-1989 had a sub-group pooled estimate of 2.01% (95%CI 1.14-2.89) of maximum
damage, and those between 1990-2000 reported a sub-group pooled estimate of 2.03% (95%CI
1.05-3.01) of maximum damage (See Figure 3.2).
3.3.2 Annual rate of change
In the second analysis the overall annual rate of change was estimated at 1.08% (95%CI 0.72-
1.44) of maximum damage. The sub-group pooled estimate for Larsen score was 1.38% (95%CI
1.80-5.01) of maximum damage, or 2.76 units per year, and for the SvdH score was 1.20%
(95%CI 0.88-1.88) of maximum damage, or 4.03 units per year. When stratified by recruitment
periods, 1965-1989 had a sub-group pooled estimate of 1.50% (95%CI 1.08-1.92) of maximum
damage, and for 1990-2000 was 0.68% (95%CI 0.47-0.90) of maximum damage (See Figure 3.3).
Meta-Regression
Although the small sample size (n=10 studies) limits the power to conduct meta-regression
models with appropriate number of covariates, a sensitivity analysis using meta-regression was
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Overall  (I-squared = 96.9%, p = 0.000)
Groningen cohort (1965)
NOAR (1990)
ERAS (1986)
Lund Cohort (1985)
Hienola Cohort (1973)
CLEAR I (2000)
1965-1989
Nijmegen Cohort (1985)
French Cohort (1993)
Subtotal  (I-squared = 98.3%, p = 0.000)
ID
Subtotal  (I-squared = 90.5%, p = 0.000)
Japan Cohort (1995)
Leiden (1993)
1990-2000
Study
2.02 (1.37, 2.67)
1.94 (1.29, 2.60)
5.37 (4.71, 6.03)
2.16 (1.86, 2.46)
4.07 (2.82, 5.31)
2.15 (1.49, 2.81)
0.65 (0.45, 0.84)
0.22 (-0.41, 0.85)
1.29 (0.93, 1.66)
2.03 (1.05, 3.01)
ES (95% CI)
2.01 (1.14, 2.89)
1.12 (0.72, 1.51)
1.95 (1.77, 2.13)
100.00
9.78
9.76
10.62
7.75
9.78
10.75
9.85
10.50
52.22
Weight
47.78
10.44
10.77
%
 Baseline Radiographic Score as % Max Damage 
0-3 3 6
Baseline Radiographic Score Pre and Post 1990
Figure 3.2: Forest plot of baseline radiographic scores stratified by recruitment periods
used to indicate whether differences in baseline and annual progression rates were significant
while controlling for scoring method. It was also important to investigate possible factors that
might influence the overall effect estimate given the high levels of heterogeneity between studies
(i-squared score ranging from 90.5%-98.3%).
In line with visual inspection of stratified effect sizes, the difference of 0.02% for baseline pro-
gression rates was non-significant (p>0.1), while the difference in annual progression rate of
0.79% was significant (p<0.05). Of note is that differences between Larsen and SvdH scoring
methods was not significantly different for annual progression rates (p<0.01), suggesting that
relative increase in either scoring method was comparable.
3.3.3 Predictive markers of long-term
radiographic damage
Forty-one published papers were identified that examined predictive markers of radiographic
joint damage, representing 21 different cohort studies. Despite a number of papers being based
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Overall  (I-squared = 99.1%, p = 0.000)
Lund Cohort (1985)
Japan Cohort (1995)
1965-1989
Leiden (1993)
Groningen cohort (1965)
French Cohort (1993)
Hienola Cohort (1973)
NOAR (1990)
Subtotal  (I-squared = 91.1%, p = 0.000)
Subtotal  (I-squared = 96.3%, p = 0.000)
CLEAR I (2000)
Nijmegen Cohort (1985)
ERAS (1986)
ID
1990-2000
Study
1.08 (0.72, 1.44)
1.69 (1.38, 2.00)
0.67 (0.57, 0.77)
0.97 (0.92, 1.01)
0.82 (0.60, 1.04)
0.69 (0.50, 0.87)
2.06 (1.62, 2.50)
0.41 (-0.19, 1.01)
0.68 (0.47, 0.90)
1.50 (1.08, 1.92)
0.42 (0.11, 0.72)
1.79 (1.74, 1.83)
1.22 (1.05, 1.40)
ES (95% CI)
100.00
9.88
10.56
10.63
10.24
10.36
9.18
8.22
49.66
50.34
9.89
10.64
10.40
Weight
%
 Annual Rate of Radiographic Progression as % Max Damage 
0-1 1 2 3
Annual Rate of Radiographic Progression Pre and Post 1990
Figure 3.3: Forest plot of annual rates of change stratified by recruitment periods
on the same cohort data (See Table 3.2), the analysis techniques used were sufficiently different
from each other to allow their inclusion in the analysis.
A total of 28 studies used the SvdH[117, 185, 190–215] and 13 used the Larsen scoring method[75,
77, 188, 216–225] as the primary outcome measure of radiographic joint damage. A total of 24
of the 41 studies examined radiographic damage at a single time point, while 17 investigated
radiographic damage expressed as a change in score over two time points. A total of 13 studies
transformed radiographic scores into binary variables and 27 treated the radiographic score as
a continuous score. Only one study treated the radiographic score as an ‘event’ for use in a
‘time-to-event’ analysis[223]. In total, 12 different analysis methods were used (Table 3.2).
Acute phase Markers
One of the most reported covariates was ESR, followed by C-Reactive Protein (CRP), both key
markers of the acute-phase response (See Figure 3.5). Of the 15 studies that included ESR,
13 studies reported it as a significant predictor, and of the 11 studies that included CRP 10
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reported it as a significant predictor of radiographic joint damage. Some studies examined
acute phase markers as continuous, others as a categorical predictors, using either pre defined
cut-points, or quartiles. Although there was sufficient data to conduct a meta-analysis, these
differences made formal meta-analysis inappropriate and direct comparison between the effect
estimates unfeasible.
Courvoisier et al.[185] reported that increased ESR indicated over a three-fold increase risk of
a radiological damage score above the median at 10 years. Similar effect estimates were seen
in other studies using similar analysis techniques, where an odds ratio (OR) of 2.7 (CIs not
reported) was reported by Fex et al.[216], an OR of 2.9 (95% CI 1.01-5.88) reported by Tanaka
et al.[192], and an Incidence Rate Ratio (IRR) of 2.0 (95% CI 1.4-3.0) reported by Bukhari et
al.[194]. Using linear regression techniques, Lindqvist et al.[221] reported an average increase of
0.42 (95% CI 0.62-1.04) units of the Larsen Score for every one-unit increase in CRP. Similarly,
Mustila et al.[222] reported that only ESR was significantly associated with radiographic joint
damage at 12, 36, 60 and 84-months in univariate analysis, whereas RF was only significant
at 36 months, and perinuclear Antineutrophil Cytoplasmic Antibodies (pANCA), Antikeratin
Antibodies (AKA), Antiperinuclear Factor (APF) and Age were not associated at any time.
Antinculear Antibodies (ANA) were not investigated in this study.
Anti-Cyclic Protein Antibodies (ACPA) and Rheumatoid Factor (RF)
The presence of ACPA, largely anti-CCP, was reported in 16 studies, with 14 reporting signif-
icant associations. Using linear regression, Lindqvist et al.[221] reported that patients positive
for anti-CCP had on average an increase of 37 units on the Larsen score compared to anti-CCP
negative patients over 10 years, while Nyha¨ll-Wa¨hlin et al.[207] reported an increase of 14.74
over 5 years. Anti-CCP positive patients were also reported to have between a 2.3 and 9.3 fold
increase in risk of rapid radiological progression[201, 210].
The evidence for the predictive role of RF was reported in 21 studies, with 12 reporting sta-
tistical significance. Four studies investigating radiographic progression based on low or high
radiographic damage groups indicated that patients positive for RF were between 1.8 and 2.8
times more likely to have high rates of long-term radiographic joint damage[77, 192, 194, 210].
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To assess the relative strength of anti-CCP and RF, all studies reporting OR and their relative
95%CIs were entered into a random effects meta-analysis. Five of the 13 studies reporting Anti-
CCP, and ten of the 21 studies reporting RF were included in the meta-analysis. Reasons for
exclusion included insufficient data, lack of data on measures of variation, or did not calculate
ORs. The overall pooled effect estimate for anti-CCP was 2.49 (95%CI 1.96-3.15) and for RF
was 2.07 (95%CI 1.61-2.65) (See Figure 3.4). While this does suggest a moderate difference
between the two markers, with Anti-CCP proving to be more strongly associated, the overlap
of the 95%CIs would indicate this difference is non-significant. All five studies included in the
meta-analysis for anti-CCP showed an increased risk, with only one reporting a non-significant
result, which was also the only adjusted effect estimate included[218]. All but two of the studies
included in the RF analysis reported an increased risk[205, 218].
NOTE: Weights are from random effects analysis
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Anti-CCP
Courvoisier, et al.
de Rooy et al.
Houseman, et al.
Kaltenhauser, et al.
Meyer, et al.
Subtotal  (I-squared = 9.5%, p = 0.352)
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Bukhari, et al.
Combe et al.
Courvoisier, et al.
de Rooy et al.
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Kraan, et al.
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Tanaka, et al.
Subtotal  (I-squared = 56.0%, p = 0.015)
HLA-DRB1
Bukhari, et al.
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Park et al.
Subtotal  (I-squared = 68.6%, p = 0.004)
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2.40 (0.63, 9.18)
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2.49 (1.96, 3.15)
2.80 (1.90, 4.10)
3.50 (1.70, 7.00)
3.19 (1.28, 7.91)
1.76 (1.50, 2.02)
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2.78
3.02
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3.96
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6.88
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13.93
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Figure 3.4: Forest Plot of RF, Anti-CCP and HLA-DRB1
Genetic factors
Of the 16 studies investigating the influence of genetic factors on radiographic progression, 12
found a statistically significant association. Four studies used follow-up data of at least 5 years,
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while 12 were restricted to between 3 and 4 years follow-up. ORs for the presence of HLA-
DRB1-SE ranged between 1.31 and 2.6[194, 195, 210]. Constantin et al. demonstrated in two
studies that presence of HLA-DRB1 was associated with increased radiographic progression over
4 years[196, 197].
Seven of the 16 studies provided sufficient data for meta-analysis. A random effects model
indicated an overall pooled estimate of 1.53 (95%CI 1.09-2.14) (see Figure 3.4). Two of the
seven studies included reported a decreased risk[185, 208].
Other factors
The evidence for age and female sex as predictors of radiographic joint damage were limited,
with only 4/12 and 4/15 studies reporting significant results respectively. The reported effect
sizes of both age and sex was low, with age indicating a 1.14[210] and 1.2[194] increase in risk,
and female sex indicating a 25% reduction in risk[210]. The paucity of studies in this review
investigating swollen joint counts, tender joint counts, DAS, Matrix MetalloProteinase-3 (MMP-
3) and functional disability makes it impossible to draw any conclusions about their impact on
radiographic damage. Due to the lack of data provided by studies investigating these predictive
markers, it was not possible to conduct a meta-analysis for these markers.
3.3.4 Quality Assessment
All studies included in this review were assessed for study quality through the use of the Downs
and Blacks Quality Assessment Checklist[180] (See Table 3.7 and Figure 3.6). Generally the
studies were of good quality, all reporting clear aims and objectives, outcome measures and
recruiting representative patients. However, only 3 studies (6%) reported on missing data, and
only 7 (15%) reported on any losses to follow-up over time. The use of appropriate statistical
methods was variable, particularly in the 3-5 year follow-up predictive studies. Only 13 (27%)
were using appropriate statistical methods, many of which used step-wise regression models,
that is the process of systematically removing covariates that do not satisfy a pre-defined level
of statistical significance, that can omit important confounders despite being statistically non-
significant.
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27.	  Did	  the	  study	  have	  suﬃcient	  power	  to	  detect	  a	  clinically	  important	  eﬀect	  where	  the	  probability	  
value	  for	  a	  diﬀerence	  being	  due	  to	  chance	  <5%	  	  
26.	  Were	  losses	  of	  paHents	  to	  follow-­‐up	  taken	  into	  account?	  	  
25.	  Was	  there	  adequate	  adjustment	  for	  confounding	  in	  the	  analyses	  from	  which	  the	  main	  ﬁndings	  
were	  	  drawn?	  
24.	  Was	  the	  randomised	  intervenHon	  assignment	  concealed	  from	  both	  paHents	  and	  health	  care	  
staﬀ	  unHl	  	  recruitment	  was	  complete	  and	  irrevocable?	  
23.	  Were	  study	  subjects	  randomised	  to	  intervenHon	  groups?	  	  
22.	  Were	  study	  subjects	  in	  diﬀerent	  intervenHon	  groups	  (trials	  and	  cohort	  studies)	  or	  were	  the	  
cases	  and	  controls	  (case-­‐control	  studies)	  recruited	  over	  the	  same	  Hme?	  
21.	  Were	  the	  paHents	  in	  diﬀerent	  intervenHon	  groups	  (trials	  and	  cohort	  studies)	  or	  were	  the	  cases	  
and	  controls	  (case-­‐control	  studies)	  recruited	  from	  the	  same	  populaHon?	  
20.	  Were	  the	  main	  outcome	  measures	  used	  accurate	  (valid	  and	  reliable)?	  	  
19.	  Was	  compliance	  with	  the	  intervenHon/s	  reliable?	  	  
18.	  Were	  the	  staHsHcal	  tests	  used	  to	  assess	  the	  main	  outcomes	  appropriate?	  	  
17.	  In	  trials	  and	  cohort	  studies,	  do	  the	  analyses	  adjust	  for	  diﬀerent	  lengths	  of	  follow-­‐up	  of	  
paHents?	  
16.	  If	  any	  of	  the	  results	  of	  the	  study	  were	  based	  on	  “data	  dredging”,	  was	  this	  made	  clear?	  	  
15.	  Was	  an	  aVempt	  made	  to	  blind	  those	  measuring	  the	  main	  outcomes	  of	  the	  intervenHon?	  	  
14.	  Was	  an	  aVempt	  made	  to	  blind	  study	  subjects	  to	  the	  intervenHon	  they	  have	  received?	  	  
13.	  Were	  the	  staﬀ,	  places,	  and	  faciliHes	  where	  the	  paHents	  were	  treated,	  representaHve	  of	  the	  
treatment	  the	  majority	  of	  paHents	  receive?	  
12.	  Were	  those	  subjects	  who	  were	  prepared	  to	  parHcipate	  representaHve	  of	  the	  enHre	  populaHon	  
from	  which	  they	  were	  recruited?	  
11.	  Were	  the	  subjects	  asked	  to	  parHcipate	  in	  the	  study	  representaHve	  of	  the	  enHre	  populaHon	  
from	  which	  they	  were	  recruited?	  
10.	  Have	  actual	  probability	  values	  been	  reported	  	  
9.	  Have	  the	  characterisHcs	  of	  paHents	  lost	  to	  follow-­‐up	  been	  described?	  	  
8.	  Have	  all	  important	  adverse	  events	  that	  may	  be	  a	  consequence	  of	  the	  intervenHon	  been	  
reported?	  	  
7.	  Does	  the	  study	  provide	  esHmates	  of	  the	  random	  variability	  in	  the	  data	  for	  the	  main	  outcomes?	  	  
6.	  Are	  the	  main	  ﬁndings	  of	  the	  study	  clearly	  described?	  	  
5.	  Are	  the	  distribuHons	  of	  principal	  confounders	  in	  each	  group	  of	  subjects	  to	  be	  compared	  clearly	  
described?	  	  
4.	  Are	  the	  intervenHons	  of	  interest	  clearly	  described?	  
3.	  Are	  the	  characterisHcs	  of	  the	  paHents	  included	  in	  the	  study	  clearly	  described?	  	  
2.	  Are	  the	  main	  outcomes	  to	  be	  measured	  clearly	  described	  in	  the	  IntroducHon	  or	  Methods	  
secHon?	  	  
1.	  Is	  the	  hypothesis/aim/objecHve	  of	  the	  study	  clearly	  described?	  
Downs	  and	  Blacks	  Quality	  Assessment	  
Yes	  
No	  
N/A	  
Figure 3.6: Figure of each item of the Downs and Blacks Quality Assessment
3.4 Discussion
Progression of radiographic damage
This review is the first to use meta-analysis techniques to provide more accurate estimates of
overall radiographic damage in patients with early RA, both at presentation and over a 20 year
period. Using data from 10 studies, the overall radiographic damage rate at presentation was
2.02% of maximum damage, and the overall annual rate of progression was 1.08% of maximum
damage.
Previous reports[38] have estimated the total annual radiographic progression rate to be 1.9%
of maximum damage, with the Larsen score progressing 3.8 units per year (2.5% of maximum
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Author Year 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Progression Papers
Bridges Jr., et al. 2010
Courvoisier, et al. 2008
James, et al. 2004
Kapetanovic, et al. 2011 Yes
Kaarela et al. 2002 No
Knevel et al. 2013 N/A
Kuper, et al. 1997
Tanaka, et al. 2005
Viatte, et al. 2013
Predictive Papers
5+ Years Follow-up
Bukhari, et al. 2002
Courvoisier, et al. 2008
Fex, et al. 1997
Fex, et al. 1996
Houseman, et al. 2012
Kaltenhauser, et al. 2007
Kapetanovic, et al. 2011
Kraan, et al. 2004
Kroot et al. 2000
Kuper, et al. 1997
Lindqvist, et al. 2005
McQueen, et al. 2003
Meyer, et al. 2003
Meyer, et al. 2006
Mustila, et al. 2000
Nyhall-Wahlin, et al. 2011
Roux-Lombard, et al. 2001
Sokka, et al. 2004
Tanaka, et al. 2005
Wolfe, et al. 1998
3-5 Years Follow-up
Boyesen et al. 2011
Combe et al. 2001
Constantin et al. 2002a
Constantin et al. 2002b
de Vries et al. 1993
Dixey et al. 2004
Gourraud et al. 2006
Kaltenhauser et al. 2001
Kuiper et al. 2001
Machold et al. 2007
Park et al. 2011
Posthumus et al. 2000
Salaffi et al. 2011
van Aken et al. 2004
van der Helm-van Mil et al. 2005
van der Helm-van Mil et al. 2008
van Gaalen et al. 2004
van Leeuwen et al. 1993
Wagner et al. 2003
Figure 3.7: Table of each study assessed by the Downs and Blacks Quality Assessment
damage) and the SvdH score progressing 4.3 units per year (1.3% of maximum damage) over
the first 15 years. This review provides relatively similar rates, at an overall rate of 1.08% (95%
CI 0.72-1.44) of maximum damage, with Larsen scores progressing 2.76 units per year (1.38% of
maximum damage), and the SvdH score progression at 4.03 units per year (1.20% of maximum
damage) over the first 20 years of disease. The differences in rates between this review, and that
conducted by Scott et al.[38] , are more than likely to be multifaceted. Firstly, meta-analytical
techniques to calculate pooled effect estimates will produce different rates compared to methods
relying only on averages. The former is a more robust method since studies with higher patient
samples are given a higher weighting, thereby reducing the influence of less precise estimates
derived from smaller studies, along with providing an estimate of precision (95%CI). Secondly,
inclusion criteria for this review were different, i.e. only observational cohort studies recruiting
patients with early RA. This ensured a more homogenous study sample, since patients included
in RCTs are highly selected and likely to have higher levels of disease activity and higher rates
of radiographic progression[183, 208], whereas this review describes data based on patients from
‘true-to-life’ clinical settings.
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By stratifying studies by recruitment year, the annual rate of progression in studies recruiting
between 1990-2000 was more than half the rate reported for those recruiting between 1965-
1989. Baseline radiographic damage however, remained similar across the recruitment periods.
The reduction in radiographic progression from 1965-2000 is concordant with data published
by Finckh et al.[226], which indicated decreased radiographic progression rates from 1970 to
1990, and Sokka et al.[224], who found decreased 5-year radiographic progression rates across
three cohorts spanning 1983-1985, 1988-1989 and 1995-1996. Finkch et al. argue that this is
likely to be a consequence of increasingly more intensive therapies, since the effect over time
was diminished once DMARD use was controlled for in their model[226]. More recent data from
RCTs have demonstrated the impact of modern treatment on radiographic progression, with
combination synthetic DMARDs and biologics proving to be effective in slowing the progression
of radiographic joint damage[227], especially when used early, during the ‘Window of Opportu-
nity’[182]. The differences found in the two recruitment periods examined in this review also
coincides with large changes in clinical management, with increased use of early, more inten-
sive treatment in the 1990s, with methotrexate the anchor DMARD, as either monotherapy or
in combination therapies[228]. Indeed, Pincus et al.[229] reported that not only radiographic
related outcomes have improved from 1985 to 2000, but there have also been significant im-
provements in joint scores, functional capacity and mortality outcomes. The extent to which
this is directly attributable to advances in treatment strategies is however difficult to determine,
due to non-randomised study designs[224, 229].
While both the Larsen and SvdH score showed similar levels of annual progression when ex-
pressed as a proportion of maximum damage, it is worth noting the difference between the
scoring methods at baseline. it is likely that these differences in baseline scores is due to dif-
ferences in the way the scoring methods quantify both erosions and JSN, and ultimately the
differences in the maximum value of both scoring methods.
Of interest is the paucity of observational cohort studies in more recent years, which is likely to
be multifactorial. The advent of biologics resulted firstly in many more clinical trials of erosive
damage and secondly led to the development of national biologic registers. In addition, fewer
cohorts may report radiographic assessments.
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Predictive factors of radiographic damage
The predictive factors found in this review are in agreement with review paper by Scott et al.[38],
which found increased levels of acute phase markers and RF positivity to be the most consistent
predictive markers. This review also found strong evidence for the association between anti-CCP
positivity and long-term radiological damage.
In support of the predictive use of acute phase reactants, Navarro-Compa´n et al.[177] recently
published a systematic review specifically on the relationship between radiographic joint damage
and Disease Activity Indices (DAI), such as the Disease Activity Score (DAS). They found that,
while DAIs are clinically useful, the individual components of the DAI’s, particularly SJC and
acute phase markers, were much more predictive of radiographic joint damage compared to DAI
score itself. Interestingly in the current review, the extent to which measures of function and
disease activity were used as covariates was relatively rare, with the majority of studies opting to
examine individual components of disease activity measures, rather than the composite measure
itself.
To the author’s knowledge, this is the first review to summarise evidence of associations of anti-
CCP and genetic factors with radiographic progression in long-term cohort studies. De Rooy et
al.[210] found HLA-DRB1 shared epitopes to increase the risk of radiographic joint damage at
5 years, although this study did not include anti-CCP in the models. More recent studies[230,
231] have highlighted the importance on the dependence of RA related genetic markers on anti-
CCP for associations with radiographic progression. Kaltenhauser et al.[218], reported that
a combination of both anti-CCP and DRB1*04 SE as a compound marker was significantly
associated with increased radiographic damage at 4 years and yielded the highest specificity,
although Kroot et al.(26), found anti-CCP to be significantly associated, but not HLA-DRB4
in multivariate analysis. This evidence is suggestive of an association between SE-positive
alleles and anti-CCP antibodies, however the exact pathogenetic mechanisms are unclear[218].
Further study of specific HLA-DRB1 haplotypes may determine a prognostic role[231], but at
the present time, in the context of current clinical practice, the assessment of genetic markers
does not provide much, if any, additional prognostic value, which is already available in an
ordinary setting.
A number of studies included in the current review[205, 217, 218] found RF was not a significant
predictor in the presence of anti-CCP, suggesting that anti-CCP may be a superior marker of
long-term radiographic damage. This was further evidenced by our meta-analysis, which found
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Anti-CCP to be more highly associated with increased risk of radiographic damage. Although, it
should be noted that differences in specific RF antibodies and titre levels could explain variations
between studies.
Given the large heterogeneity of the methods and analysis techniques used, it was not possible
to conduct a formal meta-analysis that would allow a direct aggregation of these results for
predictive markers. The most likely explanation for contrasting predictive factors is differences in
study design[232]. When investigating novel markers in the absence of multivariate methods, the
importance of well-established factors, such as seropositivity and acute phase reactants, are not
appropriately accounted for[177]. In these cases, it is likely that the effect of the single marker
has been masked, or over-exaggerated in the absence of these other, already established factors.
Novel protein markers, such as MMP-3[201, 223], have been found from this review to have
potentially strong associations with radiographic joint damage, but more evidence is needed,
particularly with large patient samples using appropriate multivariate modelling techniques.
Strengths and limitations
This review is the first to apply meta-analytical techniques to investigate radiographic progres-
sion rates from a large pool of long-term observational cohort studies of patients with early
RA. The methodologies used are novel and provide interesting new insights into the general
progression of radiographic joint damage, and how they have changed over time. This review
has shown evidence for the importance of multivariate analysis, and highlighted the potential
strength of anti-CCP antibodies over RF for predicting both erosive damage and progression in
medium to long-term observational cohort studies. It is unfortunate that while a large number
of studies examining predictive markers have been conducted, the variability between studies
in analytical methods made pooling the results of these studies inappropriate.
A further limitation is that it was not possible to stratify patients based on important disease
markers, such as seropositivity, when modelling radiographic progression rates. The review on
predictive markers presented in this paper highlights the difference in radiographic progression
in patients with anti-CCP positivity. Producing separate radiographic progression rates for
both seropositive and seronegative patients would have been more ideal, as it would allow the
investigation of whether similar patterns that were found in the current review are also observed
in these patient sub-groups.
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It was also not possible to obtain substantive information on the impact of treatment. While
the investigation into recruitment years provides a surrogate marker of changes in treatment
practices, it was not possible to model the effect of treatment directly. Nevertheless, given
the cohorts represent a ‘true-to-life’ clinical setting, those studies that recruit patients during
the same years are likely to be following published guidelines on treatment regimes, and would
therefore be largely similar.
Conclusions
In conclusion, the progression of radiographic damage has more than halved since 1990, with
advances in treatment likely to be the cause. There is good evidence that anti-CCP positivity
is a more consistent and a stronger marker of severe radiographic damage over RF positivity
in the long-term, and increased markers of acute phase reactants have continued to be strongly
associated with radiographic damage. In the context of clinical management, other novel an-
tibodies need further study, and genetic data at present does not prove to be a cost-effective
marker of disease that provides additional prognostic value independent of anti-CCP positivity.
3.5 Concluding remarks
The aim of this chapter was to review the current evidence base and identify common methods
in measuring and reporting radiographic outcomes. Much of this chapter has provided the
background for the primary analyses to be conducted in Chapters 6 and 7. The findings from
the meta-analysis of progression rates indicate that radiographic progression has significantly
fallen post 1990. This will be of interest when the progression of radiographic damage is modelled
in both the ERAS and ERAN cohorts, representing roughly the same transition in time periods.
The review has also highlighted the prominent role that seropositive RA has on increased
radiographic progression, therefore the analysis in Chapter 6 will also explore seropositive and
seronegative sub-groups to ascertain what impact this has on the long-term progression of
radiographic progression in both cohorts.
Critically, this review has demonstrated that the statistical methods used to explore long-term
radiographic data have been varied and often inappropriate. The next chapter of the thesis will
therefore look at the methodological aspects of the thesis. Chapter 4 will introduce the ERAS
and ERAN datasets in detail and explore the radiographic data contained within. Then Chapter
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5 will look at the various statistical methods used in the studies examined in this systematic
review and ascertain which models are most suitable for analysing longitudinal radiographic
data collected in observational studies.
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Author Year Sample Cohort Scoring Method (Max)
Max 
Follow-
up
Data Used for 
Analysis Data Type
Analysis 
Used Multivariate
5+ Years Follow-up
Bukhari, et al. 2002 439 NOAR Larsen (200) 5 Years Single time point Continuous
Negative 
Binomial 
Regression
Yes
Courvoisier, et al. 2008 117 French Cohort Sharp (448) 10 Years Single time point Binary Logistic Regression Yes
de Rooy et al. 2011 676 Leiden Cohort Sharp (448) 5 Years Change in score Continuous Linear Regression Yes
Fex, et al. 1997 113 Lund Cohort Larsen (200) 5 Years Single time point Continuous Linear Regression Yes
Fex, et al. 1996 113 Lund Cohort Larsen (200) 5 Years Change in score Binary Logistic Regression Yes
Houseman, et al. 2012 58 Portsmouth Cohort Sharp (448) 8 Years Change in score Binary Logistic Regression Yes
Kaltenhauser, et al. 2007 93 Leipzig Cohort Larsen (200) 6 Years Single time points Binary Logistic Regression Yes
Kapetanovic, et al. 2011 183 Lund Cohort Larsen (200) 10 Years Single time point Continuous Linear Regression Yes
Kraan, et al. 2004 36 Netherland/Australia Study Larsen (200) 6 Years Change in score Binary
Logistic 
Regression Yes
Kroot et al. 2000 273 Nijmegen Cohort Sharp (448) 6 Years Single time point Continuous Linear Regression Yes
Kuper, et al. 1997 157 Nijmegen Cohort Sharp (448) 6 Years Single time point Continuous Linear Regression Yes
Lindqvist, et al. 2005 157 Lund Cohort Larsen (200) 10 Years Single time points Continuous Linear Regression Yes
McQueen, et al. 2003 31 Auckland Cohort Sharp (448) 6 Years Single time point Continuous Linear Regression Yes
Meyer, et al. 2003 156 French Cohort Sharp (448) 5 Years Single time points Binary Logistic Regression No
Meyer, et al. 2006 99 French Cohort Sharp (448) 5 Years Single time point Binary Logistic Regression No
Mustila, et al. 2000 82 Helsinki Cohort Larsen (210) 7 Years Single time points Binary Logistic Regression Yes
Nyhall-Wahlin, et al. 2011 191 BARFOT Sharp (448) 5 Years Single time points Continuous Linear Regression Yes
Roux-Lombard, et al. 2001 24 Lund Cohort Larsen (200) 5 Years Change in score Survival
Cox 
Regression 
Model
Yes
Sokka, et al. 2004 197 Jyväskylä Cohort Larsen (100) 5 Years Change in score Continuous Quantile Regression Yes
Tanaka, et al. 2005 114 Japan Cohort Sharp (448) 10 Years Change in score Binary Logistic Regression Yes
Welsing et al. 2004 185 Nijmegen Cohort Sharp (448) 9 Years Score at each time point Continuous
Auto-
regressive 
GEE
Yes
Wolfe, et al. 1998 256 Wichita Cohort II Sharp (448) 19 Years Change in score Continuous Linear Regression Yes
3-5 Years Follow-up
Boyesen et al. 2010 55 Diakonhjemmet Cohort Sharp (280) 3 Years Change in score
Continuous - 
Square Root
Linear 
Regression Yes
Combe et al. 2001 172 French Cohort Sharp (448) 3 Years Single time point Binary Logistic Regression Yes
Constantin et al. 2002a 96 Rangueil Cohort Sharp (448) 4 Years Change in score Continuous ANOVA No
Constantin et al. 2002b 96 Rangueil Cohort Sharp (448) 4 Years Single time point Continuous ANOVA No
de Vries et al. 1993 111 Nijmegen Cohort Sharp (448) 3 Years Change in score Continuous - Square Root ANOVA Yes
Dixey et al. 2004 866 ERAS Cohort Larsen (200) 3 Years Single time point Binary Logistic Regression Yes
Gourraud et al. 2006 144 Rangueil Midi-Pyrénées Cohort Sharp (448) 4 Years Single time points Continuous
Rank Sum 
Tests No
Kaltenhauser et al. 2001 48 Leipzig Cohort Larsen (200) 4 Years Change in score at each time point Continuous
Mixed 
Effects 
Linear 
Regression
Yes
Kuiper et al. 2001 332 Nijmegen Cohort Sharp (448) 3 Years Single time point Continuous - Square Root
Linear 
Regression Yes
Machold et al. 2007 55 Austrian Early Arthritis Cohort Larsen (168) 3 Years Change in score Binary
Logistic 
Regression Yes
Park et al. 2010 184 CPR Cohort Sharp (406) 3 Years Change in score at each time point Continuous
Cluster 
Analysis Yes
Posthumus et al. 2000 33 Groningen Cohort Sharp (448) 3 Years Change in score Continuous Correlation Analysis No
Salaffi et al. 2011 48 Italian Cohort Sharp (448) 3 Years Change in score Continuous Linear Regression Yes
van Aken et al. 2004 153 Leiden Cohort Sharp (448) 4 Years Change in score Continuous Rank Sum Tests No
van der Helm-van Mil et al. 2005 324 Leiden Cohort Sharp (448) 4 Years Single time points Continuous Chi-Square No
van der Helm-van Mil et al. 2008 488 Leiden Cohort Sharp (448) 3 Years Single time point Continuous Linear Regression Yes
van Gaalen et al. 2004 268 Leiden Cohort Sharp (448) 4 Years Single time point Continuous Linear Regression Yes
van Leeuwen et al. 1993 110 Groningen/Nijmegen Cohort Sharp (448) 3 Years Single time points Continuous ANOVA Yes
Wagner et al. 2003 77 Leipzig Cohort Larsen (200) 4 Years Single time point Binary Logistic Regression Yes
Table 3.2: Summary table of studies included with predictive factors of long-term radiographic
progression
Chapter 4
Methodology I - Data
4.1 Introduction
The aim of the following two chapters of the thesis is to detail the methodology behind the
primary analyses conducted in Chapters 6 and 7. This chapter marks the first part of this
methodology section, and provides an in depth look at the observational cohorts, which collected
the radiographic data used to conduct the analyses. The second part of the methodology section
detailed in Chapter 5 looks at the statistical models that will be used to analyse this data
appropriately.
The chapter will begin by providing an overview of both the observational cohorts that provided
the primary data for this thesis; ERAS and ERAN. The main focus of this chapter will be on
the radiographic data collected by both these cohorts, including the methods used to score this
data. Specific properties of the radiographic data will then be explored, as understanding the
data in detail will inform the statistical methods used, and is crucial in interpreting radiographic
outcomes. Importantly, since each cohort had the radiographs read by individual readers, the
level of agreement will be assessed by Bland and Altman plots and measures of inter-reader
reliability. This will enable the data from both cohorts to be combined for subsequent analyses.
Finally, the chapter will look at the extent of missing data for the radiographic outcomes and
discuss what limitations and implications this has on the statistical methods used.
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4.2 ERAS and ERAN
Both ERAS and ERAN were briefly introduced in Chapter 2, outlining some of the more
general aspects of the observational studies. While conceptually identical, there were a few
methodological differences between them. By study close, ERAS had recruited 1,465 and ERAN
1,236. While ERAS recruited patients at first presentation to 9 rheumatology outpatient clinics
across the UK, ERAN recruited from 23 centres, two of which were shared between the two
cohorts. These geographical locations were specifically selected to represent as much of the
UK population as possible, including rural, urban and ethnically diverse populations. The
maximum follow-up for ERAS was 25 years (median 10 years), although many centres opted to
stop follow-up at 10 years in line with the studies original aim. As ERAN began much later,
maximum follow-up is 10 years (6 years). Patients were enrolled into the ERAS if they satisfied
the 1987 ACR criteria for RA, had a disease duration of <2 years, and no previous treatment
with DMARDs, whereas patients in ERAN needed to satisfy the 1987 ACR criteria, had a
disease duration of <3 years and some patient had received some treatment prior to first visit.
The data collected on these patients were a myriad of demographic, standard clinical and
laboratory measures; including age, sex, disease activity measured using the DAS 44-joint count
method in ERAS[64] and the DAS28 method in ERAN[65], functional disability measured using
the HAQ[233], biomarkers, such as acute phase markers (ESR), RF status and haemoglobin
(HB), and co-morbidities. Alongside these, more specialised outcome measures not often seen
in observational and clinical trials in early RA were also collated, such as work disability,
psychological wellbeing (Hospital Anxiety and Depression Scale (HADS)[234] and Short-Form 36
(SF-36)[235]) and orthopaedic surgical outcomes. Both cohorts also collected yearly radiographs
on all patients, which were later assessed using both the Larsen scoring method[106] and SvdH
method[101] in ERAS, and the SvdH method in ERAN. The combination of both ERAS and
ERAN provides a powerful database in which data from 2,701 patients with maximum follow-up
of 25 years is available. It documents the changes in clinical management since the 1980s with
the increased used of methotrexate, to the adoption of earlier and more intensive therapies in
the 1990s, and finally the beginnings of the biologic era in RA in the early 2000s.
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ERAS (1986-2001) ERAN (2002-2013) Total
Demographics
Age (Mean (SD)) 55.3 (14.6) 57.1 (14.0) 56.1 (14.4)
Female (%) 66 68 67
Clinical Markers
RF+ (%) 63 60 62
Baseline HAQ (Median (IQR)) 1.00 (1.25) 1.00 (1.13) 1.00 (1.13)
Baseline ESR (Mean (SD)) 42.2 (28.8) 30.3 (24) 37.2 (27.5)
Baseline SJC* (Mean (SD)) 15.5 (9.46) 5.94 (5.74) - (-)
Baseline TJC* (Mean (SD)) 11.7 (8.67) 7.25 (6.89) - (-)
Baseline PGA* (Mean (SD)) 44 (26.4) 43.4 (25.6) - (-)
Baseline Low HB (%) 41 28 35
Months to First Visit (Median (IQR)) 6 (7) 6 (9) 6 (8)
Observations 1465 1236 2701
Note: *SJC, TJC and PGA measured differently in ERAS and ERAN
Table 4.1: Summary Statistics for the ERAS and ERAN cohorts
4.3 Baseline differences between the cohorts
ERAS and ERAN reflect different eras of RA management. As such, improvements in healthcare
nationwide alongside improvements in daily living have led to some notable changes in the
characteristics of patients presenting in both cohorts. Some of these differences can be seen in
Table 4.1. Patients in ERAN tended to present slightly older, reflecting the increasingly ageing
population in the UK. There is some evidence that patients in ERAN were presenting with
less severe forms of RA, with slightly lower proportions of RF positive patients, and marginally
lower ESR scores at baseline. However, direct comparisons using the DAS is made impossible
due to differences in the methods used to measure SJC and TJC. Although, of particular note is
the marked decrease in the proportion of patients in ERAN presenting with low HB compared
to ERAS. This was defined as a HB count of <12 for men and <13 for women.
Treatment strategies used for patients in both ERAS and ERAN reflect the common practices
of RA management in the UK at the time. Patients in ERAS were typically treated with
conventional DMARDs in combination with steroids. DMARDs were commonly prescribed in
sequential monotherapy, with those with more severe disease treated using step-up combination
therapy. The 1990s saw two major advances in the treatment of RA[236]. The first was the
adoption of a pyramidal treatment strategy, whereby more aggressive treatments were prescribed
earlier, and the second was the increased use of methotrexate as the first line DMARD of choice.
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These changes in UK treatment guidelines were reflected towards the later stages of ERAS and
the early stages of ERAN.
Figure 4.1 indicates similar levels of patients on monotherapy treatment, however there is a
marked increase in the use of DMARD add-on and the use of combination DMARD in both
double and triple therapy. ERAN also documents the first cases of early RA patients treated
with biologic DMARDs in the UK.
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Figure 4.1: Prescription of DMARDs in ERAS and ERAN over the first 12 months
Figure 4.2 then highlights the dramatic increase in use of methotrexate as the first DMARD of
choice in ERAN. In ERAS, the most popular DMARD of choice was sulphasalazine, followed
by methotrexate and intramuscular gold.
4.4 Radiographic data
Radiographic data was recorded in ERAS using the SvdH and Larsen scoring method, while
ERAN data was scored using only the SvdH method. These methods were explained in detail
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Figure 4.2: First DMARD of choice in both ERAS and ERAN over the first 12 months
in Chapter 2, but briefly the Larsen score evaluates 42 joints in the hands and feet, and ranges
from 0 to 200. The score incorporates both the prevalence and severity of the erosions and JSN
in one total score. The SvdH score evaluates the same number of joints, and assess the JSN
(0-168) and erosion score (0-280) as separate scores. The total score ranges from 0 to 448.
For ERAS, a total of 1,234 patients had SvdH data and 1,157 patients had Larsen data at any
time between baseline and 9 years follow-up, while for ERAN, a total of 447 had SvdH data at
any time from baseline to 9 years follow-up. A box plot, indicating the total SvdH over the first
9 years for both ERAS and ERAN, is depicted in Figure 4.3 and shows the total SvdH score
increasing at a linear rate over time in ERAS. In contrast, the total SvdH score in ERAN does
not indicate a similar linear progression over time, with the median score increasing at a much
slower rate.
The Larsen score over the first 9 years for the ERAS cohort is depicted in Figure 4.4. Much
like the total SvdH score for ERAS, the Larsen score shows a similar trend over time, with the
median Larsen score increasing at a fairly linear rate. Comparisons between Larsen and SvdH
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Figure 4.3: Box plot of Total SvdH score for ERAS and ERAN over first 9 years follow-up
in the ERAS cohort are difficult given the difference in the way erosions and JSN are scored by
the methods, as well as differences in the maximum scores (Larsen = 200, SvdH = 448).
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Figure 4.4: Box plot of Larsen score for ERAS and ERAN over first 9 years follow-up
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Investigation of both the mean and median scores indicate large differences between the two
across all follow-up measures. Figure 4.5 highlights not only the differences in the progression
of both ERAS and ERAN seen in Figure 4.4 above, but also that the mean score is consistently
estimated to be higher than the median score. Investigation of the Standard Deviation (SD)
also highlights the large variation around the summary estimate, where the SD is often higher
or equal to the mean estimate.
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Figure 4.5: The mean and median score over the first 9 years for the Total SvdH score in
ERAS and ERAN
These differences in summary estimates, along with the high SD relative to the mean, are
suggestive of highly non-normal data distributions. Understanding the properties of the data,
including its underlying data distribution, is pivotal in the interpretation of any summary statis-
tics, as well as guiding the decision about which statistical methods to use to model the data.
As such, the next section will look to explore the data distribution of radiographic outcomes in
more detail.
4.4.1 Data distribution
The histogram in Figure 4.6 depicts the data distribution for the baseline SvdH scores for
patients in the ERAS cohort. The solid red line indicates the mean score at 17.4 (SD 24.7).
This has a variance of 608.4, nearly 35 times higher than the mean. The histogram highlights
that the majority of the data lies on the left, with many patients presenting with no radiographic
damage at baseline. The distribution then shows a large tail on the right, highlighting the high
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positive skew of the data (also driven by the large range of scores seen on the SvdH scoring
method). This high positive skew is denoted by a large positive skewness value of 2.9, confirming
the asymmetry of the data distribution shape. The distribution also estimates a high kurtosis
score of 15.3, highlighting the impact of the extreme values across the range of the score. The
median is shown on the figure as a dashed red line and is reported at 8 (IQR 23), again showing
the difference between these two summary estimates.
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Figure 4.6: Histogram of Baseline Larsen Scores from ERAS. Solid red line indicates the
mean, the dashed red line indicates the median
The fact that the median score lies closer to the left hand side, where the majority of the data
lies, has led to many studies advocating the use of the median, rather than the mean, when
summarising radiographic data[183, 237]. While the data is not shown, similar data distributions
are seen for the Larsen score in ERAS, and the SvdH scores in ERAN. These data distributions
are also consistent across the different follow-up measures.
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4.4.2 Agreement analysis
For the SvdH score, one reader scored the x-rays in ERAS (Keeran Jayakumar) and one reader
scored the x-rays in the ERAN cohort (Daniel McWilliams). To ensure good internal validity of
the score between both cohorts, it is important to test the level of agreement between the two
readers. An agreement analysis was conducted whereby the scorer from ERAN (DM) scored 40
radiographs from the ERAS cohort. A sub-sample of 20 patients from ERAS were chosen at
random, and both their radiograph at 1 year and 5 years were assessed. Due to missing data
from either the erosion or JSN score as a result of unreadable radiographs, only 25 total scores
were analysed.
To assess levels of agreement for these radiographs Bland and Altman plots were used[238].
These plots graph the mean score between the two readers against the difference between the
two readers with an incorporated trend line to highlight changes over the scale of the score[239].
This was calculated for the total SvdH score, JSN score and erosion score.
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Figure 4.7: Bland and Altman plots for the total SvdH, JSN and erosion score. The shaded
grey area indicates the 95% confidence intervals, while the dashed red line shows the mean
difference between the readers
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The Bland and Altman plots for the total SvdH, JSN and erosion score are given in Figure 4.7.
For the total SvdH score and erosion score, there is a small increase in the difference as the
average score increases. This suggests that agreement between the two scorers decreased at the
higher ranges of the radiographic score. For the total JSN score however, the level of agreement
was uniform across the range of the radiographic score.
A common method of measuring the agreement between two continuous measures is to calculate
the Intra-class Correlation Coefficient (ICC). A Pearson correlation coefficient, which is typically
used to summarise the correlation between two variables, would not be appropriate in the
context of agreement. A situation where two readers consistently score the same radiograph
with a difference of 5 units would indicate a near perfect Pearson correlation, but far from
perfect agreement[240]. The Pearson correlation is insufficient because it does not estimate
both the within-subject (intra-observer), and the between subject (inter-observer) reliability. In
contrast the ICC estimates both the within and between subject variability, and can therefore
provide a meaningful coefficient to indicate the level of agreement between two readers. Much
like the Pearson coefficient, a value of 0.3, 0.5 and 0.8 indicate a low, moderate and high effect
size [241].
For the erosion, JSN and total score, the ICC was estimated at 0.95, 0.98 and 0.98 respectively.
This represents a very high level of agreement, indicating that any error between the two scorers
is likely due to measurement error alone, rather than systematic bias between the two scorers.
4.4.3 Missing Data
Missing data is inherent in both RCTs and observational cohorts[242]. This can occur for a
variety of reasons; for RCTs, this is likely to be due to patient drop-outs over the follow-up.
In the context of an observational cohort missing data can occur due to missed clinical visits,
patients moving away, being referred to another hospital or death. Specific to radiographic data,
missing data can also be caused by missing x-ray records, lack of radiographs at follow-up visits
and unreadable radiographs.
The proportion of missing data for the Larsen score in the ERAS cohort was 27%, 35%, 48%,
72% and 74% for baseline and years 3, 5, 7 and 9 respectively. For the SvdH score, the proportion
of patients with missing data in ERAS was 26%, 37%, 52%, 73% and 89% and in ERAN was
58%, 79%, 82%, 99% and 99% for baseline and years 3, 5, 7 and 9 respectively. The extent of
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missing data for the SvdH score and the Larsen score in ERAS is depicted in Figure 4.8, while
the extent of missing data for the SvdH score in ERAN is depicted in Figure 4.9. This is shown
for baseline and follow-up years 1 to 9. Radiographs were collected from all 9 recruiting centres
in ERAS and all 23 recruiting centres in ERAN, however radiographs were only scored from
6/23 centres recruiting patients to ERAN. Investigation of those patients recruited from those
6 centres versus the entire cohort indicated no significant difference in demographic or baseline
clinical characteristics.
Figure 4.8: Missing data for the total SvdH and the Larsen score in ERAS over the first 9
years follow-up
4.5 Discussion
This chapter has provided an in depth overview of the ERAS and ERAN cohorts, along with
the radiographic data collected. It has shown how radiographic outcomes typically produce very
skewed data distributions, largely due to a large number of patients with early RA experiencing
no radiographic damage. This results in a high number of zero scores. The effect of this high
positively skewed distribution is that there is a large discrepancy between the mean and median
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Figure 4.9: Missing data for the total SvdH Score in ERAN over the first 9 years follow-up
summary estimates, along with very large values for the variance, often 20 to 30 times larger
than the mean. Therefore, the median rather than the mean provides a more accurate summary
estimate of the data.
Investigation of the SvdH data from both ERAS and ERAN indicate a tendency for a linear
increase over the first 9 years in ERAS, with a much slower progression in ERAN. While the
agreement analysis conducted does indicate that combining the data from both the ERAS and
ERAN cohort is appropriate, the large amount of missing data from the ERAN cohort does
restrict the statistical power to evaluate trends beyond 5 years in the ERAN data.
The implications of the data distribution on which statistical methods should be used to model
radiographic data will be explored in detail in the second part of the methodology section in
Chapter 5. It will evaluate common statistical methods used in the literature and look at which
model is best placed for accounting for the unique data distribution created from radiographic
outcomes. Finally, it will look at the impact of the missing data in longitudinal data and
evaluate methods for handling this missing data to reduce the bias that can be introduced.
Chapter 5
Methodology II - Statistical Models
5.1 Introduction
Radiographic data produced from scoring methods such as the Larsen and SvdH methods are
well known for producing skewed data distributions[126, 243, 244]. This was highlighted in
the first part of this methodology section (Chapter 4), which explored the radiographic data
from the ERAS and ERAN cohorts. Radiographic scores are more accurately defined as a
semi-continuous weighted count score, where each affected joint is counted, and then weighted
by the severity of the erosions or JSN present. This produces skewed distributions with high
frequencies of zero scores, due to a large number of patients in early RA presenting with no
observable radiographic damage. The non-normality of these radiographic outcomes results
in a wide variety of statistical methods being used in the literature, as was evidence in the
systematic review conducted in Chapter 3. Often the methods used are inappropriate as they
do not account for the unique properties of the radiographic data and violate fundamental
assumptions.
In the context of secondary analyses, large heterogeneity makes it difficult to compare and con-
trast results. Furthermore, while there rarely is a ‘right’ approach to statistical analyses, there
are inherent advantages and disadvantages to the different analysis methods used. Understand-
ing these is imperative, and choosing the most appropriate method to analyse data ensures more
precise and less biased estimates. This will not only allow for a more coherent understanding
of the underlying effect, but general agreement of the most suitable analysis methods will also
reduce the heterogeneity between studies to allow for more effective secondary analyses.
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The objective of this chapter is to address the second aim of the thesis and determine which
statistical methods are best suited to modelling longitudinal radiographic data. To begin, the
chapter will first explore some of the methods used from previous studies identified from the
systematic review conducted in Chapter 3. Using the information gained from Chapter 4 on
the specific properties of radiographic data from the ERAS and ERAN cohorts, the chapter
will begin by looking at the general linear models and why they are not suitable for use on
radiographic data due to the non-normal data distributions they create. The chapter will then
look at Generalised Linear Models (GLM) and the methods that can be used to account for
this non-normality, including logistic regression and two main types of count regression; Poisson
and Negative Binomial (NB). The chapter will focus specifically on count regression methods
and their suitability to modelling radiographic data. The chapter will then look at methods for
modelling longitudinal data, and introduce the concept of multi-level models to analyse data
over time. Finally, the issue of multivariate regression techniques and missing data will be
examined. The ultimate aim of this chapter is to provide a statistical framework, from which
the primary analysis conducted in Chapters 6 and 7 can be based on.
5.2 General Linear Models
Regression analysis is commonly used in the medical literature to develop prognostic models,
whereby the researcher wishes to be able to predict a value of a dependent variable based on
the value of a/several independent variable(s). General linear models is one form of regression
analysis, which is used when the dependent variable being modelled is a continuous outcome. If
only one independent variable is specified in the model, it is referred to as univariate regression,
and if more than one independent variable is used it is referred to as multivariate regression. For
a general linear model to be deemed suitable it must satisfy a range of pre-defined assumptions
concerning the data. The general linear model assumes that: 1) the dependent variable is a
continuous outcome, 2) the relationship between the dependent and independent variable(s) is
linear, 3) each observation is independent, 4) the variance is homoscedastic (i.e. variance is
constant at each value of the dependent variable) and , 5) the residuals (predicted - observed)
are normally distributed.
A simple linear regression with one independent variable (univariate) can be denoted using the
formula given in Equation (5.11), where yi is the dependent variable of the ith observation,
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α denotes the intercept, β denotes the slope, x denotes the independent variable of the ith
observation and ε denotes the error term.
yi = α+ βxi + ε (5.1)
This equation can be extended to multivariate linear regression through the formula given in
Equation (5.2), where β1, β2, and βx is the 1st, 2nd and x th covariate in the model.
yi = α+ β1x1 + β2x2 + ....+ βxxi + ε (5.2)
A linear regression will estimate a coefficient for each covariate in the model, which is interpreted
as the change in the dependent variable given a 1-unit increase in the independent variable.
While it is not a requirement for the outcome to be normally distributed for linear regres-
sion, data that follows a normal distribution is favourable, since skewed data distributions and
extreme outliers can have a large impact on the normality of the residuals. Ensuring the resid-
uals are normally distributed is one of the major assumptions, as it can have a large impact
on the calculation of confidence intervals, and therefore the reliability of the significance test.
In cases where data are highly skewed, and the residuals are found to be highly non-normal,
other regression techniques should be used, which assume some other data distributions that
are non-normal.
5.2.1 Linear regression for radiographic outcomes
As was seen in Chapter 4, radiographic outcomes produce highly positively skewed data distri-
butions. It is therefore likely that linear regression techniques will not be suitable to this data.
This is demonstrated in Figure 5.1, which shows the observed frequency of the baseline Larsen
and SvdH scores (black line with black crosses), along with the predicted probability density
from a general linear model (red line).
As expected, the general linear model fails to adequately model for the large number of zero
scores, and the predicted probabilities tend to be over estimated across the range of the score.
Furthermore, examination of the variance and the distribution of the residuals indicates that the
model violates two key assumptions; homoscedascity of the variance and normally distributed
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Figure 5.1: Observed Score vs. Predicted Probabilities from Linear Regression for the Larsen
and SvdH Score in ERAS
residuals. Figure 5.2 depicts the heteroscedastic nature of radiographic outcomes, with the
variance narrower at the low end, but increased at the high end, while Figure 5.3 shows the
non-normally distributed residuals when applying linear regression to both the baseline Larsen
and SvdH scores.
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Figure 5.2: Residual vs. Fitted Plot to investigate Homoscedasticity for the Larsen and SvdH
Score in ERAS
Despite its unsuitability, linear regression models are widely used in studies investigating the
relationship between radiographic damage and functional disability[245]. The systematic review
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Figure 5.3: Distribution of the Residuals vs. Normal Density plot for the Larsen and SvdH
Score in ERAS
conducted in Chapter 3 identified a host of published papers where linear regression was used
to predict the level of radiographic damage based on data from clinical markers.
5.2.2 Data transformation
A common method for dealing with non-normal data is to transform it using functions that are
known to reduce any positively or negatively skewed data. Common methods include squared,
cubic, natural log, or square-root transformation. The aim is to transform the data so that it
is normally distributed, and then apply general linear models. Once the model estimates have
been estimated from the transformed data, the coefficients are then back-transformed so that
they can be interpreted based on the original scale. The systematic review conducted in Chapter
3 found that square-root transformation was the most popular method of transformation, with
log+1 transformation also being used.
However, the main issue with radiographic data is the preponderance of zero scores. Any method
of transformation will only shift this large frequency count to a different value. This can be
clearly illustrated in Figure 5.4, which shows the baseline SvdH scores being transformed using
square, cubic, square-root, and natural log + 1 transformation methods. In all instances, the
data still exhibits a degree of non-normality as a result of the large frequency of zero scores. In
the case of the natural log +1 transformation, there is evidence of a mixture of distributions,
with a binary zero, non-zero score, then log-normal if damage is present.
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Figure 5.4: Common methods of transformation on Baseline SvdH Scores in ERAS
Figure 5.5 indicates how the use of log+1 transformed data still does not enable the general
linear model to accurately predict the skewed distribution of the radiographic outcomes. In
both the models using the baseline Larsen and total SvdH score, the number of zero scores was
underestimated and the density of the low scores was greatly overestimated.
5.3 Generalised Linear Models (GLM)
and non-normal distributions
This chapter has so far demonstrated that general linear models, even with data transformation,
are not suitable in modelling radiographic outcomes. To address the issue of non-normally
distributed data that is produced by radiographic outcomes, it is therefore imperative that
non-normal models that assume the correct data distributions are used.
Generalised Linear Models (GLM) are extended versions of the general linear model that allow
for the specification of non-normal distributions. Many different data distributions can be
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Figure 5.5: Observed Score vs. Predicted Probabilities from Linear Regression (Log Trans-
formed) for the Larsen and SvdH Score in ERAS
specified, including Bernoulli, Poisson, Gamma, Binomial and multinomial. This section will
focus on the application of the Bernoulli, Poisson and Gamma distributions, which are used to
conduct logistic, Poisson and Negative Binomial (NB) regression. It will look at the application
of these non-normal modelling techniques in the context of radiographic outcomes.
5.3.1 Logistic Regression
Logistic regression is the analysis of binary data. Whereas general linear models apply a normal,
Gaussian distribution, a logistic regression applies a Bernoulli distribution to account for the
dichotomous nature of the dependent variable. The data is modelled using the log of the
dependent variable, and the resulting coefficient is interpreted as the anti-log (exponentiated)
of the log score to create a ratio. Whereas the coefficient from the general linear model is
an estimate of the mean change in the dependent variable for every 1-unit increase in the
independent variable, logistic regression estimates the change in probability for every 1-unit
increase in the independent variable, expressed as an Odds Ratio (OR).
The equation for a simple logistic regression is given in Equation (5.3), where ln
(
P
P−1
)
is the
log of the OR, and P is the probability of belonging in either category. The OR is defined as
the probability of being in the category divided by the probability of not being in the category.
As with the linear regression, α is the intercept parameter, β is the slope parameter, x is the
independent variable and ε is the residual.
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ln
(
P
P − 1
)
= α+ βx + ε (5.3)
The logistic regression model is estimated based on the log of the OR, as this allows any value
of the model parameters to be estimated, while confining the log of the OR between 0 and 1.
The log OR can then be exponentiated to provide the OR.
5.3.1.1 Logistic regression for radiographic outcomes
With radiographic data, categorisation is typically dichotomised into 2 groups consisting of
a ‘low/slow’ group and a ‘high/fast’ group. These groups can be based on the score at the
final follow-up visit, or based on a change in score over time. However, defining the cut-off
is often arbitrary and various different methods are used. These include using the median
value, a value clinically agreed to show clinically meaningful change[122, 246, 247], or a value
determined through statistics, such as the Smallest Detectable Change (SDC)[124]. The SDC
attempts to identify a threshold whereby any increase above this threshold reflects a true,
meaningful increase in radiographic damage, rather than a change that might be expected due
to measurement error alone[248]. For example, if the SDC is found to be 4 Larsen units, then
any changes of less than 4 units may be due to measurement error alone, whereas any change in
score greater than 4 units is likely to indicate true progression. This is particularly important
in studies where the radiographer has scored the x-rays in a random order, and the chances of
negative change, i.e. erosive healing, is more likely[89, 249, 250]. Further still, the method of
estimating the SDC is based on the assumption of normality, with homoscedastic errors. As
was demonstrated in Figure 5.3, the residuals are heteroscedastic, with the variance increasing
at the high end of the radiographic score.
The ability to use statistical methods to quantify measurement error has been investigated, but
with varying degrees of success[248, 251]. While the estimation of SDC and clinically meaningful
change is very similar for the Sharp score, there is less consensus between these thresholds for
the Larsen score, making the decision about what threshold to use more difficult[251]. Deciding
how to categorise the data and which method to use becomes challenging and can introduce
systematic bias if not defined a-priori to the analysis. Furthermore, if the goal is to facilitate
the use of meta-analysis, this becomes difficult if separate studies are using different cut-points,
with varying definitions of ‘high/fast’ progression.
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5.3.2 Count Data
Count data is the number of times an event or outcome of interest occurs. In a clinical context
this could be number of the hospital visits, the number of sick days off work or the number of
times a particular prescription has been administered. In the case of count variables, very often
the underlying distribution is positively skewed, that is the mass of the data distribution is at
the lower end of the scale, with a low mean score, and a variance equal to, or greater than,
the mean. Since the count cannot be negative, the variability of scores above the mean will
typically be higher than those below the mean, meaning that the SD as a measure of variation
is also inappropriate.
When modelling count data, it is therefore imperative that appropriate distributions are speci-
ficed in order to obtain relevant, unbiased and appropriate estimates. A variety of count distri-
butions exist, the two most popular of which are the Poisson and NB. Both the Poisson and NB
distributions can also be extended to account for increased or decreased zero counts, through
the addition of either a zero-inflated or zero-truncated parameter.
The following section will introduce the Poisson and NB distributions and explain how their
application in GLM makes them ideal for analysing count outcomes.
5.3.3 Poisson distribution
The Poisson distribution is outlined in Equation (5.4), where P is the probability, x is the
number of events, e is Euler’s constant, μ is the average number of events and x! is the factorial
of the total number of events.
P (x) =
e−µµx
x!
(5.4)
The mathematical term μ is used in the Poisson distribution to describe both the mean and the
variance of the distribution. The Poisson distribution assumes these are both the same, referred
to as equidispersion. As the value of μ increases (i.e. the number of counts or events increases)
the distribution curve shifts further to the right (See Figure 5.6). When the estimates of μ are
>10, the Poisson distribution is approximately symmetric with a similar cumulative density
function to the normal distribution. The difference however, is that the normal distribution
allows for non-integer values, where as the Poisson does not.
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Figure 5.6: Poisson Probability Distributions
When the Poisson distribution is specified as part of a GLM, each observation i is drawn from
this Poisson distribution with a mean of μ. Since the count of any observation cannot be less
than 0, the linear estimate of the mean is based on log-linear scale. This is shown in Equation
(5.5), where μ is the expected mean, x is the independent variable from the ith observation and
β is the slope.
µi = e
{
x
′
iβ
}
(5.5)
The predicted effect estimate is the exponentiation of the predicted log count, and is interpreted
as a Rate Ratio (RR). That is, the ratio of the expected count divided by the expected count
when the covariate increases by 1 unit, where δ is the change in score. This is depicted in
Equation (5.6).
E(y | x, xk + δ)
E(y | x, xk) = e
βkδ (5.6)
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5.3.4 Negative binomial (NB) distribution
While the Poisson distribution assumes a equidispersion, the NB distribution includes an addi-
tional parameter that accounts for data where the variance is larger than the mean, commonly
referred to as overdispersion. In general, overdispersion is where there is greater variability than
is expected given the chosen statistical test used. In the context of Poisson regression, there is
not an additional parameter whereby the variance can be defined independently of the mean, so
the Poisson regression is unable to model instances where the variance of the outcome is much
larger than the mean of the outcome.
The mean structure of the NB is identical to that seen in the Poisson, and therefore the estimated
mean by both models can be similar. However, it is the standard errors that will change if the
data is found to have overdispersion. The Poisson will have spuriously large z -scores and
therefore small p-values where the variance is larger than the mean, whereas the NB, which
accounts for this overdispersion, will provide accurate estimates of the standard errors, and un-
biased p-values (N.B. It is worth noting that the NB regression can account for underdispersion,
but this is not discussed, since it does not occur in radiographic outcomes).
Pr (yi|xiδi) = e
−µ˜i µ˜yii
yi!
(5.7)
Equation (5.7) shows the equation for the probability distribution of the NB, where δ is the
additional overdispersion parameter, which is drawn from a gamma distribution.
5.3.5 Excess zero scores and zero-inflated models
GLM incorporating a Poisson distribution is a useful way of modelling count data where the
mean and the variance are equal. In cases where the count data has a variance of greater
than the mean, the NB distribution is useful at modelling this overdispersion and estimating
more precise standard errors. This overdispersion is typically caused by high frequency of zero
scores. However, the probability of the zero score occurring in the data may be varied between
observations. As a result, there are instances where modelling the probability of the zero score
occurring is also needed.
Any zero score in count data can be thought to occur in one of two ways. To illustrate this,
an example using the number of fish caught by fishermen will be used. Each observation is a
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fisherman, and the count data is the number of fish caught. They all went on a camping trip
near a river, however, not all of them made it to the river to fish. There were those who went on
the trip and had time to fish in the river, and those that never made it to the river to fish. For
those fishermen who made it to the river, they could have caught any number of fish. For those
that made it to the river, if no fish were caught then their zero score would be considered a
‘sampling zero’, since the zero score occurred as a product of the random sampling distribution.
However, for those who never made it to the river , they would also record a zero score, but their
probability of catching any fish is very different to those who went to the river. As a result, it
would be useful to record these zero scores differently, as ‘structural zeros’, since the structure
of the data means the probability of achieving a non-zero count is different within the group.
A zero-inflated function is a useful way of incorporating this difference in probability of experi-
encing the count outcome (i.e. accounting for sampling zeros). This can be applied to either the
Poisson or NB functions. A Poisson or NB zero-inflated models the data over two-components.
The first component for a Poisson zero-inflated model is depicted in Equation (5.8) an shows
the first binary process of determining structural zeros. The second component is depicted in
(5.9), and shows the count model part for non-zero scores using Poisson distribution introduced
in Equation (5.4), for when x is greater than or equal to 1.
Pr(yj = 0) = pi + (1− pi)e−λ (5.8)
Pr(yj = xi) = (1− pi)λ
xie−λ
hi!
, xi ≥ 1 (5.9)
Understanding whether to use a zero-inflated parameter in either a Poisson or NB model is
dependent on the data structure, and whether the zero scores occur purely as a product of
the sampling distribution, or whether some zero scores could occur due to the fact that the
observation had no opportunity to experience the event.
5.3.5.1 Count models for radiographic data
The use of count data regression models, such as Poisson and NB regression, has been shown
in previous studies to effectively account for these skewed data distributions observed by ra-
diographic data[252–254]. In the systematic review conducted in Chapter 3, two of the studies
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identified used count models to look at predictive markers of radiographic damage[191, 194].
Rather than treating the radiographic score as a continuous outcome, it is treated as a count
outcome, weighted by the severity of the erosion of JSN.
The predicted probability functions of a GLM with a Poisson (blue line) and NB (green line)
distribution specification, applied to both the baseline Larsen and total SvdH score, are depicted
in Figure 5.7.
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Figure 5.7: Observed vs. Predicted Probabilities from PR and NB for the Larsen and SvdH
Score in ERAS
The Poisson (blue line) does not fit the observed data well, mainly due to the excess zero scores.
It also greatly overestimates the scores at the low end of the scale. However, the NB (green
line) does a very good job predicting the observed counts, appropriately accounting for the
overdispersion that is present in the data. In the case of the SvdH score, it would appear that
the NB does underestimate the zero count.
The predicted probability functions for the zero-inflated Poisson and NB models are shown in
Figure 5.8. The zero-inflated Poisson (dashed blue line) is better for modelling the high level
of zero counts compared to the Poisson, but still overestimates the scores at the low-end. The
zero-inflated NB (dashed green line) is similar to the standard NB for the baseline Larsen and
total SvdH score.
The probability density functions have provided a good means of looking at how well each
distribution can accurately model radiographic outcomes. Model fit can also be presented sta-
tistically through the use of the Akaike Information Criterion (AIC) and Bayesian Information
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Figure 5.8: Observed vs. Predicted Probabilities from Zero-inflated PR and NB for the Larsen
and SvdH Score in ERAS
Criterion (BIC) fit statistics. The lower the value of the AIC or BIC, the better the model
fit. Table 5.1 indicates that the NB regression models provided the best AIC and BIC values,
whereas the Poisson provided the worst model fit. For reference, the linear regression model fit
statistics were also supplied.
Linear Poisson NB ZI-Poisson ZI-NB
Larsen Score
Observations 1070 1070 1070 1070 1070
AIC 7904.8 14502.8 4537.5 8899.9 4538.8
BIC 7909.8 14507.8 4547.4 8909.8 4553.8
Total SvdH Score
Observations 1077 1077 1077 1077 1077
AIC 9961.8 31891.9 7978.3 22286.3 7873.0
BIC 9966.8 31896.9 7988.2 22296.2 7888.0
AIC = Akaike information criterion, BIC = Bayesian information criterion
Table 5.1: Model fit statistics of linear and count regression for the total SvdH score in ERAS
In the case of the baseline Larsen score, the NB and zero-inflated NB were very similar, however
the zero-inflated NB was found to provide a small improvement in model fit over the standard
NB for the baseline total SvdH.
Estimation of the proportion of zero counts estimated by each count model is provided in Table
5.2.
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Larsen SvdH
Zero Counts Zero Counts
Observed 0.54 0.25
PR 0.01 0.00
ZI-PR 0.54 0.25
NBR 0.53 0.20
ZI-NBR 0.53 0.20
Table 5.2: Predicted Zero Counts for baseline Larsen and SvdH scores in ERAS
The zero-inflated Poisson, NB and and zero-inflated NB all provide a reasonable estimate of the
zero counts for both the baseline Larsen and total SvdH. Interestingly the zero-inflated Poisson
provides the closest prediction to the observed count for both the Larsen and SvdH. However, the
substantially larger AIC and BIC highlights how in all other aspects, the zero-inflated Poisson
fails to adequately model the data.
To illustrate the impact of model fit on the model estimates, a series of count models will be
applied to the baseline Larsen score and SvdH score (from the ERAS cohort only) with a set
number of covariates of interest; sex, age at disease onset, baseline HAQ, baseline DAS, baseline
HB and RF positivity. As before, the following count models will be estimated: Poisson, zero-
inflated Poisson, NB and zero-inflated NB. The interpretation and prognostic abilities will not
be assessed at this point, and the model is purely being used for illustrative purposes in order to
assess how the goodness of fit impacts on the model estimates when covariates are introduced.
Table 5.3 and Table 5.4 provide the model estimates, including their standard errors, for each
of the four count models. Investigation of the Pearson Chi2, AIC and BIC once again indicates
that both the NB and the zero-inflated NB have consistently lower test statistics compared to
the Poisson and zero-inflated Poisson.
The Poisson typically under estimates the standard errors, thereby increasing the Z -score and
increasing the chances of reporting a significant estimate. Given that the fit statistic is so high
compared to the NB or zero-inflated NB, it can be deduced that these estimates for the standard
errors are biased, and therefore the chances of a Type-I error is greater.
Finally, the difference in the Rate Ratios (RR) between the standard and zero-inflated versions
of both Poisson and NB indicates that additional parameterisation of the excess zero scores as
structural zero scores has a marked effect on the estimation of the effect estimate.
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The connotations of this in the context of radiographic damage is that there could be two types
of RA patients with respect to zero radiographic scores. There are those patients that have
an erosive form of RA, but do not experience any damage (sampling zero), and those with a
form of non-erosive RA, and therefore do not have radiographic damage as they do not have
the capacity to experience the event (structural zero).
Poisson ZI-Poisson NB ZI-NB
Baseline Larsen Score
Female 0.95 0.87 0.86 0.72
(0.03) (0.03) (0.12) (0.11)
Age at Onset 1.03 1.01 1.03 1.02
(0.00) (0.00) (0.00) (0.01)
Baseline HAQ Score 0.97 0.94 1.00 1.04
(0.02) (0.02) (0.11) (0.12)
Baseline DAS Score 1.17 1.05 1.21 1.08
(0.02) (0.02) (0.07) (0.08)
Baseline HB 0.91 0.86 0.89 0.80
(0.00) (0.01) (0.02) (0.04)
RF Positive 1.27 1.16 1.39 1.36
(0.04) (0.04) (0.20) (0.19)
Chi2 12049.1 398.5 440.5 65.3
AIC 13081 8254 4405 4401
BIC 13111 8294 4440 4446
Exponentiated coefficients (IRR); Standard errors in parentheses
Table 5.3: Model Estimates from Count Models on Larsen Scores in ERAS
Finally, the importance of using the NB model to account for the overdispersion between the
mean and the variance can be graphically depicted after running these multivariate models.
Both the mean and variance were estimated for each patient based on modelling the Larsen
and SvdH score. The mean values were then grouped into twenty groups and their associated
variance were depicted in Figure 5.9. It can be seen how for both the baseline Larsen and total
SvdH score, the NB model (blue line) is much better at accounting for the high variance at the
higher mean values when compared to the Poisson model (red line).
5.4 Longitudinal data
Longitudinal data is the process of collecting data on participants at multiple time-points,
sometimes referred to as repeated measures. The time interval between each time-point can
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PR ZI-PR NBR ZI-NBR
Baseline SvdH Score
Female 1.47 1.16 1.44 1.16
(0.02) (0.02) (0.13) (0.10)
Age at Onset 1.04 1.02 1.04 1.02
(0.00) (0.00) (0.00) (0.00)
Baseline HAQ Score 0.94 0.98 0.92 0.97
(0.01) (0.01) (0.07) (0.06)
Baseline DAS Score 1.08 1.01 1.10 1.01
(0.01) (0.01) (0.04) (0.04)
Baseline HB 1.01 0.93 1.01 0.91
(0.00) (0.00) (0.01) (0.02)
RF Positive 1.10 1.04 1.12 1.07
(0.02) (0.02) (0.10) (0.08)
Chi2 164603.8 1624.7 3810.1 94.4
AIC 27220 20016 7763 7666
BIC 27250 20056 7798 7711
Exponentiated coefficients (IRR); Standard errors in parentheses
Table 5.4: Model Estimates from Count Models on SvdH Scores in ERAS
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Figure 5.9: Mean–Variance Relationship for Baseline Larsen and SvdH Scores in ERAS
either be at fixed intervals, such as every year, or unequal. It is not suitable to use cross-
sectional regression techniques, such as those described above, since these models assume that
each observation is independent. In the context of longitudinal data, it is almost certain that a
participant’s score at one time point is highly correlated to their previous or indeed subsequent
scores[255]. To appropriately handle longitudinal data analysis it is crucial to estimate the likely
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intraclass correlation between their time points. There are two main methods in which this can
be appropriately modelled, Generalised Estimating Equations (GEE) and multi-level modelling.
This section will explore both methods, and explain why the use of multi-level models are the
most suitable for modelling longitudinal radiographic outcomes.
5.4.1 Generalised Estimating Equations (GEE)
GEE can be regarded as an extension of GLM, which were defined earlier in this chapter. They
allow the estimation of parameters from GLMs, while incorporating a correlation structure
between observations. GEE can be depicted in the Equation (5.10), where μij is the mean for
the ith subject at the j time point, β is the regression coefficient and V is the variance.
U(β) =
N∑
i=1
∂µij
∂βk
V −1i {Yi − µi(β)} (5.10)
Unlike the other regression methods detailed so far, GEE does not rely on the maximum likeli-
hood estimation (MLE) method of estimating the model parameter. Instead, GEE is described
as a semi-parametric method and does not require specification of the data distribution[256].
This approach is often referred to as a quasilikelihood function and looks at estimating the
population-averaged estimates[256]. As with GLM, categorical and count based distributions
can be specified in any GEE model.
5.4.2 Multi-level modelling
Multi-level modelling, sometimes referred to as mixed-effects or hierarchal models, is a method
that allows the incorporation of multiple levels of data. The general linear model and GLMs,
described so far, assume a single data structure. However, data can often be structured over
multiple levels. They are therefore seen as an extension of GLMs. As with the GEE, observations
within each level of the data are likely to be related to one another, and therefore it is crucial
that the model accounts for the correlation within these levels of data. Classic examples of multi-
level data structures include patients in a study all being recruited from a particular hospital,
or children being assessed in different classes across different schools. In the later example,
each child is clustered within a class, which is clustered within a school, thereby creating 3
‘levels’ of data; child, class and school. In the context of longitudinal data, the additional ‘level’
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of data is time, with each patient having multiple data points. The advantage of multi-level
models over GEE is that level-specific estimates can be obtained, whereas GEE only provides
population-averaged estimates. In longitudinal data, multi-level models allow for the estimation
of individual change over time, as well as the variance between subjects.
The equation for simple linear regression is outlined in Equation (5.11).
yi = β0 + β1xi + ε (5.11)
Where β0 = intercept and β1 = the slope, adjusted by covariate xi in the model, and e =
residual error.
The equation for the multi-level linear regression has some subtle, but important differences as
seen in Equation (5.12). The addition of the j denotes that each parameter will be estimated
for j time point. This is referred to as Level 1 of the multi-level model.
yij = β0j + β1xij + εij (5.12)
Level 2 of the multi-level model is the calculation of the intercept and slope parameter given the
group level mean. Equation (5.13) refers to the constant (intercept) and Equation (5.14) refers
to the subject-specific regression coefficient (slope), where γ00 indicates the overall constant,
γ01 and γ10 indicates the regression coefficient between the dependent variable and the level 1
predictor, and the dependent variable and the level 2 predictor respectively. Finally, u0j and u1j
indicates the error component of the constant and regression coefficient respectively (i.e. the
deviation from the overall intercept/slope and the group level intercept/slope).
β0j = γ00 + γ01Wj + u0j (5.13)
β1j = γ10 + u1j (5.14)
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5.4.3 GEE vs. Multi-level
Both GEE and multi-level modelling appropriately handle the correlated data seen in longitu-
dinal studies, and as such, the decision of which approach to use for any particular study should
be based on the research questions asked.
While GEE benefits from not having to specify the specific data distribution, it is restricted
to only providing population average effects, and not the group level effects that may be of
interest. Secondly, since it does not rely on MLE it cannot handle missing data through ML
techniques, and therefore in cases where data are largely missing, it will be restricting the data
to only those patients with complete data.
In contrast, multi-level models are able to specifically estimate the group level effects, and its
use of MLE enables it to handle missing data in the analysis. As a result however, this does
require the correct specification of the data distribution to ensure the mean and associated
standard errors are appropriately modelled.
Given that this particular thesis is concerned with radiographic data, which does suffer from
missing data, and is also interested in quantifying the group level effect (that is the effect over
time), the multi-level approach was chosen as the preferred method. The next section will
explore its application to radiographic outcomes, and assess how multi-level negative binomial
models accurately fit the data, and the ways in which it handles missing data.
5.4.3.1 Multi-level count models for radiographic outcomes
As was observed in the cross-sectional data of baseline radiographic scores, the skewed distri-
bution of the radiographic score produces different values for the mean and median estimate.
Figure 5.10 demonstrates how the radiographic score can be much higher at any point in time
when looking at the mean compared to the median score over time of the Larsen and SvdH data
in ERAS.
To illustrate the need for using multi-level models, the total SvdH scores for patients in the ERAS
are plotted in Figure 5.11 along with a Locally Weighted Scatterplot Smoothing (LOWESS) of
this data. The plot highlights a large variation in the total SvdH score at baseline (intercept)
and different rates of progression over the 9 years follow-up (slopes). A multi-level model will
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Figure 5.10: Mean and median Larsen and SvdH scores over the first 9 years for ERAS
patients
allow for the intercepts and slopes to vary over individuals, thereby accounting for the additional
variance within, as well as between individuals.
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Figure 5.11: The total SvdH score (grey plot) and LOWESS smoother (black plot) over the
first 9 years for patients in ERAS
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As with the cross-sectional data earlier in the chapter, comparisons between the Poisson and
NB models can also be compared in the multi-level context. To understand how the multi-level
Poisson and NB regression methods differ in modelling change over time, the estimated sample
means for the Larsen and SvdH score from the ERAS dataset have been calculated using each
of these models. The estimates are given in Table 5.5 and graphed in Figure 5.12.
Larsen Total SvdH
Poisson NB Poisson NB
Follow-up Year 1.20 1.28 1.20 1.27
(0.002) (0.006) (0.001) (0.005)
Chi2 16199.02 2436.88 44233.33 4003.53
AIC 48773 38381 74669 51394
BIC 48793 38408 74689 51421
Exponentiated coefficients - Rate Ratios (RR); Standard errors in parentheses
Table 5.5: Estimated yearly progression rates for the Larsen and total SvdH Score using
multi-level Poisson and NB regression in ERAS
0
10
20
30
La
rs
en
 S
co
re
0 1 2 3 4 5 6 7 8 9
Year
Poisson
Negative-Binomial
Estimated Larsen Rates
0
25
50
75
10
0
12
5
To
ta
l S
vd
H 
Sc
or
e
0 1 2 3 4 5 6 7 8 9
Year
Poisson
Negative-Binomial
Estimated SvdH Rates
Figure 5.12: Estimated radiographic rates over first 9 years for the Poisson and NB multi-level
models for the Larsen and SvdH Score in ERAS
The estimated coefficients and standard errors for the follow-up year covariate (slope) for both
the Larsen score and the total SvdH score are shown in Table 5.5. For both radiographic scores,
the coefficient and the associated standard errors are smaller for the Poisson compared to the
NB. Given the lower Chi2 test, AIC and BIC, it can be concluded that the multi-level NB
provides better model fit, and therefore a less biased estimate of the yearly progression.ftb
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The differences in yearly progression are also highlighted in Figure 5.12, which illustrates how
the NB has accelerated progression from year 5 and onwards.
5.4.3.2 Multi-level models and missing data
Chapter 4 outlined the extent of missing data for both radiographic outcomes in ERAS and
ERAN. The application of general linear models and non-linear GLMs for cross-sectional data
will exclude patients case-wise, meaning that a case, or patient, with any missing data will result
in the complete omission of that case in the analysis. This is commonly referred to as ‘complete
case analysis’. Complete case analysis makes various assumptions about the characteristics of
those cases that have been omitted. In order to assume that the complete case analysis is
not biased by the fact that it only includes patients with complete data, it assumes that all
those cases with missing data are missing at random. That is to say that their characteristics
are similar to those cases included in the complete case analysis, and that if their data were
complete, and they were included in the analysis, similar effect estimates would be obtained.
Whether this assumption is valid can be difficult to ascertain. Understanding the nature of the
missing data is the first step, and understanding whether the data is indeed Missing At Random
(MAR), or whether there could be a reason for the missing data, can help understand whether
there is any bias in a complete case analysis.
Once the the data is assumed to be MAR, various methods can be applied to impute this missing
data to reduce the bias inherent in complete case analysis. Various methods have been devised,
such as mean imputation; however these methods have been shown to bias results further than
complete case analysis, as they artificially accentuate any mean effect by reducing the variance
around the mean point estimate. In contrast, multiple imputation chained equations (MICE)
have been recommended as a more appropriate way of reducing the bias from missing data.
Using data from the outcome of interest, as well as covariates included in the model, MICE
imputes data using chained equations to provide a range of imputed values that could represent
the missing value. These imputations are then combined under Rubins Rule[257] to estimate
one specific value for estimation in the analysis. Simulation data has shown the use of MICE
to provide more robust and less biased effect estimates, namely standard errors[242].
With longitudinal data, missing data is even more likely to occur, and attrition is likely to
increase over the follow-up period. Unlike GLM, which as we discussed will omit cases with
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missing data list wise, multi-level modelling has the advantage of using full-information max-
imum likelihood (FIML) estimation. For example, if a patient only has radiographic data at
baseline and year 3, that data will be used to estimate the rate over the full follow-up pe-
riod, thereby maximising all information for the model. While the methods are very different
to MICE, the assumptions are similar and studies have shown it to yield similar results[258].
However, it must be noted that MICE is able to impute values for missing predictor variables,
as well as the dependent variable, whereas multi-levelling methods will only apply FIML esti-
mation for the dependent variable. Multiple Imputation methods in multi-level modelling has
received little attention, however methods are being explored, and the added benefit of using
these more complicated models where missing data for the independent variables are low is not
clear[259].
5.5 Multivariate models
In epidemiology, choosing the covariates to include in a predictive model is challenging[260].
There is a variety of different methods available to the researcher when deciding which variables
to include, and which to exclude. Some of these methods rely on prior theory and knowledge
generated from previous studies, while other methods look at developing statistical algorithms
that aim to include only those variables that, for example, satisfy a pre-defined level of statistical
significance.
In 2009, Walter and Tiemeier[260] looked at current practices involving variable selection in
epidemiological studies. They found the most common methods used were either based on prior
knowledge, automated techniques, such as stepwise selection, or a combination of the two. This
was directly in line with the systematic review on predictive factors of radiographic progression
in Chapter 3. Selecting variables based on previous research remains the most encouraged
method of model building amongst statistical circles[260], however Walter and Tiemeier argue
that more referencing of the previous research is needed so that the rationale behind its selection
can be discussed and examined.
In contrast, the use of statistical methods to determine which covariates to include, such as
stepwise selection, is highly debated in epidemiological research[260–262]. Stepwise selection
looks at systematically including each variable in the data based on a pre-defined statistical
criterion. The most popular of which is the statistical significance level, whereby only those
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variables below a certain significance level are included. While other statistical criteria, such as
the information criterion, are much more favoured, they are rarely used. This is likely due to
the way in which most statistical software packages apply stepwise selection, where the default
is commonly based on the significance test.
5.6 Discussion
This chapter looked at addressing the second aim of the thesis; to provide a strong statistical
framework for the primary analyses conducted in the subsequent chapters. There is seldom a
‘one size fits all’ approach to statistical analysis. Often there are multiple methods available to
researchers to summarise the data, and provide evidence on a given hypothesis. However, this
chapter has provided a comprehensive overview of the modelling methods typically used to look
at radiographic data, which were identified from the systematic review conducted in Chapter
3. This chapter has highlighted why the skewed data distribution of radiographic outcomes
renders general linear models inappropriate, even following data transformation techniques.
While categorisation of the radiographic score to conduct logistic regression does overcome the
issues with the skewed distribution, other assumptions about how the data should be categorised
have also been shown to introduce bias. Although this chapter has demonstrated the inherent
bias with adopting these modelling techniques to radiographic outcomes, the interpretation and
conclusions drawn from the literature which have applied these methods are unlikely to change
completely. However, the magnitude of the effect estimates, and ultimately the precision of the
standard errors, and therefore the confidence intervals and associated level of significance could
be over estimated.
An in-depth assessment of count regression models was undertaken, along with their suitability
in modelling radiographic outcomes. The high preponderance of zero scores, along with large
overdispersion, led to the conclusion that NB regression models were able to provide the most
precise effect estimates with the best model fit. This was in comparison to other count models,
such as Poisson regression. The chapter also explored the use of zero-inflated count models
and the impact this has on the theoretical conception of zero scores in radiographic damage.
The use of zero-inflated parameters would suggest that forms of non-erosive RA exist, and
therefore the estimates would be adjusted based on the probability that some patients will not
experience any damage throughout the course of the disease. However, while there are patients
that do not exhibit radiographic damage, it is unclear whether they have a specific form of the
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disease that would mean they would never develop radiographic damage. A recent study[263],
using primary cross-sectional data and secondary data from a systematic review, found that the
prevalence of non-erosive RA was rare, only occurring in around 2% of established RA patients.
The justification for the use of zero-inflated NB over NB regression is therefore not valid from
a theoretical or statistical stand-point.
With longitudinal data, it is important that appropriate methods are used to account for the
correlated data structure. This chapter looked at two popular methods, GEE and multi-level
modelling. Given the interest of cluster-specific estimates, and the use of FMIL estimators,
the multi-level procedure was favoured and this section went on to explore how the multi-level
NB regression continued to provide best model fit to longitudinal data compared to multi-level
Poisson regression methods.
This chapter also highlighted the importance of accounting for missing data in a study, partic-
ularly in longitudinal observational studies where missing data is likely to occur over time. The
role of MICE in reducing the bias of complete case analysis was discussed, as well as the inherent
benefit of multi-level models, given their use of FMIL estimators. Finally, the chapter looked
at the importance of multivariate methods, as well as the correct methods for model building.
While automated procedures, such as stepwise selection, remain popular, they are typically
chosen based solely on their level of significance. This can result in two main problems. Firstly,
it can omit variables of interest that while non-significant, are important to control for in order
to produce unbiased estimates for the variables of interest. Secondly, they are often based on
arbitrary thresholds of significance, which can lead to selection bias and overestimation of the
standard errors and overall model fit[264]. This results in capitalisation on chance findings,
where effect estimates are larger in the sample than might be found in the true population.
In summary, radiographic damage provides complex data that, in the context of longitudinal
analysis, is increasingly more complex to model. This section has shown the appropriateness of
count models, specifically NB regression in both the cross-sectional and longitudinal context.
These models will be used throughout the thesis in order to establish the progression of radio-
graphic damage in both the ERAS and ERAN cohort, as well as its association with disease
activity and functional disability over time.
Chapter 6
Secular Declines in Radiographic
Damage
6.1 Introduction
Published literature has suggested that the incidence of Rheumatoid Arthritis (RA) has de-
clined over the last three decades[5, 19, 20, 265–270]. This corresponds with reports of declines
in disease activity[271, 272], functional disability[226, 273], orthopaedic surgery [274] and ra-
diographic progression[224, 226, 275].
While the causal nature of this decline is not entirely clear, it is hypothesised that these
declines in disease severity are related to widespread changes in treatment strategies during
the 1990s[229]. Data from RCTs has demonstrated that early initiation of conventional syn-
thetic DMARDs can significantly improve patient outcomes, particularly the increased use
of methotrexate in combination with other DMARDs[53, 142, 276, 277], and indeed biologic
DMARDs[56, 149, 151, 152].
Radiographic joint damage is often used in RCTs as a primary outcome, and has been shown
to be strongly related to levels of functional disability[86] and disease activity[177]. Although
commonly expressed as a global score[278], radiographic joint damage comprises of two main
components; erosions and joint space narrowing (JSN). While related, they are thought to be the
result of two distinct pathophysiological mechanisms[279, 280]. Possible causes of erosive joint
destruction is the product of invading synovium into the boney structures of the joints, and in-
creased osteoclast activity[93]. Likewise, JSN has been hypothesised to reflect cartilage damage
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as a result of metalloproteinases, which are upregulated by pro-inflammatory cytokines[94]. JSN
is common to a range of pathologies, including osteoarthritis (OA), and is a common comorbid
condition in people with RA[281]. Despite this, much of the focus of longitudinal data concern-
ing radiographic damage has reported the combination of these two processes as one composite
score[279, 280], for example using the radiographic scoring methods of Ratingen or Larsen, that
lack the ability to distinguish progression of erosions and JSN as separate domains[224, 226,
275].
Further still, seropositive status has been strongly associated with worse radiographic progres-
sion[38, 282]. However, to date no study has looked at whether the relative strength of this
association has changed given the wider demographic changes seen in many other aspects of
RA, including disease severity. It might be hypothesised that radiographic measures of RA
will show significant changes given recent declines in disease activity, but whether previously
demonstrated risk factors for progression continue to be influential remains unclear.
The aim of this chapter is to present the first analysis looking at the progression of radiographic
damage in both the ERAS and ERAN cohorts. This chapter will address the third aim of the
thesis and look at the natural progression of radiographic damage in early RA. Furthermore, this
chapter will look to extend the findings of the meta-analysis conducted in Chapter 3 and examine
whether the progression of radiographic damage has changed between ERAS and ERAN. Using
radiographic data from the SvdH, the total score, as well as the separate JSN and erosion
score will be investigated. The review also highlighted how seropositive RA remains one of the
strongest predictors of increased damage, so the association of seropositive RA on long-term
radiographic progression within each cohort will also be examined.
6.2 Methods
6.2.1 Sample
The analysis focuses on a sub-sample of patients from both the ERAS and ERAN cohorts with
SvdH data over the first 5 years follow-up. The sub-sample consists of a total of 1,662 with SvdH
data. Of these, 1,216 were from ERAS, while 446 were from ERAN. Due to the availability of
data from the ERAN cohort, the analysis was restricted to just the first 5 years. This was to
allow direct comparisons between the cohorts, and although data up to 9 years was available,
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the substantial amount of missing data would have resulted in imprecise estimates during years
5 to 9.
6.2.2 Statistical analysis
To assess differences in the use of first-line conventional DMARDs between the two cohorts, the
cumulative incidence of time to first DMARD within the first 12 months from first outpatient
appointment was estimated. This was estimated for any DMARD use, as well as separate esti-
mates for the two most commonly used first-line DMARDS; methotrexate and sulphazalasine.
As was established in Chapter 5, a multi-level NB regression will be used to model the progres-
sion of radiographic damage in both cohorts. Cohort membership (either ERAS or ERAN) was
the main covariate of interest. To assess the impact of missing data and the potential selection
bias that may occur as a result, a sensitivity analysis based on the availability of radiographs
will investigate the baseline characteristics of those with and without radiographic data. Fur-
thermore, as detailed in Chapter 5, the use of multi-level models with FIML estimators ensures
the use of all available data under the missing at random assumption, so that all patients with
data are included.
To model the progression of radiographic damage, time was defined as years from enrolment
and was included as a continuous variable. The maximum number of years follow-up was 5
years. Seropositive RA was the secondary covariate of interest and entered as a main effect,
along with a three-way interaction term with cohort and time to allow for progression rates to
be estimated separately by seropositivity status for each cohort. Sex, age, DAS28, HAQ, low
Hb (<12/13), months from symptom onset to first rheumatology visit, steroid use prior to first
assessment and DMARD use within first 12 months were all entered into the model to control
for any potential confounding effects. To allow direct comparisons of the DAS score between the
two cohorts, the DAS-44 score was transformed to the DAS28 score using the formula outlined
by van Gestel et al.[67].
To aid interpretation, the results from the models were also expressed as an absolute change
in the SvdH score using the estimated mean SvdH, along with 95% Confidence Intervals [95%
CI]. This allowed for a more direct interpretation of the effect that each factor had in terms
of absolute difference in SvdH units, the percentage of maximum possible damage, and annual
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progression greater than the minimum clinically important difference of 5 units[283]. These
models were estimated separately for the total SvdH score, JSN and erosion score.
6.3 Results
The demographic and baseline clinical characteristics of both ERAS and ERAN patients, includ-
ing only those with radiographic data, are shown in Table 6.1. Reasons for missing radiographic
data included loss of records, unreadable radiographs and loss to follow-up. Patients from ERAS
were marginally younger at presentation and had higher DAS28, ESR, HAQ and more likely to
be anaemic at baseline. Patient’s characteristics with recorded radiographic data were similar
to the total number of patients in their respective cohort.
Differences in treatment strategies between the two Cohorts
For all DMARDs, ERAS reported a 12-month cumulative incidence of 71.6% [95%CI 69.2-73.8]
and for ERAN 95.3% [95%CI 93.9-96.4] (See Figure 6.1). The 12-month cumulative incidence
of sulfasalazine use was higher in ERAS (55% [95%CI 52.4-57.5]) than ERAN (33.1% [95%CI
30.4-35.8]), while methotrexate use was substantially lower in ERAS (1.4% [95%CI 0.9-2.1])
compared to ERAN (52.1% [95%CI 49.2-55.0]).
6.3.1 Radiographic progression rates of ERAS and ERAN
For the Mixed Effects Negative-Binomial Regression (MENBR) analysis, a total of 1,508 patients
contributing 5,430 observations (mean observations per patient = 3.6) were included. Overall,
the ERAN cohort exhibited a 41% lower total SvdH score at baseline compared to ERAS
(Exponentiated coefficient 0.59 [95%CI 0.50-0.70], p<0.001), along with a 65% slower annual
rate of progression over the first 5 years (Exponentiated coefficient 0.35 [95%CI 0.24-0.47],
p<0.001) (See Figure 6.2). The differences in absolute and relative scores for both cohorts are
shown in Table 6.2. When expressed as a proportion of maximum possible damage, the estimated
values indicated an increase of 1.5% [95%CI 1.4-1.7] per year for ERAS and 0.6% [95%CI 0.4-
0.7] per year for ERAN. The total proportion of patients who had annual progression estimated
to be greater than the MCID (>5 SvdH units) was 74% for ERAS and 27% for ERAN.
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Figure 6.1: 12-month cumulative incidence of DMARD use for ERAS and ERAN
Similar results were seen for the JSN score, with ERAN participants displaying lower scores
at baseline (Exponentiated coefficient 0.49 [95%CI 0.41-0.58], p<0.001) and a slower annual
rate of progression over the first 5-years compared to ERAS (Exponentiated coefficient 0.31
[95%CI 0.21-0.42], p<0.001) (See Figure 6.3A). For the erosion score, the score at baseline was
similar for both cohorts (Exponentiated coefficient 0.94 [95%CI 0.73-1.19], p=0.593), however,
ERAN exhibited a slower annual rate of progression over the first 5-years compared to ERAS
(Exponentiated coefficient 0.43 [95%CI 0.25-0.61], p<0.001) (See Figure 6.3B). See Table 6.2
for absolute and relative changes in both JSN and erosion scores between the two cohorts.
6.3.2 Association of seropositivity with radiographic progression
The absolute and relative difference in total SvdH scores for seropositive and seronegative pa-
tients in both cohorts are given in Table 6.3 and displayed graphically in Figure 6.4. For the
total SvdH score, seropositive RA was not significantly associated with increased radiographic
damage at baseline, compared to seronegative RA in either ERAS or ERAN. Seropositive RA
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Figure 6.2: Progression of Total SvdH score for ERAS and ERAN. Shaded red and blue area
denotes the 95% Confidence Intervals for ERAS and ERAN respectively
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Figure 6.3: Progression of JSN and erosion score for ERAS and ERAN. Shaded red and blue
area denotes the 95% Confidence Intervals for ERAS and ERAN respectively
was associated with a 70% increased annual rate of progression, compared to seronegative RA,
in ERAS, which was statistically significant (Exponentiated coefficient 1.70 [95% CI 1.42-1.97],
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Estimated)
means) ERAS) ERAN)
Absolute)
Difference)
Relative)
Difference)(IRR))
[95%)CI])
)
PBValue)
Total)SvdH)at)
baseline)
10.5) 6.2) 4.3)) 0.59%[0.50'0.70]%% <0.001%
Total)SvdH)
annual)rate) 6.9) 2.5) 4.5)) 0.35%[0.24'0.47]%% <0.001%
JSN)score)at)
baseline) 7.4) 3.6) 3.8)) 0.49%[0.41'0.58]%% <0.001%
JSN)score)
annual)rate) 3.9) 1.2) 2.7)) 0.31%[0.21'0.42]%% <0.001%
Erosion)score)
at)baseline)
1.8) 1.7) 0.1)) 0.94)[0.73B1.19])) 0.593)
Erosion)score)
annual)rate)
1.9) 0.8) 1.1)) 0.43%[0.25'0.61]%% <0.001%!
Table 6.2: Mean and relative difference in baseline level and annual rate of progression for
Total SvdH, JSN and erosion scores between ERAS and ERAN
p<0.001). The annual rate of progression for seropositive RA, compared to seronegative RA,
in ERAN was increased by 9%, which was not significant (Exponentiated coefficient 1.09 [95%
CI 0.51-1.67], p=0.855). This relates to decreases in the relative impact of seropositive RA on
the annual rate of progression of 36% for ERAN compared to ERAS, which although consider-
able was non-significant, as indicated by the three-way interaction in the model (Exponentiated
coefficient 0.64 [95%CI 0.29-1.07], p=0.224). The estimated proportion of seropositive patients
with an annual progression greater than the MCID was 80% for ERAS, and just 29% for ERAN.
!
!! RF$! RF+! Difference!
Relative!
Difference!(IRR)!
[95%!CI]!
P$Value!
ERAS!
Total!SvdH!
at!baseline! 9.5! 11! 1.5! 1.16![1.00$1.35]! 0.056!
Total!SvdH!
Annual!rate! 5.1! 8.6! 3.6! 1.70%[1.42)1.97]% <0.001%
ERAN!
Total!SvdH!
at!baseline! 6.0! 6.2! 0.2! 1.04![0.76$1.42]! 0.811!
Total!SvdH!
Annual!rate! 1.9! 2.0! 0.2! 1.09![0.51$1.67]! 0.855!!
Table 6.3: Mean and relative difference in baseline level and annual rate of progression for
Total SvdH score between seropositive and seronegative patients by both ERAS and ERAN
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Figure 6.4: Progression of Total SvdH score for ERAS and ERAN by seropostive status.
Shaded red and blue area denotes the 95% Confidence Intervals for ERAS and ERAN respec-
tively
The influence of seropositive RA on the separate JSN compared to seronegative RA indicated
a similar pattern to the total SvdH score (See Table 6.4 and Figure 6.5A). Seropositive RA was
not associated with increased JSN scores at baseline for either ERAS (Exponentiated coefficient
1.12 [95% CI 0.96-1.31], p=0.152) or ERAN (Exponentiated coefficient 0.92 [95% CI 0.67-
1.27], p=0.619), but was associated with a relative increase in the annual rate of progression.
When compared to seronegative RA, seropositive RA indicated a statistically significant increase
of 58% (Exponentiated coefficient 1.58 [95% CI 1.32-1.84], p<0.001) and a statistically non-
significant increase of 19% (Exponentiated coefficient 1.19 [95% CI 0.35-2.02], p=0.480) for
ERAS and ERAN respectively. The relative difference in the increased annual rate of progression
of JSN scores for seropositive RA in ERAS compared to ERAN was not significantly different,
as indicated by the three-way interaction term in the model (Exponentiated coefficient 0.72
[95% CI 0.26-1.18], p=650).
Differing from the JSN score, seropositive RA was associated with a 40% increased erosion
score at baseline, compared to seronegative RA, in ERAS (Exponentiated coefficient 1.40 [95%
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CI 1.12-1.75], p=0.003). The relative difference was reduced and non-significant for ERAN at
baseline (Exponentiated coefficient 1.17 [95% CI 0.74-1.85], p=0.495). Seropositive RA was
associated with relative increases in the annual rate of progression, compared to seronegative
RA, with a statistically significant increase of 107% (Exponentiated coefficient 2.07 [95% CI
1.61-2.52], p<0.001) and statistically non-significany increase of 21% (Exponentiated coefficient
1.21 [95% CI 0.28-2.14], p= 0.929) for ERAS and ERAN respectively (See Table 6.4 and Figure
6.5B). The relative impact of seropositive RA was reduced in ERAN, however this was non-
significantly different when compared to ERAS, as indicated by the three-way interaction term
in the model (Exponentiated coefficient 0.92 [95% CI 0.81-1.05], p=0.234).
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Figure 6.5: Progression of the JSN and erosion score for ERAS and ERAN by seropostive
status. Shaded red and blue area denotes the 95% Confidence Intervals for ERAS and ERAN
respectively
6.4 Discussion
The findings from the analysis indicates that patients with early RA with onset from 2002-2013
(ERAN) had significantly lower baseline and annual rates of radiographic progression compared
to those with onset from 1986-2001 (ERAS). Examination of the separate erosion and JSN scores
indicate that the reduction in the total SvdH score was largely driven by reductions in JSN.
Strikingly, the strong association of seropositivity and increased radiographic progression in
ERAS was markedly diminished in ERAN. The reduction in the impact of seropositive RA was
such that those with seropositive status in the ERAN cohort had markedly better radiographic
outcomes at 5 years than those with seronegative RA in ERAS.
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!
!! RF$! RF+! Absolute!Difference!
Relative!
Difference!(IRR)!
[95%!CI]!
P$Value!
ERAS!
Total!JSN!at!
baseline! 6.9! 7.7! 0.8! 1.12![0.96$1.31]! 0.152!
Total!JSN!
Annual!rate! 2.9! 4.6! 1.7! 1.58%[1.32)1.84]% <0.001%
ERAN!
Total!JSN!at!
baseline! 3.8! 3.5! 0.3! 0.92![0.67$1.27]! 0.619!
Total!JSN!
Annual!rate! 1.1! 1.3! 0.2! 1.19![0.35$2.02]! 0.480!
ERAS!
Total!Erosion!
at!baseline! 1.5! 2.0! 0.6! 1.40%[1.12)1.75]% 0.003%
Total!Erosion!
Annual!rate! 1.2! 2.4! 1.3! 2.07%[1.61)2.52]% <0.001%
ERAN!
Total!Erosion!
at!baseline! 1.5! 1.8! 0.3! 1.17![0.74$1.85]! 0.495!
Total!Erosion!
Annual!rate! 0.7! 0.9! 0.2! 1.21![0.28$2.14]! 0.929!
 
Table 6.4: Mean and relative difference in baseline level and annual rate of progression for
Total SvdH score between seropositive and seronegative patients by both ERAS and ERAN
Previous research has indicated that a change of 5 SvdH units indicates a minimal clinically
important difference[247, 283], therefore a difference of 5 units per year for ERAN compared to
ERAS on total SvdH score observed in this study demonstrates not only a statistically significant
change in progression, but also a clinically meaningful reduction. Whereas 74% of patients in
ERAS progressed, on average, >5 units per year over the 5 year period of follow-up considered,
just 27% of patients in ERAN exhibited similar levels of progression.
The data extends previous findings of reductions in radiographic damage in RA over recent
decades[224, 226, 275]. There are two plausible explanations for these findings, both of which
are likely to contribute to the reduction in radiographic damage over time. Firstly, RA may
have become milder, and secondly, earlier more intensive treatment may have improved disease
outcomes. Our models adjusted for disease severity at baseline, but it remains possible that
lower rates of progression in the more recent cohort reflect milder disease. This is supported
by the observation of lower SvdH scores in ERAN compared to ERAS at baseline, prior to
DMARD initiation for the majority of patients. However, the dramatic reductions in radio-
graphic progression, particularly the reduced impact of seropositive RA, is likely to also reflect
improvements in the treatment of RA, given the earlier and increased use of methotrexate as
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the first line DMARD observed in ERAN. This is in line with other reports[224, 226, 275].
Increasing evidence from RCTs also support the hypothesis that early, intensive treatment has
an important effect on reducing radiographic progression[140, 141, 143, 150, 153].
Separate investigation of the erosion and JSN components of radiographic damage scores showed
that JSN was the primary driver for the overall reductions seen in the total SvdH score between
the two cohorts. This finding reiterates the importance of reporting both the erosion and JSN
score separately in clinical trials. Data from ASPIRE show that more patients with early RA
have either erosions alone (8.5%) or JSN alone (4.4%), than both (3.7%) at baseline visit[280],
and that JSN may be more strongly associated with irreversible disability[279]. Despite this,
the separate scores are still rarely reported[278]. If early treatment with methotrexate was the
primary cause for the reduction in total SvdH in ERAN, this could indicate that the mechanism
by which this is achieved is through the reduction of JSN and preservation of the surrounding
cartilage. However, what is not clear is whether the JSN is directly attributable to RA JSN, or
OA JSN. A high prevalence of radiographic OA has been documented at baseline in the ERAN
cohort in the hands and feet, indicating that high levels of comorbid OA could potentially
confound any radiographic assessment of RA[281]. High JSN scores are strongly associated
with increased severity of OA osteophytosis and OA JSN[284]. More studies are needed to
quantify the exact effect that comorbid OA could be having on RA radiographic scoring.
Seropositive RA has been consistently associated with increased radiographic damage[38, 282].
This analysis also found that seropositive RA was highly associated with increased radiographic
progression. While the later cohort indicated non-significant increases in radiographic damage
when comparing seropositive and seronegative patients, the difference between seropositivity
between the two cohorts was non-significant. This is most likely due to a lack of power, with
reduced patient numbers in the later cohort. However, when investigating the absolute change
in radiographic score between seropositive and seronegative patients across the two cohorts,
seropositive patients in the later cohort no longer represented a patient sub-group with clinically
meaningful increases in radiographic progression, at least within the first 5 years of disease.
Aletaha et al.[285] analysed the effect of seropositive status on radiographic progression and
found seropositive patients displayed higher radiographic progression, compared to seronegative
patients. The estimated change in median SvdH score of 0.6 units per year for seropositive over
that of seronegative patients provides an estimate similar to this study. It should be noted that
seropositive status was primarily based on RF positivity, with only a small number of ERAN
patients having data on ACPA positivity. Research is beginning to illuminate the advantage
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of ACPA positivity over RF as a more specific antibody in predicting increased radiographic
progression[286–289].
6.4.1 Strengths and limitations
Many RCTs are restricted to seropositive patients only, and previous research has not focused
on the effect of seropositivity in the context of reduced radiographic progression in more recent
years. The two long-term observational cohorts examined in this study provide a ‘real-world’
account of patients typically seen in secondary care, and the high patient numbers over the
full 5 year follow-up also provides a unique opportunity to provide precise estimates using the
modelling techniques outlined[126]. The use of the SvdH score also provides a first look at
the two principle components of radiographic damage, erosions and JSN, in detail. Further
data from observational studies are needed to ascertain whether reductions in radiographic
progression have also resulted in the diminished association with seropositive status, particularly
in the context of anti-CCP seropositive RA, which could be more predictive of radiographic
progression when compared to RF[286–288].
Our research is subject to a number of limitations inherent in cohort studies. Recruiting centres
were hosted by enthusiastic clinicians within the UK and, although they might not necessarily
reflect people with RA in other contents, or subjected to different treatment regimens, the multi-
centre recruitment for these cohorts from district general hospitals is likely to be representative
of people with RA in the UK. Radiographs were not available for all participants, and it is
possible that those with more severe disease were more likely to have x-rays, increasing the risk
of selection bias in our study. However, baseline variables indicated minimal differences between
the whole cohorts, and those for whom radiographic data was available. The impact of such a
selection bias would overestimate rates of progression, particularly for ERAN, where data was
less complete; hence our estimates should be treated as conservative.
6.5 Concluding remarks
The aim of this chapter was to address the third aim of the thesis; to examine the natural
progression of radiographic damage. This analysis provides further evidence into the marked
reduction in radiographic damage over the last 30 years, while providing accurate, quantified
estimates of the extent of that reduction. JSN was the major driver for the overall reductions
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seen, and highlights the importance of investigating JSN and erosions separately when inves-
tigating radiographic damage. Advances in treatment are likely to be the main cause for the
decline, and adequate DMARD treatment might remove the predictive value of seropositivity
for radiographic progression in early RA. There is also evidence that RA is getting milder as
a disease. Further research should seek other predictors and mediators if residual radiographic
progression despite DMARD treatment is to be halted. The significance of these reductions on
patients of varying disease severity, and whether these reductions have led to improved long-
term functional disability will be crucial in fully realising the impact of these results on clinical
care.
Chapter 7
Radiographic Progression, Disease
Activity and Functional Disability
7.1 Introduction
The systematic review conducted in Chapter 3 identified several major predictors of radio-
graphic progression. There is overwhelming evidence to suggest that seropositive RA (RF and
Anti-CCP) and increased acute phase markers (ESR and CRP) are associated with increased
radiographic progression. In Chapter 6 radiographic progression rates were examined in both
the ERAS and ERAN cohorts, indicating that overall rates of radiographic progression have
significantly decreased between the two cohorts, possibly due to a combination of milder disease
and improved treatments. One key finding from this analysis was that seropositive RA was sig-
nificantly associated with increased radiographic damage. However, large reductions in overall
rates of radiographic damage in ERAN meant that the effect of seropositive RA on increased
radiologic damage was relatively modest when compared to ERAS.
The aim of this chapter is to address the fourth and final aim of the thesis; to expand the
models from Chapter 6 and investigate the long-term relationship with two important clinical
outcomes; disease activity and functional disability, with radiographic progression over time.
The most common measure of disease activity in RA is the DAS, which incorporates an acute
phase marker, along with other clinical and patient reported measures of disease activity. The
aim is to quantify disease activity as a simple clinical tool to guide therapeutic management.
Disease activity indices (DAI) have become more popular in day-to-day clinical practice, as well
109
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as being used as a primary outcome measure in clinical trials, since they are more reliable as an
overall measure of disease activity compared to their individual components[177]. They have
also grown particularly fast in the last few years with the advocation of the ‘Treat-2-Target’
(T2T) initiative in the UK and across Europe[49, 57], where DAS cut-offs are the target.
In the UK, disease states that are defined by thresholds of the DAS28 form the basis of biologic
DMARD prescription decisions, with only those patients with a DAS28 >5.1 eligible for biologic
DMARDS. Those patients with moderate disease (i.e. those falling just below the 5.1 threshold)
are of particular interest, as there has been emerging evidence that these patients exhibit signif-
icant levels of radiographic progression, with some reports indicating that they exhibit the same
level as those with high disease[176, 290]. Combe` et al. found that those patients with sustained
moderate disease (DAS28 3.2-5.1) continue to progress radiographically[176] compared to those
in low disease states, and other studies have found that those patients with sustained moderate
RA on methotrexate continued to exhibit significant radiological progression (SvdH >3 from
baseline to years 2 and 3), with one third of patients (n=33) showing a change in SvdH score
from baseline to 3 years of >3 units[290]. It is currently unclear whether standard conventional
DMARD therapies alone are appropriate in controlling the disease for this patient sub-group,
and forms the basis of the TITRATE project; a multi-centre trial funded by a National In-
stitute for Health Research (NIHR) Programme Grant. Along with the collection of primary
data from RCTs, this project will also be supplemented using data from observational cohorts,
including ERAS and ERAN, to ascertain if there is currently an unmet clinical need in this
patient group. Furthermore, recent evidence from the ERAS and ERAN cohorts highlight the
consequences of sustained moderate disease on functional disability and orthopaedic surgical
rates[74], demonstrating the need to examine the use of biologic DMARDs in moderate disease
activity based on these outcomes alone. Studies have already shown the benefit of the early
use of biologics in both moderate and high disease activity groups in other countries applying
the T2T philosophy[73, 291], although the economic argument of whether this is cost-effective
is not clear.
Early theories regarding the relationship between disease activity, radiographic damage and
functional disability were suggestive of a monotonic relationship[85]. Increased inflammation
caused by the disease would lead to an increase in the destruction of the bones and cartilage.
Over time, this would lead to increased disability through painful deformities in the joints,
ultimately limiting the patients ability to carry out tasks in everyday living. This monotonic
relationship can be illustrated using a box and arrow diagram, as displayed in Figure 7.1.
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Figure 7.1: Box and arrow diagram presenting a single pathway monotonic relationship be-
tween disease activity, radiographic damage and functional disability
However, it became apparent from longitudinal analysis that radiographic progression and func-
tional disability had very different patterns of progression over time. Radiographic assessments
using the Larsen and SvdH scores were found to increase steadily over time[38, 85], while func-
tional disability measured using the HAQ was found to follow a ‘J-shaped’ trajectory over time.
Unlike radiographic joint damage, HAQ scores improved in the first year as treatments were in-
troduced, then steadily rose over the coming years as the disease progressed[38, 85, 292]. These
differences in long-term trajectories, coupled with weak correlations between the two outcomes
in early disease, are suggestive of two distinct disease processes, which differ between early onset
RA and established RA[293, 294]. This was originally conceptualised by Kirwan in 1992[295],
who described the interrelationship between disease processes (e.g. inflammation) and disease
outcomes (e.g. disability) and how they interact in the prognosis of RA. Kirwan explained why
it is important to describe this interrelationship over different stages of the disease; from early
onset, through established, to late disease[295], as the disease progresses and its interaction with
disease outcomes evolves over time. As a result, the prevailing theory today is that acute in-
flammation causing pain and swelling in the joints during early RA leads to increased functional
disability at disease onset, which improves as treatment using NSAIDs, steroids and DMARDs
are introduced. When not suitably controlled, the increased disease activity then leads to ra-
diographic damage over time, resulting in increased functional disability in later disease[214,
296].
In 2002, Escalante and Rico´n[297] presented the theory of two distinct pathways that lead to
the development of disability in RA; one caused by pain, and the other by damage. Figure 7.2
indicates how both the pain and damage pathway exist as separate mechanisms of disability
within the main pathway. These pathways can be further developed into a biopsychosocial
model, where these distinct stages of the disease are also moderated by other external factors,
particularly psychosocial factors. In this model, depression, stress and social support can in-
fluence all stages of the disease process and ultimately impact on the severity of functional
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disability[297].
Figure 7.2: Box and arrow diagram presenting the revised pathway to disability from Escalante
and Rico´n
Two systematic reviews examining the relationship between radiographic damage with disease
activity[177] and with functional disability[86] have identified a tendency for the associations in
both to increase over disease duration. However, both note a paucity of studies using effective
multivariate analysis methods, indicating the need for a more uniform approach to allow direct
comparisons.
Studies by Welsing et al.[214] and Salaffi et al.[211] depict the two popular methods in which the
longitudinal relationship between disease activity and radiographic progression can be analysed.
Salaffi et al.[211] investigated the association between radiographic progression and disease
activity by using time-averaged measures of disease activity. This allows for large longitudinal
data to be condensed into one explanatory variable. This has the benefit of being easier to
model, as well as being easier to interpret. However, this reductionist approach means that
trends on a more sensitive level are not possible. Yearly variations in disease activity may
be relatively low over a 3 year follow-up and using time-averaged approaches over longer time
periods may neglect important variation in disease activity over time, which could be important
in understanding the temporal relationship[214].
Welsing et al.[214] acknowledged these limitations and looked at the use of time-varying co-
variates. Using GEE techniques have non-independence of assessments within individuals cor-
relational structure and can be modelled via a residual correlational structure with respect to
radiographic outcomes over time. This allows for more sensitive time trends to be examined,
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and therefore the association between disease activity and radiographic damage can be exam-
ined on a yearly basis. However, Welsing et al.[214] modelled the radiographic data based on
a link identity function for their GEE, which does not accurately account for the non-normal
distribution, and therefore it is likely that the model estimates are biased by the overestimation
of mean scores.
The aim of this chapter is to explore the longitudinal relationship between radiographic joint
damage with disease activity and then with functional disability. Using the large sample of
radiographic data from the ERAS cohort, the first analysis will investigate the association
between 10 year radiographic damage with disease activity and functional disability, expressed
as a time-averaged covariate. The second analysis will then investigate these associations using
disease activity and functional disability as time-dependent covariates. In contrast to the study
by Welsing et al.[214], both modelling techniques will use multi-level negative binomial regression
as explained in Chapter 5. Finally, to investigate how the declines in radiographic progression
identified in Chapter 6 have impacted on these associations, a sub-analysis restricted to 5 years
will incorporate the sub-sample of radiographic data from the ERAN cohort. With regards
to the association between radiographic progression and disease activity, those patients with
moderate disease activity signify a particularly interesting clinical group and therefore will be
the focus of this analysis.
7.2 Methods
7.2.1 Sample
For the ERAS cohort, a total of 1,216 patients (83%) have radiographic data. While radiographic
data is available for up to 19 years, and disease activity and functional disability data is available
for up to 15 years, there is substantial data attrition beyond year 10. The original aim of the
cohort was to collect follow-up data for up to a minimum of 5 years, which was subsequenty
altered to 10 years. The latter was achieved by all of the centres involved, but several ceased
follow-up after 10 years. This is highlighted in Figure 7.3, which indicates the proportion of
missing data, and the proportion of patients with no data due to no follow-up, for both the
DAS and HAQ score over the first 15 years. For the DAS score, the number of patients with
data at year 10 is 604 (41%), whilst at year 11 this decreases to just 328 (22%). A similar rate
of attrition is seen for the HAQ score, where the number of patients with complete data at year
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10 is 686 (47%), which then decreases by a similar magnitude to just 380 (26%) by year 11. As
such, the decision was made to limit the analyses to the first 10 years.
Figure 7.3: Complete and missing data for the DAS and HAQ score
The secondary validation analysis extends the models to include a sub-sample of 446 (36%)
ERAN patients with radiographic data. While the level of missing data for the DAS and HAQ
is similar to the ERAS cohort for all the patients, the relatively small sample with radiographic
data restricts the follow-up data to just 5 years.
DAS measure and DAS EULAR Categories
The disease activity score (DAS) was collected for each patient at baseline, 6 months and yearly
follow-up. For ERAS, the 3 variable DAS 44-count method was used. This is an overall disease
score that is calculated from a tender joint count (TJC), swollen joint count (SJC) and acute
phase marker (ESR) using a pre-defined equation[64, 298]. While typically cited as a continuous
measure, EULAR proposed pre-defined cut-points for the DAS that could allow for clinicians
to categorise patients into low, moderate and high disease groups[70]. For the DAS-44 measure,
the groups are defined as <2.4 for low DAS, 2.4-3.7 for moderate DAS and >3.7 for high DAS.
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For the ERAN cohort, the four variable DAS28 scoring method was used, which calculates the
score using the 28-count version of SJC and TJC, along with an acute phase marker (ESR) and
a patient global score of pain[65, 299]. A pain score was also collected in ERAS, but was not
used as part of the calculation for the DAS-44. As with the analysis in Chapter 6, to combine
the data from both ERAS and ERAN, the DAS-44 score was transformed to the DAS28 score
using the formula outlined by van Gestel et al.[67].
Functional disability
Functional disability was measured using the anglicised version Health Assessment Question-
naire (HAQ) devised by Kirwan and Reeback in 1986[233]. The HAQ score measures disability
using a 20-item questionnaire over 8 core domains. These questions assess the patient’s ability to
perform daily activities. Each item is scored from 0 to 3, where 0 indicates ‘without difficulty’,
1 indicates ‘with some difficult’, 2 indicates ‘with much difficulty’ and 3 indicates ‘not able to
do the activity’. The questionnaire also includes information about aids and devices used, and
the score is adjusted to take these into account. As with the DAS score, HAQ was assessed at
baseline, 6 months, 12 months and then yearly thereafter.
7.3 Analysis
7.3.1 Radiographic damage and disease activity
The first stage of the analysis was to examine the correlation structure between the SvdH score
and the DAS, including the separate components that make up the DAS (ESR, TJC and SJC)
over the first 10 years follow-up. Chapter 5 found that the SvdH score was best analysed using
the negative-binomial model, which analyses the score based on the log count. As such, the
correlations examine the total SvdH based on the natural log transformation (+1) (lnSvdH).
Similarly, the distribution of the ESR indicates that the correlation should be based on the log
transformed score (lnESR). The pairwise correlation matrices between the lnSvdH score, the
DAS score and the lnESR over the first 10 years are shown in Tables 7.1. In order to establish
patterns in the correlation matrix, those correlations defined as having a ‘moderate’ effect (0.3-
0.4) where highlighted. Those with a Pearson’s r of greater or equal to 0.3 but less than 0.4
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are highlighted in light blue, and those with a Pearson’s r of greater than or equal to 0.4 are
highlighted in dark blue.
Overall, the correlations between DAS and lnESR with lnSvdH ranged from weak (0.1-0.2)
to moderate (0.3-0.4). There was a tendency for the correlations to increase over time, with
stronger correlations being seen between DAS and SvdH in the latter years. This was observed
for lnSvdH scores in year 4 and 9, which saw moderate strength correlations with DAS scores
from year 2 and year 5 respectively. The pairwise correlation matrix between the lnESR and
lnSvdH score shows a higher number of moderate correlations between the two, while also
highlighting the tendency for these stronger correlations to occur in later disease.
The second set of matrices in Table 7.2 indicates the correlations between the lnSvdH score and
the separate TJC and SJC. Unlike the DAS and lnESR, the majority of correlations were <0.3,
with just one correlation of 0.3 between lnSvdH score at year 9 and the TJC at year 5.
The separate components of the DAS can be split into objective and subjective markers. ESR
and SJC are typically seen as objective markers of RA as they relate to quantifiable measures of
inflammation in the blood or the clinician’s assessment of swollen joints, rather than any subjec-
tive perception from the patient[300]. Conversely, the TJC (and in the case of the DAS-28, the
Patient Global Assessment (PGA) for pain) is regarded as a subjective marker of inflammation,
as it relies on patient reported symptoms relating to inflammation and disease. As such, the
objective and subjective components of the DAS are sometimes examined individually when in-
vestigating radiographic damage, as theoretically radiographic damage would be more strongly
associated with the objective markers, rather than the subjective markers.
The relative strength of the correlations between lnESR and lnSvdH further supports the exis-
tence of a relationship between inflammation and radiographic progression in later disease. The
relative strength of this relationship in terms of number of moderate correlation coefficients over
the 10 year period also provides evidence that, of all the measures used to calculate the DAS,
ESR is the strongest for radiological damage. The tendency for these correlations to increase
over time is also suggestive that there is a lagged association with radiographic damage, and
does not occur serially, but rather a few years after the occurrence of increased inflammation.
When comparing the correlation matrices for the SJC and TJC there was little difference be-
tween the correlation structures. While the increased relationship between lnESR and lnSvdH,
and the absence of a relationship between the TJC and SvdH may be of little surprise, the SJC
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is regarded as more closely related to objective levels of inflammation. Thus, one would hypoth-
esise that it would resemble a correlation structure more similar to the lnESR, rather than the
TJC. This differentiation between objective and subjective markers of pain and inflammation
will be explored in more detail in the full analysis.
7.3.1.1 Time-averaged analysis
The first analysis will model the effect of disease activity on radiographic progression as a time-
averaged covariate. The first 10 years of DAS data was summarised into a mean score for each
patient. Based on pre-defined EULAR cut-points, patients were then grouped into low DAS
(<2.4), moderate DAS (2.4-3.7) and high DAS (>3.7) categories using the mean DAS over 10
years. Only those patients with at least two DAS scores from years 1 to 10 were included
(n=1,335, 91%). The 10 year radiographic progression of patients in each of the three DAS
categories was then estimated using a mixed-effects negative binomial regression analysis. The
primary analysis looked at the total SvdH as the dependent variable, while secondary models
examined the separate JSN and erosions components, and the Larsen score as the dependent
variables. The DAS categories, along with year of follow-up entered as a continuous variable,
were included as the primary predictors. As well as being entered as main effects, it was also
important to include an interaction term between the DAS categories and follow-up year, so
that any differences in the rate of change between the groups over time could be accounted
for. To control for possible confounding effects, each model controlled for age, sex, RF status,
baseline HAQ score, baseline HB level, months from symptom onset to first out-patient visit
and use of DMARDs within the first 12months. The Bonferroni adjustment was used to adjust
for multiple testing across groups.
The patient population by DAS categories was 466 (35%) in the low group, 456 (34%) in the
moderate group and 413 (31%) in the high group respectively. For the sub-sample with SvdH
data, there were 402 (34%), 401 (34%) and 372 (32%) patients for the low, moderate and high
categories respectively. Figure 7.4 indicates the range of DAS scores at follow-up years 1 to 10
for each of the three DAS categories. The horizontal line denotes the cut-points for the DAS
categories (2.4 and 3.7). The figure shows the relative stability of the DAS score over 10 years,
with just 211 (16%) patients having >50% of their DAS scores outside their allocated DAS
category.
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Figure 7.4: Box plot of DAS scores over the first 10 years by DAS categories
The basic demographic and clinical characteristics of patients in each DAS category are outlined
in Table 7.3. Patients in the low group tended to be slightly younger, male, and RF negative
with a lower HAQ and DAS at baseline. They were also more likely to have baseline HB levels
within the normal range. In contrast, patients in the high group tended to be older, female,
and RF positive with high baseline HAQ and DAS scores. The moderate group were similar to
the whole cohort, however they also tended to be slightly older and have low HB at baseline.
Months to first visit from referral were similar across all groups.
Table 7.4 provides a full break down of the relative differences between each of the DAS groups
from the mixed-effects negative-binomial regression. Alongside these model estimates are the
absolute scores calculated from the estimated sample means. Comparing the low to moderate
DAS category, the moderate DAS category had higher radiographic damage at year 1 for the
total SvdH score (21.9 vs. 13.5, p<0.001), JSN score (14.3 vs. 9.5, p<0.001), erosions score (5.2
vs. 2.2, P<0.001) and Larsen score (3.6 vs. 1.8, p<0.001). The relative differences ranged from
1.5 to 1.6 fold increase for the JSN and total SvdH score respectively, while increases of 2 to
2.3 fold were seen for the Larsen and erosion scores. Similar patterns were seen for the annual
rate of change, whereby the moderate category indicated increased annual rate of change for the
total SvdH (6.4 vs. 3.4, p<0.001), JSN score (14.3 vs. 9.5, p<0.001), erosion score (2.3 vs. 0.9,
p<0.05) and Larsen score (1.2 vs. 0.5, p<0.05). With all scores, the moderate DAS category
indicated around a 2 times increase in annual progression compared to the low category.
Comparisons between the low category and high category indicated a greater distinction, with
the high category having higher radiographic damage at year 1 and greater increases in the
annual rate of change than the low DAS category.
Interestingly, the model estimated similar levels of radiographic progression between the mod-
erate and high categories. The model indicated that the total SvdH, JSN, erosion and Larsen
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score at year 1 were similar between the two patient groups. Only the total SvdH indicated
an increased annual rate of change for the high DAS category (8.8 vs. 6.6, p<0.05) compared
to the moderate category, with the JSN, erosion and Larsen score also indicating similar lev-
els of increased annual rate of change (between a 21%-34% increase). However, none of these
differences reached statistical significance (p>0.05).
Low Moderate High
Moderate	vs.	
Low High	vs.	Low
High	vs.	
Moderate
Total	SvdH	
at	yr1
13.5 21.9 24 1.59	[1.32-1.92]	
p<0.001
1.70	[1.39-2.08]	
p<0.001
1.06	[0.86-1.33]	
p=0.995
Total	SvdH	
Annual	rate
3.4 6.4 8.8 1.90	[1.41-2.38]	
p<0.001
2.61	[1.93-3.29]	
p<0.001
1.38	[1.04-1.72]	
p=0.019
JSN	score	at	
yr1
9.5 14.3 15.9 1.50	[1.24-1.81]	
p<0.001
1.63	[1.33-2.00]	
p<0.001
1.09	[0.88-1.36]	
p=0.743
JSN	score	
Annual	rate
1.8 3.2 4.3 1.73	[1.28-2.18]	
p<0.001
2.32	[1.70-2.94]	
p<0.001
1.34	[1.00-1.68]	
p=0.089
Erosion	
score	at	yr1
2.2 5.2 5.4 2.32	[1.76-3.07]	
p<0.001
2.33	[1.73-3.13]	
p<0.001
1.00	[0.73-1.38]	
p=0.999
Erosion	
score	
Annual	rate
0.9 2.3 3
2.67	[1.78-3.54]	
p<0.001
3.48	[2.28-4.68]	
p<0.001
1.31	[0.88-1.73]	
p=0.410
Larsen	
score	at	yr1
1.8 3.6 3.6 1.95	[1.48-2.56]	
p<0.001
1.92	[1.44-2.58]	
p<0.001
0.99	[0.72-1.36]	
p=0.999
Larsen	
score	
Annual	rate
0.5 1.2 1.4
2.17	[1.40-2.94]	
p<0.001
2.63	[1.67-3.59]	
p<0.001
1.21	[0.79-1.63]	
p=0.330
Absolute	Score Relative	Difference																																																																																																									
Table 7.4: Estimated absolute means and relative differences of the Total SvdH score stratified
by each DAS category over the first 10 years. Relative differences expressed as Incidence Rate
Ratios (IRR). 95% Confidence Intervals in square brackets.
A graphical representation of the estimated sample means over the first 10 years for each DAS
category is shown in Figure 7.5 for the total SvdH score, in Figure 7.6 for the JSN and erosion
score, and Figure 7.7 for the Larsen score. These graphs highlight how the low category has
consistently low radiographic damage over the first 10 years, whereas the moderate and high
categories have similar progression over time. While the high category does show marginally
higher progression compared to the moderate category, this is not statistical significant, with
overlapping 95% CIs in the grey shaded area around the point estimates at each time point.
Additionally, the mean DAS over the first 10 years was also modelled as a continuous variable,
rather than categorised into low, moderate and high DAS groups. This provided similar results,
indicating that each additional follow-up year resulted in a 14% increase in radiographic damage
(IRR 1.14 [95% CI 1.12-1.17], p<0.001), while a 1 unit increase in mean DAS indicated a 16%
increase in radiographic damage (IRR 1.16 [95% CI 1.09-1.23], p<0.001). There was also a
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Figure 7.5: Estimated absolute means over the first 10 years for the Total SvdH score stratified
by DAS categories. Grey area denotes 95% Confidence Intervals
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Figure 7.6: Estimated absolute means over the first 10 years for the JSN and erosion score
stratified by DAS categories. Grey area denotes 95% Confidence Intervals
significant interaction effect between mean DAS and follow-up year, showing that higher than
average DAS levels were related to an accelerated rate of progression over time (IRR 1.01 [95%
CI 1.01-1.02], p<0.001). A sensitivity analysis including the standard deviation of each patients
mean DAS score was also included, however this had no association with the total SvdH score.
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Figure 7.7: Estimated absolute means over the first 10 years for the Larsen score stratified
by DAS categories. Grey area denotes 95% Confidence Intervals
7.3.1.2 Time-varying analysis
Using DAS as a time-averaged score, the analysis has found that those with sustained low
mean DAS over 10 years had reduced radiographic progression compared to those patients
with sustained moderate and high mean DAS over 10 years. Furthermore, those patients with
sustained moderate DAS indicated similar levels of radiographic progression compared to those
patients with sustained high DAS.
The advantage of expressing DAS collected over time as a time-averaged variable is that the
results are intuitive, and provide a clear indication of the effect of sustained levels of disease
activity on long-term radiographic progression. In this particular case, the mean DAS over the
first 10 years provided a suitable proxy marker of disease activity dose over this time period,
as demonstrated in the box plots presented in Figure 7.4. It showed how patient’s DAS over
the 10-year period was relatively stable, and there was little deviation of the yearly DAS score
outside the groups pre-defined EULAR DAS categories. However, this method is not without its
limitations. While intuitive, summarising the DAS over the 10-year follow-up could be argued
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to be too simplistic in its approach. For instance, there are instances where patients’ disease
activity does fluctuate over time, and it is not clear how this may affect the relationship with
radiographic progression. Accounting for this fluctuation has been found to be an important
factor in understanding the relationship between disease activity and radiographic damage over
time in previous studies[214].
As such, the second part of this analysis looks at modelling the yearly DAS score at each follow-
up as a Time-Varying Covariate (TVC) in a mixed-effects NB regression model. The analysis
will look at the potential time effect between radiographic damage and DAS by modelling
the two measures collected at different time points. The first will examine the association
when both are measured at the same time, while the next set of models will investigate the
effect of DAS on future radiographic damage scores as a time-lagged effect. This involves
modelling the DAS scores that occur earlier in the follow-up period on radiographic scores that
are measured later in the follow-up period. The first time-lagged model will look at a 1-year
lagged effect, while the second model will look at a 2-year lagged effect. The aim of comparing
analyses using time-lagged associations is to investigate whether the association between DAS
and radiographic damage increases as the lag time increases. Given the correlation structure
seen earlier in the chapter, it is hypothesised that higher DAS will have a stronger association
with radiographic damage progression occurring later on in the disease time period, rather
than concurrent measures. As before, these models will control for key confounding variables,
including age, sex, RF status, baseline functional disability, level of HB, months from referral
to first visit and whether DMARDS were prescribed within the first 12-months.
The impact of time-lagged effects
The correlation matrices outlined in Figure 7.1 highlight how the strength of association be-
tween radiographic damage and disease activity increases over time. It is hypothesised that the
predictive ability of the DAS on total SvdH will increase as the time-lag between the two vari-
ables increase. The three TVC models (concurrent, 1 year time lagged and 2 year time lagged)
were performed on the DAS, as well as the separate DAS components; ESR, SJC and TJC.
The DAS calculation requires the ESR to be log transformed, and the TJC to be square-root
transformed. These transformations were therefore included in the models, rather than the raw
scores, to ensure direct comparisons with the DAS.
The results of these models are shown in Table 7.5.
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(1) (2) (3)
Time-Varying
Time-Varying
(Lagged)
Time-Varying
(Lagged-2)
IRR / SE IRR / SE IRR / SE
DAS 1.01 1.03** 1.05***
(0.010) (0.011) (0.014)
DAS#Follow-up Year 1.00 1.00 1.00
(0.002) (0.002) (0.002)
DAS Components
ESR (ln) 1.01 1.06*** 1.12***
(0.017) (0.019) (0.023)
SJC 1.00 1.00 1.01*
(0.002) (0.002) (0.003)
TJC (Sqrt) 0.99 0.99 0.98
(0.014) (0.015) (0.020)
Follow-up Year#ESR (Ln) 1.00 1.00 0.99
(0.003) (0.003) (0.003)
Follow-up Year#SJC 1.00 1.00 1.00*
(0.000) (0.000) (0.000)
Follow-up Year#TJC (Sqrt) 1.00 1.00 1.01
(0.003) (0.003) (0.003)
Observations 4645 3737 3024
N 1162 1125 1108
* p <0.05, ** p <0.01, *** p <0.001. Standard errors in parentheses.
Note: IRR = Incidence Rate Ratios
Table 7.5: Modelling DAS and its separate components as time-varying predictors
Model (1) indicated that there was no significant association between disease activity and ra-
diographic damage when measured at the same follow-up time point. In contrast, models (2)
and (3) showed a significant association with DAS by including a time lagged effect. Model
(2) with a 1 year lagged-effect, had a 3% increase in total SvdH (IRR 1.03 [95% CI 1.01-1.05],
p<0.01), while model (3) for the 2 year time lagged effect had a 5% increase in total SvdH (IRR
1.05 [95% CI 1.03-1.07], p<0.001), for every one unit increase in DAS.
When this was repeated for the separate components of the DAS, the ESR(ln) had a similar
trend across the 3 models. There was no significant association with concurrent measures of
total SvdH, but an increasing statistically significant association with total SvdH in the 2 year
lagged effect model. In this model, a 1 unit increase in lnESR showed a 12% increase in total
SvdH (IRR 1.12 [95%CI 1.07-1.16], p<0.001). To provide a clearer interpretation, a proportional
increase in ESR can be used to calculate its relative increase on total SvdH. For example, a
10% increase in ESR can be estimated to increase total SvdH by 34% (1.103.06 = 1.34, where
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3.06=exp(1.12)). Only the 2 year lagged effect model shows a significant association between
SJC and total SvdH.
As with the analysis in Chapter 6, an interaction effect between the covariate of interest and
follow-up year estimates whether the association between the covariate and the outcome measure
changes as follow-up year increases. Starting with DAS model (1), we see that DAS was not
associated with total SvdH at baseline when DAS and total SvdH are measured concurrently.
The non-significant interaction effect also tells us that this association does not change as follow-
up time increases. The inclusion of time-lagged effects in model (2) and (3) does not change
the interpretation of the interaction effect, it merely shifts the time point to which these effects
are related. In model (2), which examines the association between the previous years DAS
and total SvdH, there is a significant association, where increased DAS in the previous year
results in an increase of 3% in total SvdH. Like model (1) though, the interaction effect is still
non-significant, and therefore this time-lagged effect between DAS and total SvdH also does not
change as a product of increased follow-up. The only exception was the SJC in model (3) with
a 2 year time lagged effect. However, the model estimate for the interaction effect showed a less
than 1% change for each additional follow-up year (IRR 1.00 [95%CI 1.00-1.00], p=0.045).
Modelling DAS using both ERAS and ERAN data over 5 years
As was reported in Chapter 6, the level of radiographic progression has significantly decreased
over time between the ERAS and ERAN cohorts, with ERAN reporting much lower levels of
radiographic progression over 5 years. While the analysis presented in this chapter demon-
strates how this progression is largely determined by the level of the patients disease activity
over time, the next natural question is whether increased disease activity has a similar impact
on radiographic progression in ERAN, despite the overall lower levels of radiographic damage
observed.
It is inappropriate to repeat all the analysis performed in the ERAS cohort with both cohorts
combined given the relatively small amount of radiographic data in the ERAN cohort. Cate-
gorising the time-averaged DAS into EULAR cut points in ERAN is unsuitable due to the low
levels of data over the 5 year period. This is shown in Table 7.6, where the number of patients
with SvdH data over the first 5 years are given for each mean DAS category. With many cells
within the table at the years 3, 4 and 5 indicating single figure observations, it is clear any
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modelling would not be sufficiently powered to provide robust results, such as those seen in the
ERAS cohort above.
DAS Group SvdH yr1 SvdH yr2 SvdH yr3 SvdH yr4 SvdH yr5
Remission 32 22 16 9 9
Low 18 15 7 5 5
Moderate 57 56 33 19 15
High 16 13 9 9 4
Total 123 106 65 42 33
Table 7.6: Number of observations with radiographic data stratified by DAS groups over the
first 5 years in ERAN
However, using a time-averaged model where the mean DAS score is included as a continuous
outcome reduces the parameters needed in the model. While the relative power of the effect
estimates for the ERAN cohort is much lower than those for ERAS, it does provide a means of
investigating whether the association between radiographic damage and DAS has changed as a
result of lower overall radiographic progression in ERAN.
Combining both the ERAS and ERAN data, a total of 1,085 patients (ERAS=978, ERAN=107),
contributing 3,587 observations (ERAS=3,397, ERAN=190), were entered into a multi-level NB
regression. The lower number of observations was due to missing data, as patients needed to
have at least two DAS scores between years 1 and 5, as well as radiographic data over this time
period. Year of follow-up and the mean DAS score from years 1-5 were entered as continuous
covariates. As with the RF analysis in Chapter 6, a three-way interaction effect between year of
follow-up, mean DAS score and cohort membership was also included, along side the main effect.
Age at onset, sex, RF positivity, Baseline HAQ and low HB, months from symptom onset to first
out-patient visit and use of DMARDs within the first 12months. Additionally, some patients
in ERAN received steroids or DMARDs prior to first visit, so these were included as binary
variables. The estimated sample rates were calculated for each cohort over a mean DAS score
of 2, 3 ,4 and 5 to indicate remission, low, moderate and high DAS groups respectively. The
Bonferroni adjustment was used to adjust for multiple testing across groups.
The estimated sample means from the model for both the ERAS and ERAN cohorts representing
patients in sustained remission, low, moderate and high mean DAS groups are presented in
Figure 7.8.
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Figure 7.8: Estimated sample means for the mean DAS score at 2 (Remission), 3 (Low),
4 (Moderate) and 5 (High) for ERAS and ERAN. Black error bars denote 95% Confidence
Intervals
The estimated sample means [95%CI] for the yearly increase of the total SvdH score in ERAS
were 2.9 [2.4-3.4], 4.4 [3.9-4.8], 6.5 [6.0-7.2] and 9.7 [8.7-10.7] for patients with sustained remis-
sion, low, moderate or high mean DAS respectively over the 5 years. In contrast, the yearly
increase in total SvdH score in ERAN was 1.8 [0.5-3.1], 2.2 [1.0-3.3], 2.6 [1.3-3.8] and 3.0 [1.2-4.9]
for patients with sustained remission, low, moderate and high mean DAS over the 5 years. The
model indicates that a patient in ERAN with a high mean DAS over the first 5 years of disease
had similar a rate of radiographic progression compared to an ERAS patient in sustained DAS
remission (Δ-0.2 [95%CI -2.1-1.8], p=0.864).
While the estimated sample rates for ERAN indicate no differences in radiographic progression
across the different mean DAS values, a non-significant three-way interaction effect in the model
suggests there was not sufficient power to conclude that the association of mean DAS between
the two cohorts over time was statistically significantly different (IRR 0.99 [95%CI 0.94-1.05],
p=0.804). While disease activity may still be associated with increased radiographic progression,
the relatively low rates do not signify clinically meaningful increases in radiographic rates.
Chapter 7. Radiographic damage, disease activity and functional disability 130
7.3.2 Radiographic damage and functional disability
The first objective was to examine the association between disease activity and radiographic
progression using two methods for longitudinal data; time-averaged approach and the time-
varying approach. The second objective of this analysis was to investigate the association
between radiographic progression and functional disability using the same methods.
As with the DAS analysis, the first stage of analysing this association is to examine the cor-
relation structure between the two measures. The first pairwise correlation matrix in Table
7.7 shows the pairwise correlation between the HAQ and the total SvdH score over the first
10 years. Those cells with correlations >0.3 are highlighted in light blue, while those cells
with a correlation of >0.4 are highlighted in dark blue. As with the DAS, it is clear that the
correlations are stronger towards the latter stages of the disease.
The model proposed by Escalante and Rico´n[297] in Figure 7.2 denotes that disease activity
causes radiographic damage, and that radiographic damage in turn causes functional disability.
As such, to model the impact of radiographic damage on functional disability, the outcome
measure (dependent variable) needs to be functional disability, while the covariate of interest
(independent variable) is the total SvdH score. The data distributions of the HAQ are different
to the total SvdH (See Figure 7.9), so a multi-level NB regression model is not required. Instead,
the HAQ score can be modelled as a continuous linear outcome, assuming a normal distribution.
The coefficient estimates from the model denote a mean change in HAQ.
7.3.2.1 Time-averaged analysis
To investigate the time-averaged effect of radiographic damage on HAQ scores, a summary
statistic that encapsulates the average rate over years 1-10 is needed. As has been documented
throughout this thesis, summarising this as a mean score (as was done for the DAS in the
previous analysis) would be inappropriate. Therefore, to estimate the rate of change for each
patient, a separate multi-level NB model is used, where the random-effects slope from years
1-10 for each patient is estimated and used in the final HAQ model. Rates were obtained for
1,192 (81%) ERAS patients, with a median rate of change of 3.7 units per year (IQR 5.3), which
ranged from 0.2 to 62.7 units per year. These estimated rates can now be used in the HAQ
model to investigate how the rate in change of radiographic progression can predict functional
disability over time.
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Figure 7.9: Histogram of the baseline HAQ values for the ERAS cohort
The baseline SvdH, along with the estimated rates calculated in the separate NB model, were
entered as covariates into the model as continuous variables. As before, an interaction effect
between the radiographic rate and follow-up year was also included, and the model controlled
for age at onset, sex, RF status, baseline HAQ score, baseline HB level, months from symptom
onset to first out-patient visit and use of DMARDs within the first 12 months.
A total of 1,016 patients contributed 7,330 observations to the multi-level linear model (mean =
7.2 observations per patient). The model showed that HAQ scores increased by 0.4 units per year
(95%CI 0.03-0.04, p<0.001) and that each additional unit increase in the rate of radiographic
progression was associated with a 0.1 unit increase in HAQ score (95%CI 0.01-0.02, p<0.01).
A significant interaction between follow-up year and rate of radiographic change shows that the
effect of increased radiographic progression was stronger over time (p<0.001). Baseline SvdH
score was not associated with HAQ scores (p=0.341).
To depict the model results graphically, the estimated sample means of the HAQ score over
years 1-10 were estimated for patients with a rate of 0, 5 and 10 SvdH units per year. While
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no formal cut-points exist for the SvdH score, these denote patients with no damage, complete
destruction of 1 joint, and complete destruction of 2 joints respectively.
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Figure 7.10: Estimated sample means over the first 10 years for the HAQ score stratified by
annual rates of SvdH. Grey area denotes 95% Confidence Intervals
The same models were then applied based on the rate of JSN, erosions and Larsen score.
The models showed that the effect of increased rates of JSN had a marginally higher impact
on HAQ over time (0.03 [95%CI 0.02-0.05], p<0.001), whilst increased rates of erosion score
showed similar effects to the total SvdH score (0.02 [95%CI 0.00-0.04], p=0.023). The higher
effect estimate could be suggestive that JSN is more strongly associated with HAQ than the
erosion score. The Larsen model showed similar results to the SvdH score, although direct
comparisons are difficult due to the differences in the scoring methods.
7.3.2.2 Time-varying analysis
Following the time-averaged approach detailed above, the next stage of the analysis was to look
at HAQ as a TVC. As with the TVC analysis for the DAS, three models were conducted to
look at the association of radiographic damage as a TVC with functional disability. The first
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Figure 7.11: Estimated sample means over the first 10 years for the HAQ score stratified by
annual rates of JSN and Erosions. Grey area denotes 95% Confidence Intervals
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Figure 7.12: Estimated sample means over the first 10 years for the HAQ score stratified by
annual rates of Larsen. Grey area denotes 95% Confidence Intervals
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(1) (2) (3)
Time-Varying
Time-Varying
(Lagged)
Time-Varying
(Lagged-2)
β/ SE β/ SE β/ SE
Total SvdH Score
Follow-up Year 0.031*** 0.047*** 0.032***
(0.005) (0.006) (0.006)
Total SvdH 0.002*** 0.001 0.001
(0.000) (0.000) (0.001)
Follow-up Year#Total SvdH 0.000 0.000 0.000
(0.000) (0.000) (0.000)
JSN Score
Follow-up Year 0.027*** 0.045*** 0.028***
(0.006) (0.006) (0.007)
JSN 0.002*** 0.001 0.000
(0.001) (0.001) (0.001)
Follow-up Year#JSN 0.000 0.000 0.000
(0.000) (0.000) (0.000)
Erosions Score
Follow-up Year 0.035*** 0.050*** 0.036***
(0.005) (0.005) (0.005)
Erosion Score 0.003*** 0.001 0.001
(0.001) (0.001) (0.001)
Follow-up Year#Erosion Score −0.000 0.000 0.000
(0.000) (0.000) (0.000)
Larsen Score
Follow-up Year 0.037*** 0.044*** 0.036***
(0.004) (0.005) (0.005)
Larsen Score 0.003*** 0.002 0.002
(0.001) (0.001) (0.002)
Follow-up Year#Larsen Score 0.000 0.000 0.000
(0.000) (0.000) (0.000)
Observations 4782 4064 3691
N 1161 1091 1040
* p <0.05, ** p <0.01, *** p <0.001. Standard errors in parentheses.
Table 7.8: HAQ models using radiographic outcomes as (1) TVC, (2) TVC lagged 1 year and (3)
TVC lagged 2 years
model looked at the association of HAQ with the total SvdH, JSN, erosion and Larsen score as
a TVC when measured at the same follow-up time-point. The second two models then focus on
the time-lagged effect of 1 year and 2 years. All the models also included follow-up year as a
main effect along with an interaction between the radiographic measure and follow-up year. As
before, age at onset, sex, RF positivity, DAS at baseline, low HB at baseline, months from first
visit to referral and use of DMARDs within first 12 months were controlled for in the models.
The results of these models are shown in Table 7.8.
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Overall the HAQ score increased over time, indicating an increase of between 0.03 - 0.05 HAQ
units per year over the 10 year period. For the first model looking at the association between
HAQ and radiographic outcomes measured at the same time-point, all radiographic outcomes
indicated a similar level of increase in HAQ. For the total SvdH, 1-unit increase indicated an
increase of 0.002 HAQ units ([95%CI 0.001-0.002], p<0.001), while the Larsen score indicated an
increase of 0.003 HAQ units ([95%CI 0.001-0.005], p<0.001) for every 1-unit increase. Separate
models for the JSN and erosion score reported similar increases in HAQ of 0.002 [95%CI 0.001-
0.004] and 0.003 [95%CI 0.001-0.004] respectively. A graphical depiction of the predicted HAQ
score over the range of the total SvdH, while held at the mean year of follow-up, is displayed
in Figure 7.13. It highlights the linear association between the two constructs, along with
increased variance at the higher end of the radiographic score (heteroscedasicity). Additionally,
none of the models indicated a significant interaction effect with follow-up year, suggesting
any associations were linear over time. In contrast to the disease activity models, both of the
time-lagged effect models indicated no significant association with HAQ scores.
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Figure 7.13: Estimated sample mean of the HAQ score over the range of the Total SvdH
score, held at the mean follow-up year. Grey area denotes 95% Confidence Intervals
The small effect estimates presented represent the large scale of the predictor variable. In the
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case of the total SvdH score, a 1 unit increase over a scale of 0-448 does not necessarily indicate
a clinically meaningful increase in the total SvdH. As the effect of radiographic damage was
proven to be linear, the effect estimate could be multiplied by any magnitude of change in the
SvdH to reflect the increase in HAQ score. This was demonstrated in a sensitivity analysis
looking at the total SvdH entered as a categorical variable based on the reported quartiles.
This highlighted the linear increase over the quartiles, with an increase from the 25th percentile
to the 75th percentile estimating an increase of 0.14 HAQ units ([95%CI 0.04-0.24],p<0.001).
Modelling HAQ using both ERAS and ERAN data over 5 years
As with the DAS analysis, a validation was conducted on the time-averaged models to in-
vestigate how the association between radiographic damage and HAQ has changed in light of
reduced radiographic progression in ERAN. Given the relatively small amount of patients with
radiographic data in ERAN, the models were restricted to just 5 years.
Combining both the ERAS and ERAN data, a total of 1,140 patients (ERAS=1013, ERAN=127)
contributing 4,677 observations(ERAS=4,297, ERAN=380) were entered into a multi-level lin-
ear model. Year of follow-up and the mean rate of the total SvdH score from years 1-5 (esti-
mated using the random-effects from a multi-level NB model), along with the baseline SvdH
score, were entered as continuous covariates. As before, a three-way interaction effect between
year of follow-up, rate of SvdH and cohort membership are also included along side their main
effect. Age at onset, sex, RF positivity, Baseline HAQ and low HB, months from symptom
onset to first out-patient visit and use of DMARDs within the first 12 months. Additionally,
some patients in ERAN received steroids or DMARDs prior to first visit, so these were included
as binary variables. The estimated sample rates were calculated for each cohort with a total
SvdH rate of 0, 5 and 10 to indicate patients with 0, complete destruction of one joint, and
complete destruction of two joints respectively. The Bonferroni adjustment was used to adjust
for multiple testing across groups.
The estimated sample means from the model for both the ERAS and ERAN cohorts at SvdH
rates of 0, 5 and 10 are presented in Figure 7.14.
The model indicates that there was no difference in the association between rates of SvdH and
HAQ scores over the first 5 years between the ERAS and ERAN cohorts (p>0.05). There is an
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Figure 7.14: Estimated sample means for the mean HAQ score stratified by annual rates of
SvdH for both ERAS and ERAN. Black error bars denote 95% Confidence Intervals
indication that HAQ scores for patients in ERAN were improving, however the limited data,
along with restricted follow-up limits the ability to draw any definitive conclusions on this trend.
7.4 Discussion
This chapter explored the complex, longitudinal association between disease activity, radio-
graphic joint damage, and functional disability. Using two different methods for modelling
longitudinal data; time-averaged and time-varying. The aim was to use the modelling tech-
niques described in Chapter 5 to test whether the current model proposed by Escalante and
Rico´n[297] fits with the ERAS data. Unlike previous studies, this analysis ensures more precise
estimation by using the modelling methods described in Chapter 5 and explores these relation-
ships over 10 years. Furthermore, validation analysis using a sub-sample of data from the ERAN
dataset was used to investigate whether the secular declines in overall radiographic progression
identified in Chapter 6 had any impact on the associations found in the ERAS data. Each
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analysis is broken down into sub-sections to detail the findings, and assess how they fit in with
the published literature.
DAS modelled as a time-averaged covariate
The first analysis looked at disease activity as a time-averaged covariate, and found that those
patients recruited into the ERAS cohort between 1986-2001 with sustained moderate disease
activity experienced similar levels of radiographic progression over the first 10 years as those
patients with sustained high disease activity. This finding is in agreement with recent studies,
one of which examined a similar patient group and found those patients with sustained mod-
erate and high disease activity were also at risk of increased radiographic progression over the
first 3 years[301] and 5 years[302]. A further study found that patients in persistent high disease
activity states were found to have a 2.5 times increase in rapid radiological progression (>SDD)
over the first 3 years, compared to those with persistent low disease or in remission[211]. In
the UK, under the current T2T paradigm, prescription of biologics, in combination with con-
ventional DMARDs, is reserved only for those patients with the most severe disease in order to
achieve low disease states. The main ERAS analysis found equal levels of radiographic damage
in those patients with sustained moderate disease. This gives support to the argument that a
large proportion of patients with equally disabling disease are potentially being denied access
to more effective therapies.
However, this is a historical cohort, treated with arguably less effective treatment strategies.
Chapter 6 demonstrated that radiographic progression has halved between ERAS and ERAN,
and as a result, the impact of seropositive RA on clinically meaningful radiographic progression
had diminished. The validation analysis in this chapter using the sub-sample of radiographic
data from ERAN also demonstrated that while the relative association between disease activity
and radiographic progression was still present, the absolute change did not result in clinically
meaningful increases in progression rates. That is, patients in ERAN with high disease activity
indicated similar levels of radiographic progression over 5 years as those patients in ERAS with
low disease activity. These findings have important implications on the argument of prescribing
biologics DMARDs in those patients with moderate disease activity[72–74]. Using ERAN data,
studies have shown that achieving low disease targets with conventional DMARD therapies
in the first 3 years is low[72], and that functional disability is high in those patients with
sustained moderate disease[72, 74]. In contrast, this analysis suggests that secular declines in
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overall radiographic damage do not support the introduction of biologics in those patients with
moderate disease, as radiographically they are already progressing at a clinically low rate.
Comparisons of these results with other observational cohorts is difficult, since variation in pa-
tient characteristics and treatment strategies is likely to be high. Most long-term observational
studies, looking at radiographic outcomes and disease activity longitudinally, were recruited
during the pre-biologic era, where results are similar to those found from the ERAS analy-
sis[211, 214, 301]. In contrast, data from RCTs may provide some insight into the findings
present in this analysis. The BeST study reported on radiographic outcomes over 5 years while
categorising patients into disease activity levels using a range of DAIs[302], however the analysis
looking at radiological progression across these disease groups was controlled to only report on
those patients randomised to the monotherapy treatment arm. It is perhaps unsurprising the
estimated rates of SvdH are similar to those reported in the ERAS cohort, since the treatment
strategy is likely to be similar. If the analysis were to be adjusted to look at those rates in
the combination and biologics trial arms, this would go some way in illuminating the findings
presented here with the ERAN analysis. Other RCTs have also documented very low rates of
radiological progression in methotrexate only arms, in line with rates reported in the ERAN
sub-analysis. While the biologic treatment arms are reported as being statistically significantly
lower compared to the methotrexate arms, they represent very small effects, much less than
the clinically meaningful change[291, 303]. However, these have been restricted to just 1 year,
where the association between disease activity and radiographic progression is unlikely to be
fully realised due to the delayed onset of radiographic damage[2, 177].
DAS modelled as a time-varying covariate
The second analysis looking at disease activity as a TVC in this chapter found that disease
activity was not associated with radiographic damage when measured at the same follow-up
time point, but increased disease activity in the preceding 1 and 2 years were associated with
increased radiographic damage. This was in largely in agreement with Welsing et al.[214],
however this analysis also investigates the separate JSN and erosion scores, and looks at the
individual components of the DAS. Two findings from the analysis by Welsing et al.[214] were
not replicated in this analysis; that variation around the mean DAS was significantly associated
with radiographic progression, and that radiographic progression was non-linear over time.
The differences are likely due to differences in the models used in each study. Welsing et al.
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applied an identity link function, which assumes that the dependent variable follows a Gaussian
distribution (Normal). Chapter 5 demonstrates how this is rarely achieved with radiographic
outcome data, and therefore it is likely that the non-linear associations would have seemingly
provided improved model fit, by attempting to account for the large preponderance of zero
scores. Despite the improved model fit statistics, the lack of model fit is highlighted in Figure 3
of Welsing’s et al. study, which graphs the observed versus the predicted SvdH scores. It shows
a large number of zero scores being predicted to range from 0 - 50, thereby underestimating the
zero count.
The relationship between DAI’s and radiological progression has been the subject of a number
of studies, 58 of which were summarised by Navarro-Compa`n et al.[177] in their systematic
review (40 observational studies and 18 RCTs). The DAIs that were studied were predomi-
nantly the DAS and DAS-28 measures, but studies also looked at the simplified DAI (SDAI),
the clinical DAI (CDAI), the RA DAI (RADAI) and the routine assessment of patient index
data (RAPID). As was noted in Chapter 3, large heterogeneity in study populations, statistical
methods and classification of ‘significant’ radiological progression meant that direct compar-
isons between this analysis, and indeed between the studies reported in the review, is extremely
difficult. Furthermore, restriction to cross-sectional analysis, and the lack of multivariate tech-
niques, did not allow for any longitudinal associations to be examined. Nevertheless, there were
some trends emerging through pooling of these studies’ results. Those studies that looked at
time-integrated measures of DAI and their separate components were more likely to indicate
significant associations with radiographic damage compared to those concentrating on baseline
measures only. Only 4 of the 16 studies looking at the association between DAS at baseline and
radiographic progression found a significant association [77, 304–306], whilst all studies looking
at DAS as a time-integrated measure found a significant association with increased radiographic
progression[75, 104, 211, 214, 285, 291, 301, 302, 307, 308].
The results from this study adds to the growing body of evidence that radiographic progression
is a delayed consequence of increased disease activity over time. The results are also highly
suggestive of the fact that this is largely driven by increased inflammatory markers over time,
in this particular study ESR, rather than the subjective markers such as TJC. This was also
highlighted in the systematic review paper and led to the recommendation that DAIs should,
at the very least, include a measure of SJC[177], but these results would suggest acute phase
markers, particularly ESR, is of higher importance. As discussed above, whether these prove to
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be as important in the context of overall reductions in radiographic progression needs further
review.
Radiographic progression and its association with HAQ
The next stage of this chapter’s analysis was to investigate the association between radiographic
progression and functional disability. As with the DAS analyses, the first models looked at the
time-averaged effect of functional disability with radiographic progression. The results found
that those patients with increased rates of radiographic progression over the 10 years were likely
to have increase functional disability over the first 10 years. The effect was also found to increase
significantly over time. This, coupled with the increasing correlation over time, indicated that
HAQ is indeed associated with radiographic progression, but only in later disease. This was
further substantiated in the TVC analysis, which indicates that HAQ scores increase over time
as radiographic damage increases. However, unlike the DAS, there is little evidence of a lagged-
effect. This result could suggest that while the effect of radiographic damage on patients is
only apparent in established disease, once the disease is established, increases in radiographic
progression have an immediate impact on increasing functional disability[294].
Interestingly, despite large reductions in radiographic damage in ERAN, the association with
functional disability over 5 years remained largely unchanged. There was an indication of slight
improvement by year 5 in ERAN compared to ERAS, but the reduced sample made it difficult to
draw any definitive conclusions. Earlier research using both the ERAS and ERAN cohorts found
a strong association between increased disease activity and increased functional disability[74].
While it is possible that improvements would be realised with more data, and longer follow-up
beyond 5 years, the lack of any immediate effect between reduced radiographic progression and
functional disability is suggestive of a second pathway involved in the development of functional
disability in RA[297]. The second pathway is one that is driven primarily by pain, rather
than inflammation. It could be theorised that functional disability is more highly associated
with psychosocial factors, including pain perception[309]. Although inflammation has been
adequately controlled, as evidenced by reductions in radiographic damage, pain is still largely
driving the association between the subjective components (TJC and PGA) and functional
disability[300].
Drawing parallels from this study with the previous literature is difficult, since there are large
variations in the statistical methods. Furthermore, multivariate statistical methods were rarely
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used[86]. The systematic review by Bombardier et al. does however highlight four main methods
for which radiographic damage and functional disability were compared; baseline comparisons,
correlations at specific follow-up time points, comparisons based on change scores of the radio-
graphic damage over time with either the mean or final HAQ score at follow-up, and finally
correlations between changes in radiographic damage and changes in HAQ over the follow-up.
The review found inconclusive evidence for the cross-sectional association between radiolog-
ical damage and functional disability at baseline, but did find evidence that the association
increased as disease duration increased. Those studies that assessed either the change in radio-
graphic damage with mean HAQ or HAQ at final follow-up, as well as those looking at changes
in radiographic damage with changes in disability over time indicated significant associations,
with four studies using multivariate analyses to control for important confounding effects[87,
310–312]. The authors argue these relationships are more clinically relevant, as they are sugges-
tive that changes in radiographic progression through improved treatment can alter the severity
of functional disability over time[86]. These findings are in direct agreement with the findings
presented in this analysis. Furthermore, the authors suggest that high variability in radiological
and inflammatory markers in early disease is likely to confound the association with functional
disability. This is true, particularly when, on average, patient’s HAQ score decreases in the
first year of disease as treatment is introduced[38]. The conscious effort in this analysis to
omit baseline measures limits the possible confounding effects they may have had on the model
results.
Of the two components that make up the SvdH, JSN and erosions, many studies have reported an
increased association between JSN and functional disability, as opposed to erosive damage[313–
316]. There was small evidence to suggest that JSN is more strongly associated with long-
term functional disability comapred to erosions, but the effect was small. As noted previously,
there remains a paucity of studies looking at the time-dependant association between functional
disability and the separate JSN and erosions components, with much of the literature focusing
on either cross-sectional radiographic damage at baseline, or time-averaged effects[304, 315].
Strengths and Limitations
The findings from this study provide a detailed understanding of the long-term associations
between radiographic progression and core RA outcomes in patients treated in a natural clinical
setting between 1986-2001. However, its main focus on data from the ERAS cohort restricts the
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ability to generalise these findings to RA patients treated using more contemporary treatment
strategies. Validation analysis looking at the sub-sample of radiographic data available from
the ERAN cohort, is highly suggestive of a reduced association between disease activity and
radiographic progression, although caution is needed due to the reduced statistical power, due
to the relatively low sample size. It is clear that in the context of T2T and biologic prescription,
more up-to-date data is sorely needed in order to establish whether the finding in this study is
replicated in larger datasets, with longer follow-up assessments.
Nevertheless, the analysis is one of the first to look at this relationship in such detail using the
appropriate statistical models to ensure any bias in the analysis is minimised. The extensive
analysis from the ERAS cohort serves as a comprehensive and worthwhile historical account
of how treatment during the pre-biologic period of RA management affected radiographic pro-
gression, and its relationship with disease activity and functional disability. Any documented
changes in more contemporary observational cohorts can therefore be compared and contrasted
to these results.
Concluding remarks
In summary, the findings presented here suggest that for those patients treated during the
pre-biologic era, radiographic progression is largely determined by increased disease activity
from early on in the disease. If left uncontrolled, this increased radiographic progression was
associated with increased functional disability in later disease. However, sub-analysis suggests
that large reductions in radiographic damage in recent years may have dramatically reduced the
clinical impact of increased disease activity on radiographic progression. Under current NICE
guidelines, only those patients with high disease warrant use of more effective biologic DMARD
therapies, due to increased disease burden. It is not clear whether widespread adoption of
methotrexate early on in the disease has led to sufficient control of radiological progression, as
has been demonstrated in some RCTs[56]. The association with functional disability was found
to be largely unchanged by the reductions in radiographic progression, suggesting that functional
disability may be more primarily driven by psychosocial factors, such as pain perception, rather
than acute inflammation.
Further research is needed to collect long-term radiographic data in more contemporary co-
horts to establish whether substantial treatment changes, particularly the use of very early
methotrexate in combination with other conventional DAMRDs, is sufficient at reducing the
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increased radiographic progression rates demonstrated here. There is also a need to look more
closely at psychosocial factors and their relationship with functional disability, to assess how
non-pharmacological interventions may be able to improve patients quality of life over and above
disease control[309].
Chapter 8
Discussion
8.1 Introduction
The overarching objective of this thesis was to explore radiographic damage in patients with
early RA. Four main aims were established to address this objective: (1) explore current meth-
ods for measuring radiographic damage, (2) assess the most suitable statistical techniques to
evaluate radiographic damage longitudinally, (3) evaluate the ‘natural, true-to-life’ progression
of radiographic damage using observational data, and finally (4) investigate the longitudinal
relationship between radiographic damage and two core RA outcomes; disease severity and
functional disability.
There are few observational studies with long-term radiographic data with large sample sizes,
transcending both the pre and post biologic era, and the statistical methods typically used were
inappropriate. The longitudinal data on radiographic outcomes that were available from both
ERAS and ERAN provided a unique opportunity to explore the natural (treated) progression
of radiographic damage over time in two cohorts representing distinct eras in the therapeutic
management of RA.
This chapter will collate the findings from each of the chapters and look at how they address the
specific aims of the thesis set out above, and how they fit with current evidence base. The main
strengths and limitations of the cohorts and statistical methods used will be discussed, and the
thesis will conclude by exploring what possible implications the findings from this thesis have
on the clinical management of RA, and possible directions for future research in this area.
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8.2 Aims of the thesis
8.2.1 Measurement of radiographic progression
The use of radiography in clinical practice is valuable to the clinician, as it can provide an
objective ‘snap-shot’ of joint damage at any single point in time, and indeed any progression of
this damage over time[119]. Chapter 2 provided a summary of all the scoring methods currently
used in studies on RA, however both the Larsen and SvdH were found to be the most commonly
used. Chapter 3 also confirmed that in more recent studies, the SvdH was the preferred method
of choice. This is likely due to its ability to measure both JSN and erosions as separate scores,
rather than being limited to just a single composite score, as with the Larsen method.
The Outcome Measures in RA (OMERACT) group recommends radiographic joint damage as
a core outcome measure in RA research, since it achieves all three component criteria set by the
OMERACT committee; 1) truth, in that it measures what it intends to measure with good face,
content, construct and criterion validity, 2) discrimination, in that it can differentiate between
two different situations of interest, be they time or states, and 3) feasibility, in that the plain
radiographs can be easily obtained and interpreted in a cost-effective manner[131]. However,
despite its advantages, understanding the limitations of radiographic scoring is crucial in en-
suring radiographic scoring remains the ‘gold standard’ and does not become ‘fool’s gold’[118].
One of the most notable limitations of radiographic scoring is the time and training required
to score each radiograph[118, 317]. While the use of expert radiologist to score radiographs
has proved to result in little variability between scorers[97, 318], this does restrict the ease in
which these measures can be recorded for both observational trials and clinical practice. This
is particularly true when compared with other clinical and patient reported RA outcomes, such
as the DAS and HAQ.
The Simple Erosion Narrowing Score (SENS) was developed to decrease the time taken to
score radiographs in a clinical setting[243], with further attempts made to simplify the score
further by omitting joints that do not have a large effect on the measurement performance[319].
Although some studies have found the SENS to have good agreement with the modified SvdH
score[103, 243, 320, 321], most of these studies have been restricted to early disease and very
small samples. Rau et al.[322] argue that since the SENS can only increase over time as new
joints become affected, it lacks any reliability to detect increased radiographic damage in late
disease, when no more new joints are involved.
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Another limitation is inter-reader variation. Chapter 4 highlighted how variation increased at
the higher end of the scale, and that heteroskedasicity needed to be accounted for in any anal-
ysis of radiographic outcomes. In the context of longitudinal studies, research has shown that
inter-reader variability can be reduced by reading radiographs for each patient in chronological
order[102, 323, 324]. However, this is at the expense of potentially over-estimating the pro-
gression of radiographic damage, as the reader might inherently be expecting to see increased
progression over time[102]. This has important implications on the measurement of erosive heal-
ing. Bone erosions, or osteolysis (bone loss) occurs from an imbalance whereby bone resorption
(osteoclasts) occurs more than bone formation (osteoblasts)[325]. Although physiologically pos-
sible, erosive healing remains a rare occurrence, even in those patients treated with biologics. In
an RCT looking at adalimumab treated over 1 year, erosive healing was rare[326], and appears
to occur exclusively in those joints with little to no joint swelling[327]. Although, it is noted
that there remains a lack of longitudinal studies investigating its prevalence in contemporary
cohorts[325].
While this study, and indeed other studies, have reported high inter-reader reliability scores,
disagreements still do occur[118]. The impact of other co-morbid diseases, particularly OA
on the interpretation of JSN, can easily lead to differences in how radiographic progression is
assessed over time[328]. Since osteoporosis is more difficult to quantify, it is generally excluded
from radiographic scoring methods[95].
While not without its faults, radiographic scores still represent one of the most important out-
come measures in RA, providing an objective indication of the pathological damage caused
by increased and prolonged inflammation[322]. While scores like the SENS seek to reduce the
time burden associated with the application of radiographic scoring techniques, the reduction
in sensitivity at the end end of the scores[104], and in late disease[322], do not outweigh the
advantages in time saved. While new methods that account for reading order, co-morbid con-
ditions and erosive healing are welcomed, these methods will still inevitably produce data with
non-normal distributions. As such, it could be argued that more focus should be placed on
appropriate analysis techniques, rather than development of new scoring methods.
8.2.2 Modelling of radiographic damage longitudinally
The systematic review conducted in Chapter 3 identified large heterogeneity in the statistical
methods used to look at the progression and predictors of long-term radiographic progression.
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This heterogeneity has been highlighted in previous systematic reviews[86, 313], where Bom-
bardier et al.[86] specifically point out the lack of multivariate techniques in previous research.
However, of equal concern is the apparent use of statistical methods, which are not appropriate
given the properties of radiographic outcome data. Chapter 4 demonstrated how the distri-
bution of scores are highly positively skewed due to large numbers of patients with early RA
with no perceivable radiographic damage. The result is an excess of zero scores that causes
over-dispersion.
Round table discussions in 2002[237] led to the development of guidelines on the reporting of
radiographic results in RCTs. The lack of consistency in the reporting of mean or median values
as the primary endpoint hinders the ability to produce uniform datasets for wider comprehension
of the data[237]. The recommendations includes the following; the use of two readers, the
reporting of the SDD as quality control, presentation of absolute numbers, focus on group level
estimates as the primary analysis and the use of both the mean/SD and box plots for the
median/IQR. The use of cumulative probability plots have also been presented as a means of
improving interpretability[249]. This plots the cumulative probability of the score against the
actual score, in ranked order. This method is advantageous as it is an effective method of
summarising the range of scores for either an individual over time, or for specific sub-groups
of patients (e.g. trial arms in an RCT). While these recommendations have been pivotal at
highlighting the statistical challenges involved with radiographic data in RA, they are only
useful as an aid to interpreting radiographic damage, and are not a replacement for statistical
models[249]. As such, more is needed to improve the use of statistical models in the RA literature
on radiographic progression.
The non-normal properties of radiographic data distributions is likely to explain the large vari-
ation in statistical methods used[329]. Transformation of the radiographic score into binary
groups has been seen as the most effective way of dealing with the non-normal distribution,
however, defining these groups has been far from easy. One of the core initiatives as part of the
OMERACT V meeting was to assess the application of a MCID threshold, whereby a certain
degree of radiographic progression would determine whether a patient had ‘clinically meaning-
ful’ radiological damage or not[122]. The initaitve failed to yield any decisive definitions for this
cut-point, however it was agreed that the SDD was an appropriate starting point. While the
SDD can reflect the point at which a change in score is no longer due to measurement error[124,
283], it might not reflect clinically relevant changes[330]. As such, a change in score that also re-
flects changes in other important related outcomes, such as HAQ, would ensure clinical relevance
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of any defined thresholds[330]. What has been overlooked however, is that current publicised
methods for calculating the SDD rely on the standard deviation as a measure of variance. Given
the highly positive skew of radiographic data demonstrated in Chapter 4, the asymmetry of the
data distribution renders the SD inappropriate, since the variance below the mean is likely to
be lower than the variance above the mean. For these reasons, this thesis looked at alternative
methods of modelling radiographic damage that did not rely on categorisation or forms of data
transformations.
Chapter 5 demonstrated why linear models, even with data transformation methods applied,
are not appropriate for radiographic outcomes. Given that radiographic scores are more ac-
curately defined as a weighted count outcome, the chapter explored the suitability of count
based regression methods. This would allow the radiographic score to be modelled without any
transformation, while still accounting for its non-normal distribution. The two main count dis-
tributions investigated were the Poisson and NB. The Poisson distribution failed to adequately
account for the high frequency of zero scores, since it assumed the data had equidispersion (that
is the mean was equal to the variance). It was clear from the data that radiographic outcomes
suffer from overdispersion (variance was much larger than the mean), therefore the NB was
needed. The NB method provided very good model fit and was able to accurately predict the
large proportion of zero scores.
Zero-inflated Poisson and NB were also explored in Chapter 5, where a two-component or two-
part modelling process is undertaken. The first component models the probability of the count
being a zero or non-zero score (binary model), while the second component models the frequency
count of all non-zero scores (count model). Park et al.[126] conducted a similar study looking
at the suitability of count regression methods on radiographic data, using data from 190 RA
patients with follow-up for up to 3 years. They also found the NB method to be superior to
the Poisson in terms of model fit. However, when including the zero-inflated parameter in both
Poisson and NB models, they concluded that the zero-inflated Poisson model provided the best
model fit over both the NB and zero-inflated NB.
For the analysis conducted in this thesis as part of Chapter 5, both the Poisson and zero-inflated
Poisson indicated the worst model fit. There were only marginal gains in predicted zero counts
and model fit statistics by adopting the NB zero-inflated model over the standard NB model.
This was evidenced by the predictive probability plots in Figure 5.8, which demonstrated that
both the Poisson and zero-inflated Poisson did not accurately predict the lower proportion of
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the scores as well as either the NB or the zero-inflated NB. The differences could be explained
by differences in the mean-variance relationship in the ERAS data versus the data used in the
study by Park et al.[126].
Further support for the suitability of the models is provided by Xie et al.[331]. They note how
for instances where the mean count is low due to rare events, zero-adjusted models are not
always necessary, and the adoption of zero-inflated methods can lead to over-fitting and less
parsimonious models. Additionally, while zero-inflated methods are an effective means of dealing
with excess zero scores, the application of both of these modelling techniques make theoretical
assumptions about the nature of the zero-scores. In the context of radiographic progression, a
zero-inflated model assumes that non-erosive forms of RA exist. That is, there is a probability
that some patients have a form of RA where radiographic damage will never occur. There is
little evidence of non-erosive forms of RA[263], and it is believed that all forms of RA have the
capacity to incur radiographic damage if not suitably controlled. Conceptually, trying to tease
apart those patients that have non-erosive forms of RA, compared to those that have milder
forms of RA but are suitably controlled by DMARD therapies, becomes very difficult in the
observational study setting. This thesis therefore argues that the use of zero-inflated methods
should be decided based on conceptual grounds, rather than purely statistical grounds[331],
and as yet, there is little theoretical evidence for the use of zero-inflated in the application of
radiographic outcomes.
Finally, the importance of using either GEE or multi-level models in longitudinal data was
outlined. While both are acceptable methods for modelling data over time, the advantages of
looking at within-group estimates, and the use of FIML estimators to handle missing data, led
to the conclusion that multi-level NB regression is the preferred modelling technique of choice.
It was therefore subsequently used in the primary analysis of this thesis.
8.2.3 Progression of radiographic joint damage
The third aim of the thesis was ‘to understand the natural (but treated) progression of radio-
graphic damage in RA using data from two UK inception cohorts’. Chapter 6 outlined the first
primary analysis of radiographic data from the ERAS and ERAN cohorts, using the statistical
models outlined in Chapter 5. The results found that patients in ERAN (treated from 2002-
2012) have approximately half the radiographic damage at baseline, and approximately half the
annual rate of radiographic progression over the first 5 years, compared to patients in ERAS
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(treated from 1986-2001). This was largely driven by reductions in JSN, with reductions in
erosions contributing in later disease only.
Despite reflecting slightly different periods, the meta-analysis in Chapter 3 indicated similar re-
sults, with patients treated post-1990 estimated to have half the yearly rate of radiographic dam-
age compared to those patients treated pre-1990. This trend towards decreasing radiographic
progression has been documented in other studies[224, 226, 275], with decreased radiographic
progression in more recent years. In contrast, the difference in baseline radiographic rates in
Chapter 6 was only demonstrated in the study by Fiehn et al.[275]. The systematic review
in Chapter 3 and the studies by Finckh et al.[226] and Sokka et al.[224] demonstrated similar
rates of radiographic damage at baseline between the periods analysed. It is likely that these
differences between baseline rates reflects a secular trend. The systematic review in Chapter 3
and the studies by Finckh et al and Sokka et al. all compared patients from the 1980s to those
patients from the 1990s. The analysis in Chapter 6 and the study by Fiehn et al. primarily
compare patients from the 1990s to those recruited from the 2000s. Overall, the evidence sug-
gests that baseline rates of radiographic damage was similar for those patients treated in the
80s and 90s, but patients treated in the 2000s and onwards have significantly lower radiographic
damage at presentation.
While the non-randomised nature of the study means it is not possible to directly test the
causal nature of this secular decline, it is hypothesised that the early use of methotrexate in
the ERAN cohort, during the so-called ‘window-of-opportunity’[54], is likely to explain these
improvements. However, the reduction of radiographic damage at baseline observed between
ERAS and ERAN could be evidence of less severe disease. While direct comparisons between
the DAS is complicated by the use of the DAS-44 in ERAS and the DAS28 in ERAN, the median
ESR at baseline, the proportion of patients with low HB and the proportion of seropositive;
RA in ERAN was substantially lower. Fiehn et al.[275] also demonstrated reduced radiographic
damage in their later cohort, along with significantly reduced ESR at baseline.
While the model controlled for the use of DMARD and steroid treatment in the ERAN cohort,
capturing the full extent of actual use and dosage of these drugs is complex. It is also possible
that the reduction in radiographic damage seen at baseline in the ERAN patients is a reflection of
early initiation of steroids in primary care in a small proportion of patients, for which duration
and dosage was not fully captured, and which occurred much less in the ERAS cohort. It
is also possible that the effect of milder disease at presentation may have also contributed
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to the decreased radiographic progression rates over the following 5 years. The systematic
review in Chapter 3 found that acute phase markers were consistently associated with increased
radiographic progression over the long-term, insinuating that the decreased progression is due
to a combination of both a milder form of disease at presentation and improved treatment early
on.
The second major finding in Chapter 6 was the changing contribution of seropositive RA on
the progression of radiographic damage between the two cohorts. While seropositivity was
associated with increased radiographic progression in both cohorts, the absolute change in score
was much lower in ERAN, compared to ERAS. This resulted in seropositive patients in ERAN
demonstrating significantly lower radiographic progression over the first 5 years compared to
seronegative patients in ERAS. It should be noted that seropositivity in both cohorts was
restricted to RF positivity, with only a very small proportion of patients being tested for ACPA
positivity. In a recent study by Hecht et al.[332], the impact of RF and ACPA on erosive damage
was evaluated using high-resolution peripheral quantitative CT (HR-pQCT). They found an
interdependence of both RF and ACPA anti-bodies on bone erosions, where the presence of
both led to an additive effect on the cumulative prevalence and size of bone erosions. However,
when van Steenbergen et al.[333] investigated this hypothesis using radiographic data scored
using the SvdH method from two early RA cohort studies in the Netherlands, they found that
the rate of radiographic progression for those patients who were ACPA positive had similar levels
of radiographic progression regardless of RF status. This does not support the additive effect,
as suggested by Hecht et al.[332]. These studies do indicate increased radiographic damage in
those patients that are ACPA positive compared to just RF positivity, a finding that has been
replicated in other studies[288, 289]. Both studies utilise linear longitudinal methods, and were
restricted to just the erosion score. Future research needs to investigate the added association
of ACPA positivity over RF positivity on total radiographic damage, while using appropriate
methods described in this thesis. The impact of secular changes on ACPA positive RA is also
currently unknown.
8.2.4 Radiographic damage, disease activity and functional disability
The final chapter, Chapter 7, addresses the fourth aim of the thesis; to investigate the longi-
tudinal relationship between radiographic damage and two core RA outcomes; disease severity
and functional disability. Disease activity measures are crucial in the therapeutic management
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of RA, as they provide the targets which clinicians aim for under the current T2T paradigm[49,
57]. It is important to understand the progression of radiographic damage, and its relationship
with disease severity, as previous studies have shown it to be associated with important pa-
tient outcomes, namely functional disability[86]. The analysis presented in Chapter 7 indicated
that increased disease activity is associated with increased long-term radiographic progression
and functional disability. Looking at the longitudinal relationship, there was evidence of a
time-lagged effect between markers of inflammation, namely ESR and SJC, and radiographic
progression. This finding is in agreement with previous systematic reviews investigating the
association between radiographic progression and DAIs[177].
In the earlier ERAS cohort, moderate disease is associated with similar rates of radiographic pro-
gression as those patients with high disease. However, sub-analysis looking at patients from the
ERAN cohort indicated that dramatic reductions in overall radiographic rates means that the
progression of radiographic damage was relatively low across all disease groups. This has very
important implications on the debate about whether biologic therapies need to be introduced
to those patients in moderate disease. RCTs, looking at the addition of combination biologic
DMARDs in patients with moderate disease, have concluded that the inclusion of biologics lead
to significant improvements in radiological damage[291, 303]. However, investigation of the re-
ported annual rate of radiographic damage over 1 year was just 0.8 units for the methotrexate
only group[303], and just 0.6 units per year over 7 years[291]. As was shown in this analy-
sis, while the association with disease activity is statistically significant, it indicates only very
minor increases in radiological progression, much lower than reported rates deemed clinically
meaningful.
While the introduction of biologic therapies will undoubtedly lead to improved radiographic
outcomes, the economic argument for introducing biologics in moderate patients needs to be
explored. From purely a radiographic standpoint, early combination therapy with methotrexate
is evidenced to reduce radiographic progression to a similar level to that of combination biologic
therapies[56, 334]. The need to use biologic therapies in relation to other RA outcomes is more
striking. Studies using the data from both ERAS and ERAN have demonstrated that those
patients with persistent moderate disease over the first 5 years were found to have increased
functional disability and increased incidence of orthopaedic surgical rates[74], and that ERAN
patients with moderate disease at baseline, were unlikely to achieve clinical remission by year 3
on conventional DMARD therapies[72]. Data from the BSRBR has also demonstrated that the
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use of biologic DMARD’s can significantly reduce the level of functional disability over 1 year
in patients with moderate RA[73].
The reduction in radiographic damage in ERAN also correlates with improvements in other
outcomes related to radiography. Nikiphorou et al. found that the incidence of intermediate
orthopaedic surgical procedures (involving the small joints of the hands and feet) have sig-
nificantly declined in more recent years[274], which may be explained in part by reductions in
radiological progression. However, although the analysis shows a significant association between
radiographic damage and functional disability, one which does not occur until later in the dis-
ease, there was little, if any, evidence that the association improved in the ERAN cohort. These
findings are supportive of the model proposed by Escalante and Rico´n in 2002, where functional
disability can be a result of either inflammation and radiographic damage, or through pain,
mediated by psychosocial factors[297]. It could be hypothesised that the increased relation-
ship between disease activity and functional disability seen in this patient group[74], is being
largely driven by the subjective markers of DAS (TJC and PGA), and that other aspects of the
biopsychosocial model proposed by Escalante and Rico´n should be targeted to reduce functional
disability[297].
8.3 Strengths and Limitations
The data comes from two of the largest early RA cohorts in the UK, which recruited a combined
total of 2,701 patients followed-up for up to 25 years. All patients were treated in rheumatology
outpatient clinics across the UK, based on published clinical guidelines at the time. The patients
were recruited from centres all over the UK, ensuring high generalisability to a large number
of patient groups. The analyses presented within concentrates on radiographic data. A total
of 7,100 plain x-rays collected from 1,678 patients were scored using the SvdH method over
the first 10 year period, while 5,763 radiographs from 1,662 patients were scored using the
SvdH method over the first 5 year period . This large data sample allowed for multi-level,
multivariate modelling techniques to provide precise estimates on the natural progression of
radiographic progression transcending over 3 decades.
Although the use of evidence hierarchies in evidence based medicine has helped clarify the quality
and usefulness of a specific study design in answering a research question, its simplified approach
has also resulted in a lot of misconceptions[335]. Clinical trials are widely regarded as the most
Chapter 8. Discussion 156
effective means of determining the effect of an intervention[134]. However, different research
questions require different research designs in order to provide the most valid results[133]. In
the case of this thesis, observational cohort data is the most appropriate means of examining
the natural progression of the disease in specific patient sub-groups over a long time period[336].
However, understanding the potential causal links surrounding the results found is difficult
without the randomised nature of clinical trials. Potentially important confounding effects,
both known and unknown, can be minimised through random allocation of patients, and blinded
assessment of outcomes[133]. Although, that is not to say that causal effects are impossible to
investigate using observational data. Statistical techniques, such as propensity scoring, can be
an effective means of looking at treatment effects in observational data[337]. However, as with
all methods, it is imperative that the methods are correctly applied[337]. The approach taken
by this thesis was not to apply methods such as propensity scoring, but to ensure the analysis
made every effort to control for potential confounding effects through the use of multivariate
regression techniques. The analysis avoided automated covariate selection techniques, such as
stepwise selection, as those have been shown to introduce bias[338]. Instead, the selection of
covariates was selected based on prior research and theory about which factors are important in
the progression of radiographic damage. Potential causal associations, namely treatment effects
and milder disease, were highlighted based on the findings, and the weight of this evidence
was supplemented by findings from experimental studies. The result is that the conclusions
regarding why these patterns are emerging are subject to further scrutiny, and can only be
confirmed or indeed denied by further research.
Another key limitation of observational data is missing data. The analyses in Chapter 7 largely
utilise the radiographic data from the ERAS cohort, for which the proportion of patients with
missing data is small. Missing data beyond 10 years was high due to non-participation of
centres beyond the 10 year mark, leading to the decision to restrict analyses to 10 years only.
Missing radiographic data within these 10 years was accounted for by the use of multi-level
modelling, which utilises FIML estimation, allowing for radiographic rates over the full 10 years
to be estimated for each patients with at least 1 available data point[339]. Furthermore, the
characteristics of those patients with and without radiographic outcomes was found to be very
similar, leading to the conclusion that the bias from missing data was likely to be small, and it’s
likely the MAR assumption is satisfied. Nevertheless, the possibility that those patients with
greater number of radiographs represent a sub-group of patients with more aggressive forms
of RA (hence the need for more x-rays), is still present. In contrast, there was a significantly
Chapter 8. Discussion 157
reduced amount of radiographic data for the ERAN cohort. While radiographic data was
available for all centres, scoring of those radiographs using the SvdH method was only conducted
for 6 of the 23 centres. Although, it was found that patients from these 6 specific centres were
similar to the whole cohort with regards to demographic and baseline characteristics, suggesting
that the data was MAR. As with the ERAS cohort, those patients with radiographic data were
similar in demographic and clinical characteristics to those without radiographic data. The
reduced data sample did however restrict the ability to apply longitudinal models over 5 years,
whilst maintaining high levels of precision around the model estimates. Further scoring of the
digitised radiographs from the ERAN cohort would allow for more accurate estimates from the
ERAN cohort, as well as extending the analysis to longer follow-up periods of up to 10 years.
Missing data from the covariates included in the model were fairly low, and driven more by
missing radiographic data. While the incorporation of multiple imputation methods into multi-
level models is possible, it is complex[340]. Given the relatively low missing data on DAS and
HAQ measurements compared to the radiographic data, it is unlikely that the incorporation of
these complex methods would have yielded remarkably different findings.
8.4 Clinical Implications
The clinical utility of radiographic assessment has been challenged on several grounds[119].
Many clinicians question their use in routine clinical practice due to the lagged effect between
pathological changes and the manifestation of erosions and JSN that can be detected on plain
radiographs[119]. However, elsewhere it is regarded as an indispensable and a readily available
tool in the clinical setting to guide therapeutic management[119]. EULAR recommendations in
2013[84] on the use of imaging in the clinical management of RA indicated strong support of
periodic radiographs to monitor disease progression. In light of the secular declines displayed
in this thesis, showing relatively low rates of radiographic progression, the continued need for
routine x-rays is debatable. While the thesis has focused primarily on the use of plain x-rays,
EULAR does highlight the use of other imaging modalities, such as MRI and ultrasound, in
detecting soft tissue inflammation. However, the availability, practicality and cost effectiveness
of these modalities in routine care is still yet to be determined[84].
At the other end of the spectrum, sub-clinical inflammation has been shown to progress, even in
those patients in clinical remission[341, 342]. Clinical remission defined using DAS thresholds
is not uncommon, even in historical cohorts, such as ERAS[343–345]. While not the focus of
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this thesis, radiographic progression was evident in patients with sustained remission in both
ERAS and ERAN, albeit at a much lower rate compared to other disease activity groups. This
is supported by additional research that looked at the Larsen score in the same data[346]. As a
result, many argue that there is a need to incorporate radiographic measures within the ‘clinical
remission’ definition set by disease activity scores[347, 348].
The analysis looking at the association between disease severity and radiographic progression
has also provided unique insight into the debate surrounding the use of biologic DMARDS in
the UK. Current guidelines permit the use of biologics in patients with sustained high disease
activity, and there have been recent calls to reduce this threshold to include moderate disease
in order to achieve the target of remission[72–74]. Data from the ERAS study provided more
evidence that those patients with moderate RA follow a similar level of radiographic progression
compared to patients with high RA. However, the large secular decline seen in the ERAN cohort
again suggests that, from purely a radiographic perspective, patients overall are not progressing
at a rate seen in historical cohorts. While the introduction of biologic DMARDs in more patients
with less severe disease would undoubtedly lead to improvement in radiographic outcomes, the
magnitude of this effect needs to be established. This has been shown in RCTs[56, 334], where
tight management through the use of early combination DAMRDs with methotrexate, according
to T2T principles, has been proven to be as effective as combination methotrexate with biologic
therapies.
The possibility of a two pathway model driving functional disability highlights the pressing need
to look at other psychosocial interventions in the management of RA[297, 349]. Patients with
RA report higher levels of depression and anxiety when compared to healthy individuals[350].
Impaired cognition brought about by depression and anxiety can reduce the ability for an RA
patient to manage pain, bringing about a cyclical pattern whereby depression causes increased
pain, and increased pain causes further depression[309]. Pharmacological treatments are aimed
at modifying the disease, which lead to pain through inflammation. However, patients typically
require the additional use of analgesics to further manage their symptoms[300]. The assessment
of quality of life measures in the ERAN cohort has shown improvements in the first 12 months
of up to 20%. Although, rates remained the same over the next 4 years, at lower levels than
the rest of the UK[300]. A systematic review has shown that non-pharmacological interventions
can lead to improvement in RA outcomes, including functional disability[351], although the
methodological quality of these studies was found to be relatively poor. Further emphasis is
needed in understanding how interventions can improve patients’ quality of life[309, 352, 353],
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and how psychosocial factors can influence disease outcomes, such as functional disability, so
that more holistic treatment strategies can be implemented in routine care to address all aspects
of the disease; from inflammation to quality of life.
8.5 Future Research
The natural next step in continuing this research is to apply the models developed within this
thesis to larger, more contemporary, cohort data. In particular, increased radiographic data from
patients treated in the biologic era would enable the findings from this thesis to be extended.
RA encompasses a wide spectrum of disease severity, ranging from mild and remitting, to severe.
This thesis has highlighted the high variation in radiographic progression between patients over
time, and the subsequent need to apply modelling techniques to account for this. While these
methods are appropriate for estimation of single group trajectories, there is perhaps an argument
to define sub-group trajectories of patients that progress in different ways over time. Research
by Park et al.[208] examined the possibility of different patterns of radiographic progression
by using statistical clustering methods. Using this method, they identified 3 distinct patterns
of radiographic progression using data from 190 early RA patients examined over 3 years;
increasing, increasing then decreasing and flat. These patients represent a relatively small sub-
sample of RA patients, treated during the pre-biologic era only. Future research could extend
these findings to see whether these sub-groups of patients exist in both a larger cohort in the
pre-biologic era (such as ERAS), and whether differences in disease severity and treatment in
the post-biologic era, has led to differences in the patterns of radiographic progression.
Further still, the increased patient numbers and follow-up could also allow for more novel statis-
tical methods to be utilised to identify these sub-group trajectories. A recent paper by Norton
et al.[292] looked at the use of Growth Mixture Modelling (GMM), a form of latent class mod-
elling, to investigate distinct trajectories of functional disability (HAQ) over 10 years using the
ERAS data. The traditional methods of multi-level modelling used in this thesis assume that
a single trajectory can adequately approximate the entire sample[292]. Latent based modelling
relaxes this assumption and allows for distinct sub-group trajectories to be examined. As a
result, a total of 4 distinct HAQ trajectories were identified; low stable, moderate stable, mod-
erate increasing and high stable. Understanding the potential factors that could predict patient
membership into these sub-groups could prove to be an invaluable tool in shaping treatment
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and management of RA. Norton et al.[292] highlighted how the Larsen score was significantly
increased at baseline, 3 and 5 years in the moderate increasing and high stable HAQ groups.
Increased radiographic data through scoring of more radiographs in the ERAN cohort would
also allow these more complex models to be conducted in both cohorts, allowing for a more
detailed look at radiographic progression between the two.
The long-term association with other important factors also need to be investigated. Smoking,
for example, has also been shown to be related to radiographic damage[34, 354, 355]. However,
there was insufficient data to investigate this relationship within this thesis. Collection of
smoking data in ERAS was not started until the 1990s resulting in firstly, missing data, and
secondly bias towards those still alive.
8.6 Final conclusions
RA is a disabling and chronic disease, which can lead to joint destruction and disability. Ade-
quate control is key, and recent adoption of T2T principles have shown remarkable success in
reducing the disease burden for patients now living with the disease. There is emerging evi-
dence that this has had a large impact on reducing radiographic damage. However, functional
disability has shown little improvement. While more evidence is needed to justify the increased
use of biologic DMARDs in those patients with less severe disease from a radiographic stand-
point, it could be pivotal in controlling long-term functional disability. However, it is possible
that a secondary mechanism causing disability exists, which could be entirely separate from
inflammation, and therefore more focus should be applied to looking at non-pharmacological
interventions. A more holistic treatment approach, incorporating psychosocial interventions,
with continued improvements on pathophysiological aspects, will likely lead to better disease
control, as well as improvements to patients’ overall quality of life.
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Formulae to calculate DAS with 4 or 3 variables and with ESR or CRP 
 
DAS   = 0.54 x √(Ritchie) + 0.065 x SJC44 + 0.33 x lognat(ESR) 
   + 0.0072 x GH  
 
DAS-CRP   =  0.54 x √(Ritchie) + 0.065 x SJC44 + 0.17 x 
lognat(CRP+1) + 0.0072 x GH  + 0.45 
 
DAS-3   =  0.54 x √(Ritchie) + 0.065 x SJC44 + 0.33 x lognat(ESR) 
+ 0.224  
 
DAS-3 CRP  = 0.54 x √(Ritchie) + 0.065 x SJC44 + 0.17 x 
   lognat(CRP+1) + 0.65  
 
Formulae to calculate DAS28 with 4 or 3 variables and with ESR or CRP 
 
DAS28    =   0.56 x √(TJC28) + 0.28 x √(SJC28) + 0.70 x  
lognat(ESR) + 0.014 x GH   
 
DAS28-CRP  =   0.56 x √(TJC28) + 0.28 x √(SJC28) + 0.36 x 
lognat(CRP+1) + 0.014 x GH + 0.96 
 
DAS28 -3   =   [0.56 x √(TJC28) + 0.28 x √(SJC28) + 0.70 x 
lognat(ESR)] x 1.08 + 0.16 
 
DAS28 -3 CRP  =   [0.56 x √(TJC28) + 0.28 x √(SJC28) + 0.36 x  
   lognat(CRP+1) x 1.10 + 1.15 
	  
EULAR criteria based on DAS 
  DAS < 1.60  - remission 
	   	   DAS	  ≥1.60	  and	  ≤	  2.40	   -­‐	   low	  disease	  activity	  
	   	   DAS	  >2.40	  and	  ≤	  3.70	   -­‐	   moderate	  disease	  activity	   	   	  
	   	   DAS>	  3.70	   	   -­‐	  	   high	  disease	  activity	  
	  
EULAR	  criteria	  based	  on	  DAS	  28	  	  
	   DAS	  28	  <	  2.6	   	   	   -­‐	   remission	  
	   	   DAS	  28	  ≥	  2.6	  and	  ≤	  3.2	   	   -­‐	   low	  disease	  activity	  
	   	   DAS	  28	  >3.2	  and	  ≤	  5.1	   	   -­‐	   moderate	  disease	  activity	  
	   DAS	  28	  >	  5.1	   -­‐	   high	  disease	  activity	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HEALTH ASSESSMENT QUESTIONNAIRE (HAQ) 
 
 
Name: ………………………………………………………….         Date: …………………………. 
 
We are interested in learning how your illness affects your ability to function in daily life. 
Please feel free to add any comments at the end of this form. 
 
PLEASE TICK THE ONE RESPONSE WHICH BEST DESCRIBES YOUR USUAL ABILITIES OVER THE PAST 
WEEK 
 
 Without 
ANY 
difficulty 
(0) 
With 
SOME 
difficulty 
(1) 
With MUCH 
difficulty 
(2) 
Unable 
to do 
 
(3) 
 
1.   DRESSING & GROOMING 
Are you able to: 
 
Dress yourself, including tying shoelaces 
and doing buttons? 
Shampoo your hair? 
 
 
 
o 
o 
 
 
 
o 
o 
 
 
 
o 
o 
 
 
 
o 
o 
 
2.   RISING 
Are you able to: 
 
Stand up from an armless straight chair? 
Get in and out of bed? 
 
 
 
o 
o 
 
 
 
o 
o 
 
 
 
o 
o 
 
 
 
 
o 
o 
3.   EATING 
Are you able to: 
 
Cut your meat? 
Lift a full cup or glass to your mouth? 
Open a new carton of milk (or soap powder) 
 
 
 
o 
o 
o 
 
 
 
 
o 
o 
o 
 
 
 
 
o 
o 
o 
 
 
 
o 
o 
o 
4.  WALKING 
Are you able to: 
 
Walk outdoors on flat ground?   
      Climb up five steps? 
 
 
 
o 
o 
 
 
 
o 
o 
 
 
 
o 
o 
 
 
 
o 
o 
 
 
 
PLEASE TICK ANY AIDS OR DEVICES THAT YOU USUALLY USE FOR ANY OF THESE 
ACTIVITIES : 
 
o   Cane o   Walking frame  o   Crutches o   Wheelchair   
 
o   Built up or special utensils  o   Special or built-up chair                        
o   Other (specify) ………………...  
 
 
PLEASE TICK ANY CATEGORIES FOR WHICH YOU USUALLY NEED HELP FROM ANOTHER 
PERSON : 
 
o   Dressing and Grooming o   Eating o   Rising  o   Walking   
 
 
 
PLEASE TICK THE ONE RESPONSE WHICH BEST DESCRIBES YOUR USUAL ABILITIES OVER THE PAST 
WEEK 
 Without 
ANY 
difficulty 
(0) 
With 
SOME 
difficulty 
(1) 
With MUCH 
difficulty 
(2) 
Unable 
to do 
 
(3) 
1. 5.   HYGIENE 
Are you able to: 
 
Wash and dry entire body? 
Take a bath? 
Get on and off the toilet? 
 
 
 
o 
o 
o 
 
 
 
o 
o 
o 
 
 
 
o 
o 
o 
 
 
 
o 
o 
o 
 
2. 6.   REACH 
Are you able to: 
 
Reach and get down a 5 lb object (e.g. a 
bag of 
potatoes) from just above your head? 
Bend down to pick up clothing from the 
floor? 
 
 
 
o 
 
o 
 
 
 
o 
 
o 
 
 
 
o 
 
o 
 
 
 
 
o 
 
o 
3. 7.   GRIP 
Are you able to: 
 
Open a car door? 
Open jars which have been previously 
opened? 
Turn taps on and off? 
 
 
 
o 
o 
o 
 
 
 
 
o 
o 
o 
 
 
 
 
o 
o 
o 
 
 
 
o 
o 
o 
4. 8.   ACTIVITIES 
Are you able to: 
 
Run errands and shop?   
      Get in and out of the car? 
      Do chores such as vacuuming,                                           
housework or  
      light gardening? 
 
 
 
 
o 
o 
o 
 
 
 
o 
o 
o 
 
 
 
o 
o 
o 
 
 
 
o 
o 
o 
 
 
PLEASE TICK ANY AIDS OR DEVICES THAT YOU USUALLY USE FOR ANY OF THESE 
ACTIVITIES : 
 
o   Raised toilet seat o   Bath rail o   Bath seat o   Jar opener  (for jars previously opened) 
o   Long handled appliances for reach  o   Other (specify) ……………….…………. 
 
PLEASE TICK ANY CATEGORIES FOR WHICH YOU USUALLY NEED HELP FROM ANOTHER 
PERSON : 
 
o   Hygiene  o   Gripping and opening things o   Reach  o   Errands and 
housework 
 
We are also interested in learning whether or not you are affected by pain because of your illness. 
 
HOW MUCH PAIN HAVE YOU HAD BECAUSE OF YOUR ILLNESS IN THE PAST WEEK ? 
 
Place a mark on the line to indicate the severity of the pain 
 
No pain ____________________________________________________ Very severe pain 
 
Appendix D
Radiographic Scoring Sheets
203
Following joints are assessed in the SvdH method for erosions: 
a. 10 MCP joints 
b. 8 PIP joints 
c. 2 IP joints of the thumbs 
d. right and left 1st metacarpal bone 
e. right and left radius and ulnar bones 
f. right and left trapezium and trapezoid as one unit 
g. right and left navicular bones 
h. 10 MTP joints 
i. 2 IP joints of the big toes  
 
Erosions are scored 1 if they are discrete and 2 or 3 depending on the surface area of the joint 
involved. In the carpal bones it is sometimes very difficult to score erosions as the bone 
collapses completely and in this case the collapsed area is given a score according to the 
surface area involved and a complete collapse is scored as 5. 
In each hand including the wrists, 16 joint areas are scored for erosions and a maximum 
erosion score for each joint is 5, whereas, in the feet 6 joint areas are scored for erosions in 
each foot with a maximum erosion score of 10 for each joint area, to increase weight of the 
feet joints in the total erosion score. Therefore, erosion score ranges from 0 to 160 in the 
hands and 0 to 120 in the feet with a total erosion score ranging from 0 to 280. 
 
 
 
Following joints are assessed in the SvdH method for joint space narrowing: 
a. 10 MCP joints 
b. 8 PIP joints 
c. right and left 3rd, 4th and 5th carpometacarpal joints 
d. right and left multangular-navicular joints 
e. right and left capitate-navicular-lunate joints 
f. right and left radio carpal joints 
g. 10 MTP joints 
h. 2 IP joints of the big toes 
 
Joint space narrowing is combined with score for (sub)luxation and is scored as: 
 0 = normal,   
 1 = focal or doubtful 
 2 = generalised but less than 50% of the original joint space,  
 3 = generalised and more than 50% of the original joint space or 
subluxation     
 4 = bony ankylosis or complete luxation   
JSN is assessed in 15 joint areas in each hand including the wrists and in the feet 6 joint areas 
in each foot are scored. Therefore, JSN score in the hands ranges from 0 to 120 and in the feet 
it ranges from 0 to 48 with a total JSN score ranging between 0 and 168. 
Erosion score and JSN score are added together to give a total Sharp score, which ranges from 
0 to 448 in the SvdH method. SvdH method has been used widely in several studies and is 
currently the most common method used in clinical trials.  
	   	  
Following	  joints	  are	  assessed	  in	  this	  modified	  Larsen	  method:	  
	   	   	  
	   Proximal	  interphalangeal(PIP)	  joints	  of	  	  both	  hands	   	   	   -­‐	   8	   	  	  
 Interphalangeal(IP) joints of both thumbs   - 2 
 Metacarpophalangeal (MCP) joints of both hands   - 10 
 Both wrists (score multiplied by 5)   - 2 
 Metatarsophalangeal joints (MTP) of 2nd -5th toes on both sides - 8 
 Interphalangeal (IP) joint of big toes on both sides   - 2 
 
Grading of radiographic abnormalities in this modified Larsen method: 
	  
 Grade 0: Normal finding  
Grade 1: Soft tissue swelling, juxta-articular osteoporosis, possibly with slight 
narrowing of the joint space 
	   Grade	  2:	   Early	  but	  definite	  abnormality	  consisting	  of	  bone	  erosion	  and	  	  
	   	   	  
	   	   distinct	  narrowing	  of	  the	  joint	  space.	  	  
	  	  
	   Grade	  3:	   Medium	  destructive	  abnormality	  with	  marked	  narrowing	  of	  the	  
	   	   	  
	   	   joint	  space	  
 Grade 4: Severe destructive abnormality. Only minor parts of the  
articular surfaces remain  
 
	   Grade	  5:	   Mutilating	  lesions	  
 
In this modified Larsen method, 20 joint areas in the hands and 10 joint areas in the feet are 
assessed with a maximum score of 5 for each joint area. The wrist is assessed as one unit and 
then multiplied by 5, which gives a maximum score of 25 for each wrist. Therefore, the total 
score in this method ranges from 0 to 200.  
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Importance of registries in informing 
clinical practice for arthritis
Lewis Carpenter1, Elena Nikiphorou2 & Adam Young*1,3
Practice Points
  Cohort studies and registries provide information on clinical guidelines and quality of 
care, drug safety and benefit–risk data, and health-related outcomes, including quality of 
life and clinical effectiveness.
  The prevalence of rheumatoid arthritis (RA) from registries in the UK in the 1990s was 
1.16% in women and 0.44% in men, which had decreased in women and increased in 
men from the 1950s. 
  RA has a very variable course, but is generally set in the first few years.
  Reduced functional ability is frequently an early feature.
  Rheumatoid factor remains the most useful prognostic factor.
  The long-term adverse effects of biologics include a slight increase in opportunistic 
infections. 
  The identification of ‘early RA’ is critical and drives forward improvements in 
management.
  The continuous use of contemporary data is important for national policy making 
organizations (the National Audit Office and NICE).
  Current databases underpin future and more ambitious national initiatives.
1The Center for Lifespan & Chronic Illness Research, University of Hertfordshire, Hatfield, UK 
2Department of Rheumatology, Addenbrookes Hospital, Cambridge, UK 
3Department of Rheumatology, City Hospital, St Albans, AL3 5PN, UK 
*Author for correspondence: adam.young@nhs.net
SUMMARY: The gold standard in research for evidence that underlies clinical practice 
is the randomized controlled trial. In recent years it has been accepted that observational 
studies, which include disease and drug registries and cohort studies, are very important 
sources of data not available from randomized clinical trials, and the two different approaches 
complement one another. In rheumatology, the development of clinical guidelines, standards 
of care and health policies, and appraisal of new drugs by NICE, all rely on clinical outcomes, 
prognostic factors and responses to drug therapies provided by both sources. Observational 
For reprint orders, please contact: reprints@futuremedicine.com
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Disease or patient registries are collections of 
secondary data related to patients with a spe-
cific condition or intervention. In previous 
decades, a disease registry in its simplest form 
would consist of a diagnostic index of patients 
collected at one point in time on paper cards 
kept by an individual physician. Now registries 
vary in sophistication from simple computer 
spreadsheets, with confined access, to very com-
plex databases, available online across multiple 
institutions. Although they may just provide 
a snapshot of a condition or drug, many have 
extended to include regular yearly follow-ups 
and collection of outcomes, either directly or 
through database linkage via unique personal 
identification codes, resulting in similar aims 
and designs to observational and longitudinal 
cohort studies. Cancer registries have been in use 
in the UK and internationally for many years, 
whereas in rheumatology most registries have 
been developed only recently to monitor the new 
biologic therapies.
The term 'cohort' is used to describe a group 
of people who have something in common 
when they are first assembled. A cohort is usu-
ally established based on a specific diagnosis, 
and individuals may be recruited either at the 
time of diagnosis (‘inception’) or any time in 
the course of their disease (‘prospective’). They 
are often referred to as long-term observational 
studies and used to describe and record the 
course and long-term complications of disease 
and its therapy. Ideally, they should be inception 
cohorts and provide assessments at specific and 
regular time-points for prolonged periods with 
as complete follow-up as possible.
Patient registries and cohort studies are very 
different from clinical trials in terms of design, 
logistics, approvals and site expectations. Success 
demands different expertise and core compe-
tencies. The main evidence for the efficacy and 
safety of medical products and therapies are pro-
vided by well-conducted randomized controlled 
trials (RCTs), considered the ‘gold standard’ 
research method. They generally study care-
fully selected groups of patients under controlled 
conditions, possibly over periods of months but 
not years. In a world of limited resources and 
patients with diverse risk factors and health con-
ditions, clinicians, patients and commissioners 
need to know which products and services are 
safer, more effective and adhered to in a variety 
of ‘true-to-life’ settings that reflect the popu-
lations of interest, in both the short- and the 
long-term. Longer follow-up is possible through 
open-label extensions of RCTs, but these again 
include positive selections of patients originating 
from the trials.
Registries and cohort studies imply differ-
ent processes to each other, and although they 
usually have different aims and designs, many 
ultimately come to resemble one another closely 
since most examine chronic conditions requiring 
prolonged follow-up. Most are related to condi-
tions responsible for the bulk of follow-up in 
clinical rheumatology, namely adult inflamma-
tory arthritis (AIA) and its subset rheumatoid 
arthritis (RA). Many have been designed for 
multiple purposes and not confined necessarily 
to answer just one research question. This article 
will examine the rationale, content and results 
of both registries and cohort studies for RA in 
the UK, although the principles and conclusions 
could apply to any medical field. Space restricts 
detailed inclusion of the many European and 
USA registries and cohort studies, which will 
be the subject of a future article.
Rationale for registries & cohort studies
Whether disease-based or product-focused, 
registries and cohort studies have been designed 
to capture data and evidence for both scientific 
and clinical governance issues. They provide the 
health community with invaluable data about 
the natural history of a disease or intervention 
under standard care practices, over periods that 
cover the development of most disease patterns 
and/or drug effects. Most aspire to regional if 
studies and registries in arthritis have promoted greater collaborations between academics 
and clinicians, and with patient support groups and public health. The main strengths of 
observational studies are that, first, they reflect ‘real-world’ practice and, second, they can 
achieve prolonged follow-up. As the management of chronic conditions such as arthritis 
becomes more complex and health economic issues more important in the 21st century, it is 
probable that more reliance will be placed on these types of studies.
725future science group www.futuremedicine.com
Importance of registries in informing clinical practice for arthritis | Review
not national coverage and many are voluntary. 
Clinical registries or cohort studies designed to 
capture operational clinical data as part of rou-
tine clinical care have the potential to promote 
better quality of treatment in general and in the 
individual patient, and specifically provide:
  Prevalence and incidence figures, geographical 
variations and secular change;
  Drug safety and benefit–risk data;
  Clinical guidelines and quality of care: 
develop ment, improvement, monitoring and 
adherence;
  Health-related outcomes, including quality of 
life;
  Clinical and cost–effectiveness;
  Immediate access to well-presented longitud-
inal patient records generated from little 
additional work for the clinician;
  Data for research questions and, with time, a 
powerful research database.
The medical care costs of chronic diseases 
account for most of the National Health Ser-
vice (NHS) budget, and some of the more 
common ones covered by national registries, 
for example cancer and diabetes. Registries are 
being increasingly developed for novel interven-
tions, for example drug products, such as the 
biologic agents.
Currently, the most common registries 
in rheumatology are the Biologic Registries, 
developed in European countries since the 
introduction in 2001 of the new, more effec-
tive and expensive TNF-blocking agents for a 
number of autoimmune inflammatory condi-
tions. At this time, the main clinical issues were 
not efficacy or short-term toxicity, which were 
not disputed, but were safety in the long-term 
and the choice of when the optimal stage of RA 
to introduce these novel agents was. The main 
reason for their initiation was because data on 
the long-term intended and unintended effects 
of biologics were relatively scarce. There were 
theoretical reasons to suspect that patients on 
biologics have increased risk of both malignan-
cies (especially lympho-proliferative) and oppor-
tunistic infections over time. Another reason in 
some countries was the requirement to register 
patients prior to securing funding for these 
agents. Initially the clinical criteria for eligibility 
for biologics varied between countries, although 
agreement has now been achieved in Europe [1]. 
Registries have the potential for improving the 
understanding efficacy of therapies in the long-
term, and provide information on whether a 
specific drug is clinically effective in real-world 
situations. 
Registries can be associated with pay-for-
performance quality-based contracts for indi-
vidual, groups of or all doctors in a country. 
For example, the UK now rewards physicians 
according to 146 quality measures related to ten 
chronic diseases that are tracked electronically, 
and linked to the best-practice tariff. 
In the USA, many registries are for surgical 
procedures or devices to monitor both long-term 
efficacy and healthcare expenses. The UK, Nor-
way, Sweden and Australia have national patient 
registries that track patients with artificial joints 
in order to assess performance over time. Regu-
lators can use such information to force manu-
facturers to justify why poorly performing hip 
or knee prostheses should remain available, and 
products have been withdrawn as a result. 
Ethical issues vary according to individual 
national laws. Generally, no ethical approval is 
needed for the publication of the results of clini-
cal audits that are based on routine collection of 
data. Research and other projects involving link-
age to other registries or biobanks require ethical 
approval. Registries generally clear their meth-
odology with data protection agencies, which are 
based on the Act of Processing of Personal Data 
that ensures that data security and protection of 
individual rights, among others, are dealt with 
correctly.
Historical account of registries 
& prospective cohorts of RA in the UK
The early population-based studies in the UK 
and USA in the 1950s–1960s provided data 
concerning the prevalence of RA and rheuma-
toid factor (RF) [2–4]. The findings suggested 
that self-limited polyarthritis was more com-
mon than progressive RA in general popula-
tions. RA inception cohorts in clinical settings 
followed, initially in the UK in the 1960s [5,6]. 
These cohorts provided, for the first time, valu-
able information on the course of hospital-based 
RA as they included strategies to follow-up the 
majority of patients using the same standard 
observations for at least 5 years. From these it 
became recognized that RA in the clinical setting 
differed from population studies. A far higher 
proportion of these patients had progressive 
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disease, supporting clinical experience. These 
differences were not widely recognized until the 
1970s–1980s when these studies had sufficient 
follow-up to report the wide spectrum of RA. 
Unfavorable outcomes were reported early on 
in the disease course and, in significant propor-
tions, were irreversible, resulting in questioning 
of management strategies.
Therapies at this time were limited to steroids 
and NSAIDs, and a small number of slow-
acting disease-modifying antirheumatic drugs 
(DMARDs). The more effective agents, such 
as intramuscular gold and d-penicillamine, had 
significant and sometimes severe toxicity, so the 
need for reliable predictors of severe RA became 
increasingly more important. 
At this time, no single marker or set of mark-
ers could be used to predict with certainty which 
patients were most likely to fare worse. The ini-
tial cohorts were disadvantaged by being single 
site and tertiary referral centers with limited 
numbers at follow-up, and not all assessments 
had been standardized. Scientific data from 
observational studies were not well regarded 
compared with randomized studies at this time, 
and it took several more years before it was rec-
ognized that if well designed and performed to 
a high standard, inception cohorts can provide 
clinical effectiveness and prognostic data to 
complement the results of RCTs [7].
Possible sources of bias in inception cohorts 
include small sample sizes at follow-up, left 
censoring (milder RA not being referred), right 
censoring (severe RA not surviving long enough 
for follow-up), and treatment effects. Assessment 
of therapies is limited in observational studies 
with nonrandom assignment of drug therapy. 
Study of drug efficacy is more reliably achieved 
with RCTs. However, newer agents can only 
be described as disease-modifying if demon-
strated to alter objective measures in the long-
term, namely x-ray damage. However, inception 
cohorts may permit comparison of the broader 
issue of clinical effectiveness of conventional and 
newer drugs in well-described historical cohorts.
A small number of single and multicenter hos-
pital- and community-based inception observa-
tional cohorts in RA were designed in the UK 
and northern Europe in the 1980s in order to 
address these issues. With greater numbers at fol-
low-up, some cohorts included the less common 
but important outcomes of clinical remission, 
work disability and orthopedic intervention. 
By the late 1990s most countries in northern 
Europe had established inception cohorts.
Most cohorts continue in follow-up, provid-
ing valuable comparative data on variations in 
therapeutic practice as well as other outcomes. 
Accumulated evidence from all RA inception 
cohorts has suggested that the course of the dis-
ease is highly variable, but is established early 
and that the most important phase for therapy 
is in the first 2 years. Most, but not all, have 
reported increased mortality compared with 
normal populations, mainly from cardiovascu-
lar disease. These factors were the main drivers 
for a more focused approach to the management 
of early RA.
Since the initiation of these cohorts, several 
major epidemiological advances in RA have been 
achieved in the last 15 years and included the 
revised classification criteria for RA [8], core sets 
of disease activity (DAS) measures [9], response 
criteria for the assessment of drug efficacy [10], 
and agreement on a core set of measures for 
longitudinal observational studies [11]. Another 
important development has been the formation 
of patient support groups in rheumatology. In 
the UK, both the National Rheumatoid Arthri-
tis Society and the Arthritis and Musculo skeletal 
Alliance have become active not only politi-
cally, but have also contributed to the forma-
tion and running of studies and interpretation 
of results [101,102]. 
An important advance of the 1990s was 
evidence to support early intervention with 
disease-modifying therapies in RA [12]. This, and 
the success of inception cohorts, just described 
above, led to the development of early arthri-
tis clinics, which are now part of standard ser-
vices in many rheumatology departments. One 
challenge in establishing early arthritis clinics 
is to collect data continuously during routine 
care when patients are seen for the first time, 
or to have a clinical research facility attached to 
the clinical unit with the capacity to perform 
immediate on-demand data collection [13]. 
The more effective and expensive biological 
agents became available at the start of the mill-
ennium and this major therapeutic develop-
ment resulted in the formation of product reg-
istries in the UK and many European countries 
including The Netherlands, Sweden, Norway, 
Denmark, France, Germany and Spain in order 
to monitor long-term adverse effects. The Brit-
ish Society of Rheumatology (BSR) established 
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the first Biologics Register (BSR-BR) in 2001 
providing invaluable data on these agents in 
several disease areas, and the model for simi-
lar registries in other specialties, for example 
dermatology [14].
Details of the main RA cohorts & biologic 
registries
Table  1 summarizes the basic details of RA 
cohorts and registries initiated in the UK from 
the late 1950s that have stood the test of time 
and have reported on important outcomes with 
adequate follow-up. These are also described in 
detail below, followed by brief descriptions of the 
more recent initiatives not in the table.
 Bath cohort
The first hospital-based early RA cohort recru-
ited patients at the Royal National Hospital for 
Rheumatic Diseases in Bath, UK, between 1957 
and 1963, and included 100 patients who met 
the American Rhematology Association criteria 
for definite or classical RA [15] and were first seen 
within 1 year of their initial arthritis symptoms 
prior to disease-modifying therapy [5]. Follow-up 
of these patients continued for up to 40 years 
and, although limited by progressively smaller 
numbers for analysis, it was the first to report 
a significant decline in functional capacity in 
as many as a third of the patients over the first 
3 years, as well as high disability rates in the 
longer term.
 The Middlesex Hospital cohort
The RAPS study was established in 1966 at 
Middlesex Hospital (London, UK) and enrolled 
consecutive patients with the same entry criteria 
as the Bath study, except that wider American 
Rheumatology Association criteria for RA were 
accepted to include less severe RA. The aim was to 
gather detailed information on the characteristics 
of disease onset in 100 patients in order to develop 
prognostic factors [6,16]. A novel finding was that 
serial x-rays of hands and feet demonstrated early 
changes, and nearly a third had structural damage 
by 1 year, rising to 71% by 5 years [17]. A subgroup 
of erosive patients was identified in whom no new 
erosions developed or progressed after approxi-
mately 3 years. This study was the first to show 
the importance of foot involvement in early RA, 
both clinically and radiographically
Only a few standardized and validated assess-
ments were available to these first two cohorts 
and sample sizes were small, but they did achieve 
15–25 years follow-up, and provided insights 
into early RA, which in this era was treated 
relatively late, mainly with intramuscular gold 
therapy as the first disease-modifying drug. Both 
demonstrated considerable fluctuation in the 
course of early RA and introduced the impor-
tance of serial follow-up of functional measures 
and x-rays of hands and feet.
 The ERAS study
In the UK the proposal for a new inception 
cohort of RA arose from the recognition by a 
group of clinical rheumatologists in the 1980s 
that the optimal management for RA was a 
major challenge and any improvements were 
unlikely to result from RCTs alone. Important 
advances in the care of RA from the 1980–1990s 
included new drug therapies and standardized 
disease assessments. Large joint replacement sur-
gery had become more routine and available. In 
order to develop prognostic factors and to cap-
ture the wide variations in clinical outcomes 
and health status, and in therapies offered in 
clinical practice, larger numbers of patients were 
required than hitherto possible. 
The ERAS study was designed to recruit RA 
patients from NHS hospital rheumatology out-
patients in nine different regions of England 
from 1986: a modernized version of RAPS. The 
aims were to establish a database of long-term 
clinical data on 1000 patients in order to moni-
tor and compare management and outcomes 
between centers, and develop prognostic fac-
tors. Standard clinical assessments by research 
nurses included DAS, function (Health Assess-
ment Questionnaire) and x-rays of hands and 
feet at baseline, 6 months and yearly for up to 
20 years. Outcomes included validated assess-
ments of functional and radiological progression, 
and mortality and comorbidity, with greater 
numbers and an improved management era com-
pared with earlier cohorts [18]. The larger sample 
size allowed examination of both standard and 
less well-documented outcomes, which included 
clinical remission, work disability and orthope-
dic interventions (joint replacement and recon-
struction) in RA patients treated with conven-
tional DMARDs of the era [19–21]. Sulphasalazine 
was the first-choice DMARD of clinicians in this 
study, followed by methotrexate and intramuscu-
lar gold, which reflected common UK practice of 
this era. Severe toxicity from these conventional 
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DMARDs was uncommon, and very rarely 
related to mortality, which was more probable 
from nonsteroidal and steroidal drugs [22]. 
This study demonstrated that it was possible 
to collect standardized assessments in ordinary 
clinical settings over time without huge expense. 
However, despite a larger sample size, predictive 
markers powerful enough to be used routinely 
in clinical settings remained elusive. The power 
and relevance of predictive factors depended 
considerably on the outcome measure of inter-
est, although RF remained consistent for most 
outcomes except function [23].
 The Norfolk Arthritis Registry
NOAR [24] is a community-based study in one 
region of the UK designed to establish the inci-
dence of inflammatory polyarthritis and RA in 
the 1990s [25], following on from the popula-
tion studies conducted mainly in the industrial 
north of the UK in the 1950s. Patients recruited 
between 1989 and 1994 and between 2000 and 
2008 in Norfolk were clinically assessed at 
baseline and at 1, 2, 3, 5, 7, 10 and 15 years by 
community research nurses. Patients recruited 
between 1994 and 2000 were followed for 
2 years. NOAR reported an overall minimum 
prevalence of 1.16% in women and 0.44% in 
men [26] and, in comparison with the first UK 
studies in the 1960s [2,3], it was evident that 
prevalence in women was decreasing in all age 
groups (except in the 75+ group) whereas the 
prevalence in men has increased. 
This study reported that even patients with 
AIA have unfavorable outcomes, significant 
morbidity and functional loss [27]. Patients who 
developed RA were followed-up in secondary 
care as a cohort study, and in these patients 
NOAR has reported on similar outcomes as 
ERAS. It is one of only a few UK studies that 
collected information on direct, indirect and 
intangible costs of the disease, based on spe-
cially designed questionnaires to capture costs 
of the disease from a personal, NHS and societal 
perspective [28].
Both NOAR and ERAS confirmed the find-
ing of previous cohorts of irreversible disease in 
significant proportions of patients within the first 
few years. Despite improved therapies, reduced 
function early on was associated with later dis-
ability. Both studies took advantage of linkage 
to national datasets and reported increased stan-
dard mortality rates in RA [22,29]. The causes of Ta
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death in patients with RA were similar to that 
of the normal population, although infectious, 
cardiovascular and respiratory conditions were 
more common. These two cohorts represent the 
full spectrum of RA, and some differences in the 
results could be explained by generally milder 
RA from community sources compared with 
hospital-based patients. 
 The Early Rheumatoid Arthritis Network
The 21st century brought in a number of rel-
evant developments: international and national 
guidelines on the management of RA had been 
published; patient support groups had become 
well organized and proactive; equitable access to 
appropriate care had become a greater issue in 
rheumatology. It was recognized that the intro-
duction of clinical governance within the NHS 
had created a need for the collation of data on 
activity, contemporary treatment patterns and 
outcomes at national, as well as at local levels. 
Such data were required to facilitate planning 
and provision of healthcare for RA patients, and 
to inform the development of appropriate and 
realistic standards against which future activity 
could be audited.
ERAN had similar aims, design, and clinical 
assessments and outcome measures as ERAS, 
which ceased recruiting in 1999, but in a wider 
geographical area that included more centers. 
ERAN also had the intent to contribute to the 
development of good clinical practice, guide-
lines and clinical governance issues, and the 
added facility to conduct nested studies. ERAN 
recruited patients between 2002 and 2012 from 
23 UK centers and was the first to report the 
variations in clinical management in the UK in 
the biologic era [30]. Follow-up data from this 
cohort provided data to support the BSR view 
that eligibility criteria for the initiation of biolog-
ics may have been set too high by NICE guid-
ance [31], and that even patients with ‘moderate’ 
disease do badly within the first few years [32].
ERAS and ERAN are the only RA cohorts 
that reflect clinical practice in different regions 
of the UK prior to and during the biologic era, 
with data on 5–20-year outcomes. Strengths 
include a rapid reporting system of feedback 
loops with participating centers, allowing review 
of individual performance and comparison with 
national guidelines, and in some centers there 
was evidence of change in practice [33]. Recruit-
ment fluctuated at certain times because some 
ERAN centers were not always able to recruit 
sequential patients, and some centers opted 
to stop recruiting new patients once a critical 
mass was achieved for that center in order to 
concentrate resources on follow-up. This is not 
an uncommon event in observational studies. 
Occurance of missing data was generally low and 
acceptable, but highest in drug start and stop 
dates (10%).
Combining the two cohorts has allowed 
examination of secular change in management 
of RA from 1986 to the present. This analy-
sis has demonstrated several important trends: 
the earlier use of DMARDs once referred into 
secondary care; changes to the recommended 
practice of more intensive approaches in drug 
therapies in early RA in the UK has been slower 
than generally perceived and expected [33]; with 
improving therapies there has been the expected 
decline in orthopedic interventions, but only in 
reconstructive surgery of hands and feet, and not 
in large joint replacement arthroplasties (mainly 
hip and knees) [34]. 
Summary of results from UK inception 
cohorts
The early hospital-based inception cohort studies 
of the 1980s in the UK, Sweden and The Neth-
erlands broadened the spectrum of RA follow-
ing the pioneering population-based research in 
the UK of Kellgren and Lawrence in the 1950s 
and explained the discrepancy between the two 
approaches. These cohorts have provided valuable 
information on the natural (but treated) history 
of early RA and insights into the etiology, patho-
genesis and outcomes of RA. They identified the 
significant proportion of patients who exhibited 
serious complications of RA at early stages of dis-
ease, not necessarily in those with conventional 
clinical features of moderate-to-severe disease. 
Measures of function (Health Assessment Ques-
tionnaire and work disability), structural damage 
(serial x-rays and orthopedic surgery) and mor-
bidity and mortality have now become standard 
outcomes in RCTs, registries and cohort studies. 
Some of the subsequent north European cohorts 
have been multicenter with larger sample sizes, 
allowing subgroup analysis and, most impor-
tantly, had more complete and longer follow-up. 
They confirmed, refined and widened the earlier 
findings, highlighting the importance of both 
standardized and validated assessments, and the 
inclusion of all important outcome measures [35].
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Several studies have provided important 
information on clinical effectiveness of disease-
modifying therapies over time in the real world, 
which RCTs cannot do, and also on treatment 
variations, both regionally and between coun-
tries. Identifying the optimal management of 
RA still remains the most important challenge 
for clinical rheumatology. The BSR has used 
these data to inform published guidelines on 
management of RA in the 21st century [36,37].
At present optimal management depends on 
the use of best clinical practice/guidelines cur-
rently available, translating results of research 
studies into routine clinical practice, and iden-
tifying patients with poor prognostic factors and 
inadequate responses to initial therapies. The 
main UK cohorts identified the degree of delay 
from, first, onset of symptoms to hospital referral 
and, second, to start of disease-modifying thera-
pies, and the possibility of improving on this. 
In the 1960–1970s patients were managed with 
NSAIDs for up to 2 years, often by primary care 
physicians, and slow-acting disease-modifying 
drugs only started in secondary care once ero-
sions had developed. During this interval it 
was now postulated that the optimal window 
of opportunity to treat RA inflammation may 
be lost. By the 1980s, rheumatologists from the 
USA were advocating earlier intervention, based 
on clinical experience and small prospective 
studies [38]. Referral times into secondary care 
in the UK have improved only minimally over 
the last 20 years, the main delay being patient 
self-referral to primary care. Time to initiation of 
disease-modifying therapies once in secondary 
care has improved (from a median of 2 months 
to less than a month), although use of intensive 
therapies at outset was lower than expected [33].
The National Audit Office (NAO; London, 
UK) used extensive data from ERAS, ERAN 
and NOAR in their report on RA, commis-
sioned by parliament in 2008 that highlighted 
these variations in current clinical practice and 
the disappointing outcomes, a key resource used 
in the HM Government Public Accounts Com-
mittee (tenth report published in 2010) [39]. 
Extensive use was made of the NAO report in 
subsequent NICE guidelines [103]. The profile of 
RA had certainly been raised by the NAO report 
[104], along with the availability and health eco-
nomic issues surrounding the expensive biolog-
ics, ultimately to the benefit of patients. NICE 
guidelines for eligibility for funding of biologics 
include specific clinical criteria that are based 
on health economic analysis as well as clinical 
evidence [105] and are more stringent compared 
with the rest of Europe [31]. These issues will 
need further exploration in UK cohorts and 
registries, as long as they continue and provide 
contemporary data.
The current therapeutic ‘treat-to-target’ strate-
gies for RA have demonstrated improvements in 
radiological change [40], but need to show con-
sistent improvements in two other important 
outcomes: function and mortality. Age, sex and 
functional ability are the most consistent risk fac-
tors reported for mortality in these RA studies, 
followed by RF and acute phase response [22,29], 
supporting other evidence that the inflamma-
tory process itself may play an important role in 
the development of ischemic heart disease. This 
is an important area as it raises the possibility 
of specific interventions to reduce mortality in 
RA. The beneficial effects of the more intensive 
therapies on mortality in RA are not yet proven, 
but these studies highlight the need for rheuma-
tologists to treat RA patients with active disease 
early and effectively, identify those at risk from 
coexisting conditions and treat them actively or 
with preventative measures accordingly [41]. Pul-
monary fibrosis is a well-recognized extra-artic-
ular feature of RA and poses an uncommon but 
severe risk, since this condition was responsible 
for 6% of deaths in one cohort [22]. This report 
prompted the formation of a register of RA-asso-
ciated interstitial lung disease by rheumatologists 
in the UK to explore the course and predictive 
factors of this condition and possible therapeutic 
approaches to improve the poor prognosis [42].
UK product registries
The BSR-BR was set up to register all patients 
with RA newly starting biologic therapy from 
January 2002 [14]. The project includes a com-
parison cohort of RA patients treated with 
standard DMARDs. The registry records basic 
demographic characteristics including disease 
duration, function, DAS and associated Euro-
pean League for Arthritis and Rheumatism 
response, adverse events and quality-of-life 
scores, at baseline and at 6-monthly intervals for 
3 years [43]. It now has data on several thousands 
of patients, estimated at 80% of patients starting 
DMARDs. The project was powered to detect a 
twofold increased risk in lymphoma, its primary 
aim, as RA patients already carry an increased 
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risk of lymphomas, thought to be linked to the 
abnormal immune system in RA. Biologics have 
a profound effect on immune mechanisms, so 
it has been reassuring that BSR-BR found no 
increased risk, although nonmelanoma skin 
cancers and opportunistic infections such as 
tuberculosis were increased [44]. The registry 
has been expanded to include patients with 
psoriatic arthritis and ankylosing spondylitis 
on biologics.
The results of BSR-BR and other national bio-
logic registers in Europe have provided important 
evidence for evaluations of not only efficacy and 
toxicity, but also regional variations in the access 
and use of biologics. The BSR-BR has been able 
to answer its primary aim concerning the risk 
of lymphoproliferative conditions because this 
study had a control group of biologic-naive RA 
patients treated with conventional DMARDs. 
After more than 10 years of widespread use, it 
is still debated whether treatment with biologic 
agents is associated with an increase in solid 
tumor cancer incidence, and longer follow-up 
linked to independent cancer registers is needed. 
A meta-analysis reported no overall increase 
compared with nonbiologic treated RA [45]. The 
main drawback of biologic registries is expense 
due to labor-intensive data entry methodology 
and processes to minimize nonmissing data sets. 
One solution is to improve operational data cap-
ture methods by convincing clinicians and/or 
health professionals to engage at this level by 
recording data at the point of clinical contact. 
Another limitation of biologic registries is in the 
interpretation of drug efficacy, owing to non-
randomization of therapies. Misleading results 
may arise from channeling bias and confounding 
by indication, as well as variations in data quality 
of influences such as comorbidity.
The National Joint Registry (NJR) of Eng-
land and Wales was established in 2002 to moni-
tor, define, improve and maintain the quality of 
care of individuals receiving hip, knee and ankle 
joint replacement surgery across the NHS and 
the independent healthcare sector [106]. In 2008, 
the NJR was incorporated into the National 
Clinical Audit and Patients’ Outcomes Pro-
gram, both managed by the Healthcare Quality 
Improvement Partnership. The NJR is funded 
through a levy raised on the sale of hip, knee and 
ankle replacement implants available and used 
in the NHS and independent healthcare sectors 
across England and Wales. 
 Data linkage
The association between biologic-treated 
patients and lymphoma was made possible fol-
lowing data linkage with national databases, 
including the Cancer Registries, and mortal-
ity data from the Medical Research Informa-
tion Service [107]. A number of other national 
databases in the UK provide invaluable data for 
cohort studies linked by NHS numbers. These 
include NHS hospital-based interventions from 
hospital episode statistics and the NJR [108], the 
General Practice Research Database, a primary 
care research databank started in 1987 covering 
7% of the UK population (a proportion that is 
increasing) [46], and the NJR [106].
Several other important f indings have 
resulted from linkage between separate and 
often quite different databases. For example, 
linkage between two unique registries, the 
NOAR and EPIC databases, revealed possible 
links between diet and the development of 
inflammatory arthritis in Norfolk [47]. Another 
example was the high incidence of pancreatic 
cancer in patients with RA exposed to leflu-
nomide, which was observed in the German 
biologics register [48]. A concerted analysis with 
the national biologics registers in the UK and 
Sweden was performed, and the results of the 
replication analyses did not support the original 
finding [48]. Orthopedic surgery in RA is con-
sidered a surrogate marker for structural dam-
age, not normally measured in large joints in 
cohort studies, and linkage of two consecutive 
RA inception cohorts with Hospital Episode 
Statistics and NJR has allowed an analysis of the 
frequency of and prognostic factors for this out-
come. ERAS and ERAN cover the management 
of RA in the UK from 1986 to 2012 and dem-
onstrated that over 20 years only certain types 
of orthopedic surgical rates have declined over 
this time [34]. The reasons for this are specula-
tive, but highlight the problem associated with 
the interpretation of other long-term outcomes 
that are subject to variable and both modifi-
able and nonmodifiable influences, for example, 
mortality and work disability. 
Other UK RA cohorts & registries 
recently initiated and/or that have limited 
publications 
 BRAGGS
Prospective cohort of RA patients from 49 clini-
cal and academic centers in England designed 
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to collect clinical information and biologic and 
genetic samples from patients being treated with 
biologic drugs, in order to investigate treatment 
response predictors [109].
 GORA
Genetic study in Sheffield (UK) that started in 
1938, currently comparing genetic samples of 
established RA patients with controls [110].
 Yorkshire Early Arthritis Register
An inception cohort for AIA (American Col-
lege of Rheumatology criteria) followed yearly 
was set up in Leeds (UK) to cover NHS hos-
pitals in Yorkshire, from 1998 to 2003 (Year 
B; 14 centers) and 2000–2009 (Year C; eight 
centers) [49].
 Clinical Audit of RA
Initiated in Scotland in 2005 in eight centers to 
monitor management of early RA mainly as an 
audit exercise, from 2005–2008 [111].
 RA methotrexate study
A recent initiative to collect and monitor data on 
physician diagnosis of RA or early undifferenti-
ated polyarthritis, about to start methotrexate 
as monotherapy or in combination with other 
DMARDs for the first time. Included 32 centers 
between 2008 and 2013 [112].
 RA-MAP
A recent initiative to identify predictors of 
remission in RA using patient-level data from 
patients who were either in the placebo arm of 
recently published RCTs examining nonbiologic 
DMARDs or biological agents, or in a longitudi-
nal observational cohort in the UK designed to 
generate a model to predict remission. Sponsored 
by the Association of the British Pharmaceutical 
Industry (London, UK) and Arthritis Research 
UK (Derbyshire, UK). Includes a literature 
review; inventory of all RCTs and long-term 
observational studies in patients with RA that 
have remission among their outcome measures; 
and a survey to map cohort characteristics (size, 
entry criteria, baseline data, duration of follow-
up, clinical and other end points, comparator 
and control/placebo treatments) [113].
 MATURA consortium
A culmination of several separate initiatives 
with the primary aim to identify biomarkers (to 
include genetic and genomic tissue responses) 
in order to stratify medicines for RA to enable 
patients to be treated with the drug they are most 
likely to respond to earlier in their disease course. 
It builds on and complements other Medical 
Research Council-funded cohorts including 
the Pathobiology of Early Arthritis Cohort [114], 
BRAGGS [109] and RA-MAP Consortia [113], 
and represents an ideal opportunity for rheu-
matologists to collaborate on several strategic 
national and international initiatives in 2013. 
It underscores the cooperative philosophy, aims 
and values in developing a national arthritis net-
work, similar to the cancer network that ena-
bles high-quality research to be translated into 
patient benefit [113].
 ARUK INBANK
The ARUK INBANK initiative will provide the 
musculoskeletal research community with web-
based software for standardized clinical data 
collection (with linked biosamples) to facilitate 
rapid and efficient acquisition and sharing of 
high-quality data for research across a network 
of UK NHS collection centers from 2014. It 
is proposed to support collection of data once 
and data reuse for multiple purposes, including 
research, clinical management, clinical audit and 
so on. Several musculoskeletal disease areas are 
proposed: the first and exemplar initiative is the 
AIA Hub (to include RA), and subsequent Hub 
developments will include other subspecialties 
in rheumatology [115].
Non-UK longitudinal cohorts & registries
Several north European countries and the USA 
initiated inception cohorts in the late 1980s and 
1990s with similar designs and aims as those 
in the UK. This article cannot do justice to 
the importance of these numerous studies in 
detail owing to limited space. However, these 
cohorts reported on the same outcomes and 
prognostic factors in the same timeframe as 
already discussed, expanding at national levels 
on similar findings. Some outcomes are less easy 
to compare owing to socioeconomic variations, 
for example those studies that collected data 
on work disability, while others have exposed 
significant differences concerning management 
issues. It became clear that several European 
countries were treating early RA with more 
intensive combination drug strategies and 
biologics than the UK. Most other European 
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countries now also have biologic registries, 
mainly in northern Europe, with many based on 
the BSR-BR model. The accumulated evidence 
from European registries confirms the relative 
safety of biologics in the long term, and that 
the initial fears of malignancy have not been 
justified, although risk of infection is higher 
than expected. 
Conclusion & future perspective
The disease and product registries and cohort 
studies in RA in the UK have generally been 
successful and have largely achieved their ini-
tial declared aims, outlined in the rationale 
list shown earlier in the opening section. The 
extent to which cohort studies have benefited the 
rheumatology community is detailed elsewhere 
[33,50], most importantly by identifying ‘early 
RA’ as a critical phase of the disease, which has 
driven the agenda for improved management, 
and by defining important outcomes.
The impressive results from registries and 
cohort studies have readdressed the previous 
imbalance perceived between observational 
studies and RCTs [7]. RCTs are limited by inclu-
sion and exclusion criteria and, owing to this 
selection bias, do not reflect the ‘real’ world, 
one of strengths of registries and cohort stud-
ies. Biologic registries may suffer from ‘chan-
neling bias’ because inclusion is often based on 
the more severe end of the disease spectrum. 
Well-designed inception cohorts that recruit all 
consecutive patients based on specific diagnostic 
criteria minimize bias, but do depend on low 
attrition rates, which should be accounted for, 
at least by notifications of mortality. The latter is 
possible in the UK due to linkage to the National 
Death Register. Missing data is a common issue 
that should be reported and to some extent can 
be addressed with modern statistical methods.
An encouraging development is the much 
greater extent of meaningful collaborations than 
previously seen between clinicians involved in 
the current registries and inception cohorts in 
both the UK [51] and Europe [52] in order to vali-
date and strengthen problem areas of research 
findings, clearly the future for rheumatology 
research. Despite the large numbers in the incep-
tion cohorts described, the development of pow-
erful prognostic factors has been disappointing, 
lacking the robustness needed for routine stan-
dard practice. In fact, it is uncertain how the 
predictive factors rheumatologist have at present 
are being used. Genetic analysis in particular 
needs large numbers, and is only available by 
combining cohorts. Great faith is being put into 
the development of biomarkers to replicate the 
models used in cancer.
After several years of planning, a number of 
national initiatives involving registries/cohorts 
in the management of AIA and RA are at last 
coming to fruition, underpinned by collabora-
tions between key consortia with sound track 
records, including genomics [109], pathobiology 
[114], clinical trials for remission with pooled 
clinical trial datasets [113], a stratified medicines 
project [116]. ARUK has invested in the develop-
ment of the national platform of clinical data 
in rheumatology, INBANK, linked to a central 
archive of stored biological samples and to NHS 
data from both primary and secondary care, for 
the acquisition and sharing of high-quality data 
for research across the NHS [115]. The pilot is 
planned to commence in 2014 and will bring 
together all the national cohorts, registries and 
current initiatives in RA described above.
The initiatives described here in rheumatology 
could promote the long-held and laudable view 
of the National Institute of Health Research to 
offer all patients the opportunity to be involved 
in research if appropriate, and patients inputting 
their own data is not far away.
Rheumatologists have been in the forefront of 
observational research, and operational data cap-
ture methodology has been developed as bespoke 
systems in some rheumatology departments, but 
as yet not on a national basis. This will be needed 
in order to accommodate the many new and 
established initiatives described here. Convinc-
ing clinicians to become involved at this level 
is a major challenge. The future brings multi-
purpose, user-friendly and cost-effective data-
bases that will accommodate the needs of busy 
clinicians, clinical audit requirements, research, 
quality standards and commissioners.
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Have radiographic progression rates in early
rheumatoid arthritis changed? A systematic review
and meta-analysis of long-term cohorts
Lewis Carpenter1, Elena Nikiphorou2, Rachel Sharpe1, Sam Norton3,
Kirsten Rennie1, Frances Bunn4, David L. Scott5, Josh Dixey6 and Adam Young2,7
Abstract
Objective. To evaluate, firstly, all published data on baseline and annual progression rates of radiographic
damage from all longitudinal observational cohorts, and secondly, the association of standard clinical and
laboratory parameters with long-term radiographic joint damage.
Methods. A comprehensive search of the literature from 1975 to 2014, using PubMed, SCOPUS and
Cochrane databases, identified a total of 28 studies that investigated long-term radiographic progression,
and 41 studies investigating predictors of long-term radiographic progression. This was submitted and
approved by PROSPERO in February 2014 (Registration Number: CRD42014007589).
Results. Meta-analysis indicated an overall baseline rate of 2.02%, and a yearly increase of 1.08% of
maximum damage. Stratified analysis found that baseline radiographic scores did not differ significantly
between cohorts recruiting patients pre- and post-1990 (2.01% vs 2.03%; P> 0.01); however, the annual
rate of progression was significantly reduced in the post-1990 cohorts (0.68% vs 1.50%; P<0.05). High
levels of acute phase markers, baseline radiographic damage, anti-CCP and RF positivity remain consist-
ently predictive of long-term radiographic joint damage.
Conclusion. Critical changes in treatment practices over the last three decades are likely to explain the
reduction in the long-term progression of structural joint damage. Acute phase markers and presence of
RF/anti-CCP are strongly associated with increased radiographic progression.
Key words: systematic review, meta-analysis, rheumatoid arthritis, radiographic progression, predictive models
Rheumatology key messages
. Progression of radiographic damage in 1990!2011 is significantly lower compared with 1965-1989 in early RA.
. Acute phase markers and RF/anti-CCP positive RA remain important predictors of erosive disease in RA.
. Longitudinal-studies are needed on whether anti-CCP is superior to RF in predicting radiographic damage in RA.
Introduction
Radiographic damage is an important outcome in obser-
vational studies and clinical trials in RA. Chronic synovitis
in RA results in irreversible bone and cartilage destruction
[1]. Erosions are indicators of failure to control the disease
[2, 3] that are associated with increased pain and func-
tional disability [4, 5].
Previous systematic reviews have shown [5, 6] 39!73%
of early RA patients to develop one or more erosions in the
first 5 years, with radiographic damage progressing at a
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constant rate for the first 20 years of the disease [5].
Subsequent systematic reviews [4, 7] concentrated on
specific predictors (functional assessment and disease
activity indices) and their relationship with radiological
damage. However, to date no review has used quantita-
tive analysis techniques, including meta-analysis, to in-
vestigate radiographic progression rates.
As structural damage is irreversible [5, 8], it would be
advantageous to identify patients at higher risk of severe
damage so their treatment could be tailored earlier on.
Predictive modelling is a relevant statistical method to
identify factors associated with primary RA outcomes [8,
9]. Previous studies have highlighted relationships be-
tween radiographic progression and functional disability
[4] and disease activity [7]. Other factors like anti-CCP
antibodies and genetic factors have yet to be fully
reviewed.
In this systematic review we have evaluated published
data on baseline and annual progression rates of radio-
graphic damage from longitudinal observational cohorts,
and defined their association with standard clinical and
laboratory variables. To date, this is the first review to
use appropriate meta-analysis techniques to evaluate
both the baseline and annual progression rates of radio-
graphic joint damage scores, as well as the predictive
markers identified, for all long-term observation cohort
studies.
Methods
A systematic review protocol was developed to ensure the
objectives and aims were outlined from the outset. This
was approved by PROSPERO in February 2014
(CRD42014007589) (supplementary data, PubMed
search section, available at Rheumatology Online).
Identifying publications
Publications were identified by computerized searches of
PubMed, Cochrane Library (including CENTRAL, CDSR,
DARE, HTA) and Scopus. Additional lateral search tech-
niques included checking reference lists, performing key
word searches in Google Scholar and using the cited by
option in PubMed. Databases were searched from 1
January 1975 to 31 February 2014. The search strategy
used key words and MeSH terms on the title/abstract and
full text as appropriate.
Inclusion/exclusion criteria
Inclusion criteria to select publications comprised the fol-
lowing: investigated the progression or predictive/prog-
nostic markers of radiographic joint damage; patients
had a diagnosis of RA, using validated classification cri-
teria like the EULAR and/or the ACR criteria; baseline as-
sessments occurred no later than 3 years from symptom
onset; prospective cohort study design; radiographic
follow-up data available for at least 5 years for progres-
sion rates, and 3 years for predictive markers; used
Larsen or Sharp!van der Heijde (SvdH) method to score
radiographic damage; and only publications in English.
Publication screening
One reviewer (L.C.) screened titles/abstracts identified in
searches, using the selection criteria to identify potentially
relevant papers. A second reviewer (E.N.) independently
screened the full text of 10% of all publications identified
against agreed inclusion criteria. Agreement was achieved
in 97% of cases with disagreements resolved through dis-
cussion. Supplementary Fig. S1, available at Rheumatology
online, shows publications identified, screened and
included in this review.
Data extraction
Two reviewers (L.C. and R.S.) extracted data using a pre-
designed form, piloted to ensure all data necessary were
captured. It included cohort name, country of study popu-
lation, scoring method used, number of patients included,
years of recruitment, length of follow-up, sex, mean age,
baseline DAS and HAQ scores, proportion of patients on
DMARDs, proportion RF positive, number, mean/median
and standard deviation/interquartile range of radiographic
scores at each follow-up visit, analysis method used, sig-
nificant and non-significant predictors identified and the
effect estimate and 95% CIs. In cases where the raw data
were not given in the published paper, the author was
contacted to provide these (n = 21).
Quality assessment
Studies were rated using the Downs and Blacks instru-
ment for non-randomized studies of health care interven-
tions [10]. Since the studies did not examine clinical
effectiveness, checklist items related to comparative
groups (e.g. randomization and blinding procedures)
were omitted. One reviewer (L.C.) scored all studies
using the amended checklist and another reviewer (R.S.)
independently scored 10% of studies drawn at random.
Discrepancies between reviewers were discussed and
consensus achieved.
Analysis
Means and standard deviations of the Larsen or Sharp
score were recorded at each follow-up time for each
study. In cases where only a median score was obtained,
the median and range was converted into a mean score
and standard deviation [11]. To estimate annual rates of
change, with standard errors, a linear regression model
was conducted with follow-up year as the independent
variable. Baseline scores and annual progression rates,
with respective standard errors, were transformed into
percentage maximum damage for each scoring method
[12, 13]. Transformed scores were entered into random
effects meta-analysis to calculate pooled effect estimates
for both baseline radiographic scores and annual rate of
change.
To assess the strength of predictive markers, the re-
gression coefficients and odds ratios (OR), with 95%
CIs, were collated. Unadjusted effect estimates were
sought. Where these were not reported the adjusted esti-
mates were used. Random effects meta-analysis was
used for all models due to the likely high level of
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Lewis Carpenter et al.
 at University of Hertfordshire on M
arch 16, 2016
http://rheumatology.oxfordjournals.org/
Downloaded from 
heterogeneity between studies. Analysis used Stata
(version 13); significance was assumed at P < 0.05.
Heterogeneity
The study entry criteria aimed to include studies as
homogeneous as possible to allow appropriate meta-
analysis. Heterogeneity between studies was predicted
a priori, mainly due to differences in when cohorts
started and differences in scoring methods. The i2 stat-
istic for each model was found to be consistently above
80%, and therefore random effects models were used
throughout. To investigate possible sources of hetero-
geneity, scoring method and recruitment year were
entered into meta-regression models and were the
basis of two separate stratified analyses. Given the
low level of studies included in the analysis, the 10 stu-
dies were stratified into two recruitment period groups,
1965!89 and 1990!2000. This provided equal group-
ings for stratified analysis. In addition, this marked a
change in the clinical management of RA, were from
1990 the focus moved toward treat-to-target, with
more intensive treatment within the first 3 months of
disease.
Narrative synthesis of predictive factors
Identified markers were recorded and counted to ascer-
tain common associations with a separate count of sig-
nificant predictors. Where possible, meta-analysis was
used to assess the strength of predictive markers.
However, for several predictive markers meta-analysis
was not possible as too few studies reported results
that could be pooled. When meta-analysis was inappro-
priate a narrative synthesis of the data was conducted.
Results
Meta-analysis of long-term radiographic
progression
Of the 28 studies identified, 10 provided the necessary
data for meta-analysis [14!22] (Table 1). Patients were
recruited from 1965 to 2000 and follow-up ranged from
5 to 20 years. The number of patients included with
baseline radiographic data ranged from 73 to 1121.
Four studies used Larsen; six used the SvdH scores.
Five recruited patients from 1965 to 1989 and five
from 1990 to 2000.
Baseline radiographic score
The first analysis examined baseline radiographic score
across all studies. The overall rate of damage at base-
line was estimated at 2.02% (95% CI: 1.37, 2.67) of
maximum damage. The sub-group pooled estimate for
Larsen score was 3.41% (95% CI: 1.80, 5.01) of max-
imum damage (6.82 U); the sub-group pooled estimate
for the SvdH score was 1.20% (95% CI: 0.60, 1.80) of
maximum damage (5.38 U). Studies recruiting patients
between 1965 and 1989 had a sub-group pooled esti-
mate of 2.01% (95% CI: 1.14, 2.89) of maximum
damage; studies recruiting between 1990 and 2000 T
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reported a sub-group pooled estimate of 2.03% (95% CI:
1.05, 3.01) of maximum damage (Fig. 1).
Annual rate of change
In the second analysis overall annual rate of change was
estimated at 1.08% (95% CI: 0.72, 1.44) of maximum
damage. The sub-group pooled estimate for Larsen
score was 1.38% (95% CI: 1.80, 5.01) of maximum
damage (2.76 U/year); the SvdH score was 1.20% (95%
CI: 0.88, 1.88) of maximum damage (4.03 U/year). In stu-
dies recruiting patients between 1965 and 1989, patients
had a sub-group pooled estimate of 1.50% (95% CI: 1.08,
1.92) of maximum damage; for 1990!2000 it was 0.68%
(95% CI: 0.47, 0.90) of maximum damage (Fig. 2).
Meta-regression
The small sample size (10 studies) limited the power to
conduct meta-regression models with an appropriate
number of covariates; however, it was important to inves-
tigate possible factors influencing the overall effect esti-
mate given the high levels of heterogeneity between
studies (i2 score ranging from 90.5 to 98.3%).
The meta-regression indicated that there was a statis-
tically non-significant difference for baseline progression
rates between recruitment periods (P > 0.1), but a statis-
tically significant difference for annual progression rates
between recruitment periods (P < 0.05), while controlling
for scoring method. The models indicated that differences
between Larsen and SvdH scoring methods were not stat-
istically significantly different for annual progression rates
(P > 0.1), suggesting relative increases in either scoring
method were comparable. Scoring method was a statis-
tically significant factor for baseline progression rates
(P < 0.05).
Review of predictive markers of long-term
radiographic damage
Forty-one papers were identified that examined predictive
markers of radiographic joint damage, representing 21
cohort studies. Although several papers were based on
the same cohort data (Table 2), the analysis techniques
used were sufficiently different from each other to allow
their inclusion in the analysis.
Twenty-eight studies used the SvdH method [1, 15, 19,
21, 23!46]; 13 used the Larsen scoring method [20,
47!58]. Twenty-four of 41 studies examined radiographic
damage at a single time point, while 17 investigated radio-
graphic damage expressed as a change in score over two
time points. Thirteen studies transformed radiographic
scores into binary variables and 27 treated the radio-
graphic score as a continuous score. One study treated
the radiographic score as an event in a time-to-event ana-
lysis [53]. Overall 12 different analysis methods were used
(Table 2).
Acute phase markers
Acute phase markers (ESR or CRP) were one of the most
frequently reported covariates (Fig. 3). Fifteen studies
included the ESR and 13 found it was a statistically sig-
nificant predictor. Eleven studies included CRP and 10
FIG. 1 Baseline radiographic score pre- and post-1990
Forest plot of baseline radiographic scores stratified by recruitment periods.
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found it was a statistically significant predictor. Although
there was sufficient data to conduct a meta-analysis, large
intra-study differences on how acute phase markers were
evaluated made formal meta-analysis inappropriate. While
some studies assessed acute phase markers as continu-
ous predictors, others used them as categorical pre-
dictors, either using pre-defined cut-points or using
quartiles. This made direct comparison between the
effect estimates unfeasible.
Courvoisier et al. [15] reported that an increased ESR
indicated over a 3-fold increased risk of a radiological
damage score above the median at 10 years. Similar
effect estimates were seen in other studies using similar
analysis techniques. An OR of 2.7 (CIs not given) was re-
ported by Fex et al. [48] and an OR of 2.9 (95% CI: 1.01,
5.88) was reported by Tanaka et al. [21]. Similarly Bukhari
et al. [23] reported an incidence rate ratio of 2.0 (95% CI:
1.4, 3.0). Using linear regression techniques, Lindqvist et
al. [51] reported an average increase of 0.42 (95% CI:
0.62, 1.04) units of the Larsen Score for every 1 unit in-
crease in CRP. Mustila et al. [52] reported only ESR was
significantly associated with radiographic joint damage at
12, 36, 60 and 84 months in univariate analysis, whereas
RF was only statistically significant at 36 months, and
pANCA, Antikeratin antibodies, antiperinuclear factor
and age were not associated at any time.
Anti-cyclic protein antibodies and RF
Anti-cyclic protein antibodies, largely anti-CCP, were
evaluated in 16 studies and 14 of these reported
statistically significant associations. Using linear regres-
sion, Lindqvist et al. [51] reported patients positive for
anti-CCP had on average an increase of 37 U on the
Larsen score compared with anti-CCP negative patients
over 10 years. Nyha¨ll-Wa˚hlin et al. [30] reported an in-
crease of 14.74 over 5 years. Anti-CCP positive patients
were also reported to have between a 2.3- and 9.3-fold
increase in risk of rapid radiological progression [24, 25].
The predictive role of RF was evaluated in 21 studies
and 12 reported statistical significance. Four studies
investigating radiographic progression based on low or
high radiographic damage groups showed RF positive pa-
tients were 1.8!2.8 times more likely to have high rates of
long-term radiographic joint damage [21, 23, 24, 55].
To assess the relative strength of anti-CCP and RF,
studies reporting OR and 95% CIs were entered into a
random effects meta-analysis. Five out of the 13 studies
reporting anti-CCP and 10/21 studies reporting RF were
included in the meta-analysis. Reasons for exclusion
comprised insufficient data, lack of data on measures of
variation and no calculated ORs. The overall pooled effect
estimate for anti-CCP was 2.49 (95% CI: 1.96, 3.15) and
for RF was 2.07 (95% CI: 1.61, 2.65) (Fig. 4). These find-
ings suggest a moderate difference between the two mar-
kers, with anti-CCP more strongly associated; but
overlapping 95% CIs suggest this difference is statistically
non-significant. All five studies included in the meta-ana-
lysis for anti-CCP showed an increased risk. Only one re-
ported a statistically non-significant result, which was also
the only adjusted effect estimate included [49]. All but two
FIG. 2 Annual rate of radiographic progression pre- and post-1990
Forest plot of annual rates of change stratified by recruitment periods.
www.rheumatology.oxfordjournals.org 5
Radiographic progression rates in early RA
 at University of Hertfordshire on M
arch 16, 2016
http://rheumatology.oxfordjournals.org/
Downloaded from 
T
A
B
L
E
2
T
a
b
le
o
f
st
u
d
ie
s
in
ve
st
ig
a
tin
g
p
re
d
ic
to
rs
o
f
ra
d
io
g
ra
p
h
ic
p
ro
g
re
ss
io
n
A
u
th
o
r
Y
e
a
r
S
a
m
p
le
C
o
h
o
rt
S
c
o
ri
n
g
m
e
th
o
d
(m
a
x
)
M
a
x
fo
llo
w
-u
p
(y
e
a
rs
)
D
a
ta
u
s
e
d
f
o
r
a
n
a
ly
s
is
D
a
ta
ty
p
e
A
n
a
ly
s
is
u
s
e
d
M
u
lt
iv
a
ri
a
te
5
+
ye
a
rs
fo
llo
w
-u
p
B
u
kh
a
ri
e
t
al
.
[2
3
]
2
0
0
2
4
3
9
N
O
A
R
L
a
rs
e
n
a
(2
0
0
)
5
S
in
g
le
tim
e
p
o
in
t
C
o
n
tin
u
o
u
s
N
e
g
a
tiv
e
b
in
o
m
ia
l
re
g
re
ss
io
n
Y
e
s
C
o
u
rv
o
is
ie
r
e
t
al
.
[1
5
]
2
0
0
8
1
1
7
F
re
n
c
h
C
o
h
o
rt
S
vd
H
(4
4
8
)
1
0
S
in
g
le
tim
e
p
o
in
t
B
in
a
ry
L
o
g
is
tic
re
g
re
ss
io
n
Y
e
s
d
e
R
o
o
y
e
t
al
.
[2
4
]
2
0
1
1
6
7
6
L
e
id
e
n
C
o
h
o
rt
S
vd
H
(4
4
8
)
5
C
h
a
n
g
e
in
sc
o
re
C
o
n
tin
u
o
u
s
L
in
e
a
r
re
g
re
ss
io
n
Y
e
s
F
e
x
e
t
al
.
[4
7
]
1
9
9
7
1
1
3
L
u
n
d
C
o
h
o
rt
L
a
rs
e
n
(2
0
0
)
5
S
in
g
le
tim
e
p
o
in
t
C
o
n
tin
u
o
u
s
L
in
e
a
r
re
g
re
ss
io
n
Y
e
s
F
e
x
e
t
al
.
[4
8
]
1
9
9
6
1
1
3
L
u
n
d
C
o
h
o
rt
L
a
rs
e
n
(2
0
0
)
5
C
h
a
n
g
e
in
sc
o
re
B
in
a
ry
L
o
g
is
tic
re
g
re
ss
io
n
Y
e
s
H
o
u
se
m
a
n
e
t
al
.
[2
6
]
2
0
1
2
5
8
P
o
rt
sm
o
u
th
C
o
h
o
rt
S
vd
H
(4
4
8
)
8
C
h
a
n
g
e
in
sc
o
re
B
in
a
ry
L
o
g
is
tic
re
g
re
ss
io
n
Y
e
s
K
a
lte
n
h
a
u
se
r
e
t
al
.
[4
9
]
2
0
0
7
9
3
L
e
ip
zi
g
C
o
h
o
rt
L
a
rs
e
n
(2
0
0
)
6
S
in
g
le
tim
e
p
o
in
ts
B
in
a
ry
L
o
g
is
tic
re
g
re
ss
io
n
Y
e
s
K
a
p
e
ta
n
o
vi
c
e
t
al
.
[2
0
]
2
0
1
1
1
8
3
L
u
n
d
C
o
h
o
rt
L
a
rs
e
n
a
(2
0
0
)
1
0
S
in
g
le
tim
e
p
o
in
t
C
o
n
tin
u
o
u
s
L
in
e
a
r
re
g
re
ss
io
n
Y
e
s
K
ra
a
n
e
t
al
.
[5
0
]
2
0
0
4
3
6
N
e
th
e
rl
a
n
d
/A
u
st
ra
lia
S
tu
d
y
L
a
rs
e
n
b
(2
0
0
)
6
C
h
a
n
g
e
in
sc
o
re
B
in
a
ry
L
o
g
is
tic
re
g
re
ss
io
n
Y
e
s
K
ro
o
t
e
t
al
.
[2
6
]
2
0
0
0
2
7
3
N
ijm
e
g
e
n
C
o
h
o
rt
S
vd
H
(4
4
8
)
6
S
in
g
le
tim
e
p
o
in
t
C
o
n
tin
u
o
u
s
L
in
e
a
r
re
g
re
ss
io
n
Y
e
s
K
u
p
e
r
e
t
al
.
[1
9
]
1
9
9
7
1
5
7
N
ijm
e
g
e
n
C
o
h
o
rt
S
vd
H
(4
4
8
)
6
S
in
g
le
tim
e
p
o
in
t
C
o
n
tin
u
o
u
s
L
in
e
a
r
re
g
re
ss
io
n
Y
e
s
L
in
d
q
vi
st
e
t
al
.
[5
1
]
2
0
0
5
1
5
7
L
u
n
d
C
o
h
o
rt
L
a
rs
e
n
a
(2
0
0
)
1
0
S
in
g
le
tim
e
p
o
in
ts
C
o
n
tin
u
o
u
s
L
in
e
a
r
re
g
re
ss
io
n
Y
e
s
M
c
Q
u
e
e
n
e
t
al
.
[2
7
]
2
0
0
3
3
1
A
u
c
kl
a
n
d
C
o
h
o
rt
S
vd
H
(4
4
8
)
6
S
in
g
le
tim
e
p
o
in
t
C
o
n
tin
u
o
u
s
L
in
e
a
r
re
g
re
ss
io
n
Y
e
s
M
e
ye
r
e
t
al
.
[2
8
]
2
0
0
3
1
5
6
F
re
n
c
h
C
o
h
o
rt
S
vd
H
(4
4
8
)
5
S
in
g
le
tim
e
p
o
in
ts
B
in
a
ry
L
o
g
is
tic
re
g
re
ss
io
n
N
o
M
e
ye
r
e
t
al
.
[2
9
]
2
0
0
6
9
9
F
re
n
c
h
C
o
h
o
rt
S
vd
H
(4
4
8
)
5
S
in
g
le
tim
e
p
o
in
t
B
in
a
ry
L
o
g
is
tic
re
g
re
ss
io
n
N
o
M
u
st
ila
e
t
al
.
[5
2
]
2
0
0
0
8
2
H
e
ls
in
ki
C
o
h
o
rt
L
a
rs
e
n
a
(2
1
0
)
7
S
in
g
le
tim
e
p
o
in
ts
B
in
a
ry
L
o
g
is
tic
re
g
re
ss
io
n
Y
e
s
N
yh
a
ll-
W
a
h
lin
e
t
al
.
[3
0
]
2
0
1
1
1
9
1
B
A
R
F
O
T
S
vd
H
(4
4
8
)
5
S
in
g
le
tim
e
p
o
in
ts
C
o
n
tin
u
o
u
s
L
in
e
a
r
re
g
re
ss
io
n
Y
e
s
R
o
u
x-
L
o
m
b
a
rd
e
t
al
.
[5
3
]
2
0
0
1
2
4
L
u
n
d
C
o
h
o
rt
L
a
rs
e
n
a
(2
0
0
)
5
C
h
a
n
g
e
in
sc
o
re
S
u
rv
iv
a
l
C
o
x
re
g
re
ss
io
n
m
o
d
e
l
Y
e
s
S
o
kk
a
e
t
al
.
[5
4
]
2
0
0
4
1
9
7
Jy
va¨
sk
yl
a¨
C
o
h
o
rt
L
a
rs
e
n
b
(1
0
0
)
5
C
h
a
n
g
e
in
sc
o
re
C
o
n
tin
u
o
u
s
Q
u
a
n
til
e
re
g
re
ss
io
n
Y
e
s
T
a
n
a
ka
e
t
al
.
[2
1
]
2
0
0
5
1
1
4
Ja
p
a
n
C
o
h
o
rt
S
vd
H
(4
4
8
)
1
0
C
h
a
n
g
e
in
sc
o
re
B
in
a
ry
L
o
g
is
tic
re
g
re
ss
io
n
Y
e
s
W
e
ls
in
g
e
t
al
.
[3
1
]
2
0
0
4
1
8
5
N
ijm
e
g
e
n
C
o
h
o
rt
S
vd
H
(4
4
8
)
9
S
c
o
re
a
t
e
a
c
h
tim
e
p
o
in
t
C
o
n
tin
u
o
u
s
A
u
to
-r
e
g
re
ss
iv
e
G
E
E
Y
e
s
W
o
lfe
e
t
al
.
[3
2
]
1
9
9
8
2
5
6
W
ic
h
ita
C
o
h
o
rt
II
S
vd
H
(4
4
8
)
1
9
C
h
a
n
g
e
in
sc
o
re
C
o
n
tin
u
o
u
s
L
in
e
a
r
re
g
re
ss
io
n
Y
e
s
3
!5
ye
a
rs
fo
llo
w
-u
p
(c
o
n
tin
u
e
d
)
6 www.rheumatology.oxfordjournals.org
Lewis Carpenter et al.
 at University of Hertfordshire on M
arch 16, 2016
http://rheumatology.oxfordjournals.org/
Downloaded from 
T
A
B
L
E
2
C
o
n
tin
u
e
d
A
u
th
o
r
Y
e
a
r
S
a
m
p
le
C
o
h
o
rt
S
c
o
ri
n
g
m
e
th
o
d
(m
a
x
)
M
a
x
fo
llo
w
-u
p
(y
e
a
rs
)
D
a
ta
u
s
e
d
f
o
r
a
n
a
ly
s
is
D
a
ta
ty
p
e
A
n
a
ly
s
is
u
s
e
d
M
u
lt
iv
a
ri
a
te
B
o
ye
se
n
e
t
al
.
[3
3
]
2
0
1
0
5
5
D
ia
ko
n
h
je
m
m
e
t
C
o
h
o
rt
S
vd
H
(2
8
0
)
3
C
h
a
n
g
e
in
sc
o
re
C
o
n
tin
u
o
u
s
-
S
q
u
a
re
R
o
o
t
L
in
e
a
r
re
g
re
ss
io
n
Y
e
s
C
o
m
b
e
e
t
al
.
[3
4
]
2
0
0
1
1
7
2
F
re
n
c
h
C
o
h
o
rt
S
vd
H
(4
4
8
)
3
S
in
g
le
tim
e
p
o
in
t
B
in
a
ry
L
o
g
is
tic
re
g
re
ss
io
n
Y
e
s
C
o
n
st
a
n
tin
e
t
al
.
[3
5
]
2
0
0
2
a
9
6
R
a
n
g
u
e
il
C
o
h
o
rt
S
vd
H
(4
4
8
)
4
C
h
a
n
g
e
in
sc
o
re
C
o
n
tin
u
o
u
s
A
N
O
V
A
N
o
C
o
n
st
a
n
tin
e
t
al
.
[3
6
]
2
0
0
2
b
9
6
R
a
n
g
u
e
il
C
o
h
o
rt
S
vd
H
(4
4
8
)
4
S
in
g
le
tim
e
p
o
in
t
C
o
n
tin
u
o
u
s
A
N
O
V
A
N
o
d
e
V
ri
e
s
e
t
al
.
[3
7
]
1
9
9
3
1
1
1
N
ijm
e
g
e
n
C
o
h
o
rt
S
vd
H
(4
4
8
)
3
C
h
a
n
g
e
in
sc
o
re
C
o
n
tin
u
o
u
s
-
S
q
u
a
re
R
o
o
t
A
N
O
V
A
Y
e
s
D
ix
e
y
e
t
al
.
[5
5
]
2
0
0
4
8
6
6
E
R
A
S
C
o
h
o
rt
L
a
rs
e
n
a
(2
0
0
)
3
S
in
g
le
tim
e
p
o
in
t
B
in
a
ry
L
o
g
is
tic
re
g
re
ss
io
n
Y
e
s
G
o
u
rr
a
u
d
e
t
al
.
[3
8
]
2
0
0
6
1
4
4
R
a
n
g
u
e
il
M
id
i-
P
yr
e´
n
e´
e
s
C
o
h
o
rt
S
vd
H
(4
4
8
)
4
S
in
g
le
tim
e
p
o
in
ts
C
o
n
tin
u
o
u
s
R
a
n
k
su
m
te
st
s
N
o
K
a
lte
n
h
a
u
se
r
e
t
al
.
[5
6
]
2
0
0
1
4
8
L
e
ip
zi
g
C
o
h
o
rt
L
a
rs
e
n
b
(2
0
0
)
4
C
h
a
n
g
e
in
sc
o
re
a
t
e
a
c
h
tim
e
p
o
in
t
C
o
n
tin
u
o
u
s
M
ix
e
d
e
ff
e
c
ts
lin
e
a
r
re
g
re
ss
io
n
Y
e
s
K
u
ip
e
r
e
t
al
.
[3
9
]
2
0
0
1
3
3
2
N
ijm
e
g
e
n
C
o
h
o
rt
S
vd
H
(4
4
8
)
3
S
in
g
le
tim
e
p
o
in
t
C
o
n
tin
u
o
u
s
-
S
q
u
a
re
R
o
o
t
L
in
e
a
r
re
g
re
ss
io
n
Y
e
s
M
a
c
h
o
ld
e
t
al
.
[5
7
]
2
0
0
7
5
5
A
u
st
ri
a
n
E
a
rl
y
A
rt
h
ri
tis
C
o
h
o
rt
L
a
rs
e
n
c
(1
6
8
)
3
C
h
a
n
g
e
in
sc
o
re
B
in
a
ry
L
o
g
is
tic
re
g
re
ss
io
n
Y
e
s
P
a
rk
e
t
al
.
[4
0
]
2
0
1
0
1
8
4
C
P
R
C
o
h
o
rt
S
vd
H
(4
0
6
)
3
C
h
a
n
g
e
in
sc
o
re
a
t
e
a
c
h
tim
e
p
o
in
t
C
o
n
tin
u
o
u
s
C
lu
st
e
r
a
n
a
ly
si
s
Y
e
s
P
o
st
h
u
m
u
s
e
t
al
.
[4
1
]
2
0
0
0
3
3
G
ro
n
in
g
e
n
C
o
h
o
rt
S
vd
H
(4
4
8
)
3
C
h
a
n
g
e
in
sc
o
re
C
o
n
tin
u
o
u
s
C
o
rr
e
la
tio
n
a
n
a
ly
si
s
N
o
S
a
la
ff
i
e
t
al
.
[4
2
]
2
0
1
1
4
8
It
a
lia
n
C
o
h
o
rt
S
vd
H
(4
4
8
)
3
C
h
a
n
g
e
in
sc
o
re
C
o
n
tin
u
o
u
s
L
in
e
a
r
re
g
re
ss
io
n
Y
e
s
va
n
A
ke
n
e
t
al
.
[4
3
]
2
0
0
4
1
5
3
L
e
id
e
n
C
o
h
o
rt
S
vd
H
(4
4
8
)
4
C
h
a
n
g
e
in
sc
o
re
C
o
n
tin
u
o
u
s
R
a
n
k
su
m
te
st
s
N
o
va
n
d
e
r
H
e
lm
-v
a
n
M
il
e
t
al
.
[4
4
]
2
0
0
5
3
2
4
L
e
id
e
n
C
o
h
o
rt
S
vd
H
(4
4
8
)
4
S
in
g
le
tim
e
p
o
in
ts
C
o
n
tin
u
o
u
s
C
h
i-
S
q
u
a
re
N
o
va
n
d
e
r
H
e
lm
-v
a
n
M
il
e
t
al
.
[4
5
]
2
0
0
8
4
8
8
L
e
id
e
n
C
o
h
o
rt
S
vd
H
(4
4
8
)
3
S
in
g
le
tim
e
p
o
in
t
C
o
n
tin
u
o
u
s
L
in
e
a
r
re
g
re
ss
io
n
Y
e
s
va
n
G
a
a
le
n
e
t
al
.
[4
6
]
2
0
0
4
2
6
8
L
e
id
e
n
C
o
h
o
rt
S
vd
H
(4
4
8
)
4
S
in
g
le
tim
e
p
o
in
t
C
o
n
tin
u
o
u
s
L
in
e
a
r
re
g
re
ss
io
n
Y
e
s
va
n
L
e
e
u
w
e
n
e
t
al
.
[1
]
1
9
9
3
1
1
0
G
ro
n
in
g
e
n
/N
ijm
e
g
e
n
C
o
h
o
rt
S
vd
H
(4
4
8
)
3
S
in
g
le
tim
e
p
o
in
ts
C
o
n
tin
u
o
u
s
A
N
O
V
A
Y
e
s
W
a
g
n
e
r
e
t
al
.
[5
8
]
2
0
0
3
7
7
L
e
ip
zi
g
C
o
h
o
rt
L
a
rs
e
n
b
(2
0
0
)
4
S
in
g
le
tim
e
p
o
in
t
B
in
a
ry
L
o
g
is
tic
re
g
re
ss
io
n
Y
e
s
a
L
a
rs
e
n
1
9
7
7
sc
o
ri
n
g
m
e
th
o
d
.
b
L
a
rs
e
n
1
9
9
5
S
c
o
ri
n
g
M
e
th
o
d
.
c
L
a
rs
e
n
!S
c
o
tt
sc
o
ri
n
g
m
e
th
o
d
.
S
vd
H
:
S
h
a
rp
!v
a
n
d
e
r
H
e
ijd
e
sc
o
ri
n
g
m
e
th
o
d
.
www.rheumatology.oxfordjournals.org 7
Radiographic progression rates in early RA
 at University of Hertfordshire on M
arch 16, 2016
http://rheumatology.oxfordjournals.org/
Downloaded from 
FIG. 3 Number of significant and non-significant predictive factors
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studies included in the RF analysis reported an increased
risk [28, 49].
Genetic factors
Sixteen studies investigated the influence of genetic fac-
tors on radiographic progression and 12 reported statis-
tically significant associations. Four studies used follow-
up data of55years; 12 were restricted to 3!4 years
follow-up. ORs for the presence of HLA-DRB1 shared epi-
tope (SE) ranged between 1.31 and 2.6 [23, 24, 34]. Two
studies by Constantin et al. showed HLA-DRB1 was asso-
ciated with increased radiographic progression over 4
years [35, 36].
Seven of the 16 studies provided sufficient data for
meta-analysis. A random effects model showed an overall
pooled estimate of 1.53 (95% CI: 1.09, 2.14) (Fig. 4). Two
of the seven studies reported a decreased risk [15, 40].
Other factors
There was limited evidence that age and female sex pre-
dicted radiographic joint damage. Only 4/12 and 4/15 stu-
dies, respectively, reported statistically significant
findings. The reported effect sizes of both age and sex
were low: age gave 1.14 [24] to 1.2 [23] times increase
in risk, while female sex reduced risk by 25% [24]. Few
studies evaluated joint counts, DAS, pANCA, MMP-3 and
functional disability making it impractical to draw conclu-
sions about their impact on radiographic damage or to
undertake meta-analyses.
Quality assessment
All studies were assessed for quality using the Downs and
Blacks Quality Assessment Checklist [10] (supplementary
Fig. S2 and supplementary Table S1, available at
Rheumatology Online). Most studies were of good quality.
All studies reported clear aims, objectives and outcome
measures and recruited representative patients. Only
three studies (6%) reported on missing data and only
seven (15%) reported on losses to follow-up. The use of
appropriate statistical methods was also lacking, particu-
larly in the 3!5 year follow-up predictive studies, where
only 13 studies (27%) used appropriate statistical
methods.
Discussion
This review is the first to use meta-analysis techniques to
provide accurate estimates of overall radiographic
FIG. 4 Forest plot of anti-CCP, RF and HLA-DRB1
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damage at presentation and over a 20-year period in early
RA patients. Data from 10 studies shows the overall radio-
graphic damage rate at presentation was 2.02% of max-
imum damage, and the overall annual progression rate
was 1.08% of maximum damage.
Previous reports [5] estimated total annual radiographic
progression rates were 1.9% of maximum damage; the
Larsen score progressed 3.8 U/year (2.5% maximum
damage) and SvdH score progressed 4.3 U/year (1.3%
maximum damage) over the first 15 years. The present
study found similar rates with an overall progression rate
of 1.08% (95% CI: 0.72, 1.44) of maximum damage. Split
by scoring method, the Larsen score progressed 2.76
U/year (1.38% maximum damage), and the SvdH score
progressed 4.03 U/year (1.20% maximum damage) over
the first 20 years of disease. The differences in rates be-
tween our findings and previous reports [5] are likely to be
multifaceted. Firstly, meta-analytical techniques to calcu-
late pooled effect estimates give different rates from rely-
ing on averages. Meta-analysis is a more robust method
as larger studies are given a higher weighting, reducing
the influence of less precise estimates from smaller stu-
dies; it also estimates precision (95% CIs). Secondly, our
inclusion criteria focused on observational cohorts of early
RA patients. This ensured a more homogeneous study
sample as patients in randomised control trials (RCTs)
are highly selected with higher levels of disease activity
and higher rates of radiographic progression [13, 40].
This review studied patients from true-to-life clinical
settings.
Stratifying studies by recruitment year showed annual
progression rates in studies recruiting between 1990 and
2000 were more than half the rate reported in studies re-
cruiting between 1965 and 1989. However, baseline radio-
graphic damage was similar across both recruitment
periods. The reduction in radiographic progression from
1965 to 2000 is concordant with data from Finckh et al.
[59], who found decreased progression rates from 1970 to
1990, and Sokka et al. [54], who found decreased 5-year
radiographic progression rates across three cohorts
(1983!85, 88!89 and 1995!96). Finckh et al. [59] sug-
gested this was a consequence of more intensive thera-
pies as the temporal effect diminished after controlling
for DMARD use. More recent data from RCTs show com-
binations of synthetic DMARDs and biologics are highly
effective in slowing radiographic progression [60], particu-
larly during the window of opportunity [12]. Reduced rates
of radiographic progression were also seen in a system-
atic review of RCTs, where more recent RCTs of patients
on MTX had less radiographic progression compared with
RCTs conducted earlier [61].
Differences between the two recruitment periods in our
review also coincide with changes in clinical management,
particularly more intensive treatment in the 1990s with
MTX the anchor DMARD [62]. Pincus et al. [62] reported
that improvements in radiographic outcomes from 1985 to
2000 were associated with better joint scores, functional
capacity and mortality outcomes. How much of these
changes should be attributed to better treatment
strategies, however, remains uncertain due to the non-
randomized study designs [54, 62].
Interestingly there is an apparent dearth of new large
observational cohort studies of new unselected RA pa-
tients. One factor could be the development of national
registers of patients treated with biologics, which diverted
expertise away from other observational cohorts. Other
factors include continuing recruitment to observational
studies and less emphasis on collecting radiographic
assessments.
The predictive factors we identified are in agreement
with previous findings [5] including the importance of
acute phase markers and RF positivity. This review also
found evidence for the association between anti-CCP
positivity and long-term radiological damage. Navarro-
Compa´n et al. [7] assessed the relationship between
radiographic joint damage and disease activity indices
(DAIs) like the DAS. It would appear that while DAIs are
clinically useful, the individual components of the DAIs,
particularly Swollen Joint Count and acute phase markers,
were better predictors.
Our review is the first to summarize associations of anti-
CCP and genetic factors with radiographic progression in
long-term cohort studies. De Rooy et al. [24] found HLA-
DRB1 SE increases the risk of radiographic joint damage
at 5 years, but they did not include anti-CCP in their
models. Recent studies [63, 64] highlight the importance
on the dependence of RA-related genetic markers on anti-
CCP for associations with radiographic progression.
Kaltenhauser et al. [49] reported that anti-CCP and
DRB1*04 SE, used as a compound marker, was statistic-
ally significantly associated with increased radiographic
damage at 4 years. However, Kroot et al. [26] found
anti-CCP but not HLA-DRB4 was statistically significantly
associated in multivariate analysis. This evidence sug-
gests an association between SE-positive alleles and
anti-CCP antibodies, though the pathogenetic mechan-
isms remain unclear [49]. Further study of specific HLA-
DRB1 haplotypes may show a prognostic role [63].
Currently, genetic markers do not provide much additional
prognostic information that can be applied clinically.
Several studies included in our review [28, 46, 49] found
RF was not a significant predictor in the presence of anti-
CCP, suggesting anti-CCP is the superior marker of long-
term radiographic damage. Our meta-analysis suggests
that anti-CCP could be more highly associated with
increased radiographic damage. However, differences in
specific RF antibodies and titre levels may explain vari-
ations between studies.
The heterogeneity of the methods and analysis tech-
niques used meant it was impossible to conduct a
formal meta-analysis on all predictive markers to allow a
direct aggregation of these results. One challenge in com-
paring studies related to differences in study design [65].
When investigating novel markers in the absence of multi-
variate methods, the importance of well-established fac-
tors like seropositivity and acute phase reactants may not
be appropriately considered. Consequently the effect of
novel markers may be masked, or over-exaggerated when
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already established factors are not considered [9]. Novel
markers like MMP-3 [25, 53] have potentially strong asso-
ciations with radiographic joint damage, but more evi-
dence is needed with large patient samples using
appropriate multivariate modelling techniques.
Another limitation is that it was not possible to stratify
patients using disease markers like seropositivity when
modelling radiographic progression rates, since it would
require more detailed and complex data from each cohort,
which would be unfeasible to obtain. Consequently, al-
though the review highlighted the potential differences in
radiographic progression in patients with anti-CCP posi-
tivity, we could not produce separate rates of radiographic
progression for seropositive and seronegative RA pa-
tients. Furthermore, the direct impact of treatment could
not be fully assessed. Evaluating recruitment years pro-
vides a surrogate marker of changes in treatment prac-
tices, but we could not directly model the effect of
treatment. Nevertheless, it is likely patients received
standard contemporary care based on published guide-
lines about treatment regimens from the time they were
being studied.
We conclude that the progression of radiographic
damage has halved since 1990, with improved treatment
providing the most likely cause. RF/anti-CCP, along with
increased markers of acute phase reactants, remains
strongly associated with radiographic damage, but the
value of other novel antibodies needs further study.
Finally, while the investigation of different haplotypes is
proving hopeful, currently the genetic data are of limited
additional prognostic value independent of anti-CCP
positivity.
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Radiographic progression over 25-years 2
Objectives: To assess 5-year progression of erosions and Joint Space Narrowing 
(JSN), and their associations with seropositive status in two large, multi-centre early-
RA cohorts spanning 25-years. 
Methods: Radiographic joint damage was recorded using the Sharp/van der Heijde 
(SvdH) method in the Early RA Study (ERAS) 1986-2001, and the Early RA Network 
(ERAN) 2002-2013. Mixed-effects negative-binomial regression estimated changes in 
radiographic damage over 5-years, including erosions and JSN separately. 
Seropositive status, along with age, sex and baseline markers of disease activity were 
included in the analysis. 
Results: A total of 1,216 patients from ERAS and 446 from ERAN had radiographic 
data. Compared to ERAS, ERAN patients had a lower mean total SvdH score at 
baseline (ERAN=6.2 vs. ERAS=10.5, p<0.001), and mean annual rate of change 
(ERAN=2.5 vs. ERAS=6.9 per year, p<0.001). The proportion with progression ≥5 units 
was 74% for ERAS and 27% for ERAN. Reductions at baseline were largely driven by 
changes in JSN (ERAS=3.9 vs. ERAN=1.2, p<0.001), rather than erosions (ERAS=1.9 vs. 
ERAN=0.8, p<0.001). Seropositive status was associated with greater progression in 
each cohort, but the absolute difference in mean annual rate of change for 
seropositivity was substantial for ERAS (seropositive=8.6 vs. seronegative=5.1, 
p<0.001), relative to ERAN (seropositive=2.0 vs. seronegative=1.9, p=0.855). 
Conclusion: Radiographic progression has significantly reduced between the two 
cohorts, with reductions associated with lower baseline damage and other factors, 
including changes in early DMARD use. The impact of seropositive status as a 
prognostic marker of clinically meaningful change in radiographic progression has 
markedly diminished in the context of more modern treatment. 
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Radiographic progression over 25-years 3
Significance and Innovations 
• Radiographic progression at baseline and over the first 5-years has 
dramatically reduced over the last 25-years. 
• Joint space narrowing is the main driver for radiographic reductions early on, 
with reductions in erosions contributing later in the disease course. 
• Seropsotive RA remains an important predictor of increased radiographic 
damage, however in the context of overall reductions, it is no longer 
associated with clinically-meaningful changes in radiographic damage. 
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Radiographic progression over 25-years 4
Published literature has suggested that the incidence of Rheumatoid Arthritis (RA) 
has declined over the last three decades
1–9
. This corresponds with reports of declines 
in disease activity
10,11
 , functional disability
12,13
, orthopaedic surgery
14
 and 
radiographic progression
12,15,16
.  
While the causal nature of this decline is not entirely clear, it is hypothesised that 
these declines in disease severity are related to widespread changes in treatment 
strategies during the 1990s
17
. Data from randomised controlled trials (RCTs) have 
demonstrated that early initiation of conventional synthetic Disease Modifying Anti-
Rheumatic Drugs (DMARDs) can significantly improve patient outcomes, particularly 
the increased use of methotrexate in combination with other DMARDs
18–21
, and 
indeed biologic DMARDs
22–25
. 
Radiographic joint damage is often used in RCTs as a primary outcome, and has been 
shown to be strongly related to levels of functional disability
26
 and disease activity
27
. 
Although commonly expressed as a global score
28
, radiographic joint damage 
comprises of two main components, erosions and joint space narrowing (JSN). While 
related, they are thought to be the result of two distinct pathophysiological 
mechanisms
29,30
. Possible causes of erosive joint destruction is the product of 
invading synovium into the boney structures of the joints, and increased osteoclast 
activity
31
. Likewise, JSN has been hypothesised to reflect cartilage damage as a result 
of metalloproteinases, which are upregulated by pro-inflammatory cytokines
32
. JSN 
is common to a range of pathologies, including osteoarthritis (OA), and is a common 
comorbid condition in people with RA
33
. Despite this, much of the focus of 
longitudinal data concerning radiographic damage has reported the combination of 
these two processes as one composite score
29,30
, for example using the radiographic 
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Radiographic progression over 25-years 5
scoring methods of Ratingen or Larsen, that lack the ability to distinguish progression 
of erosions and JSN as separate domains
12,15,16
.  
Further still, seropositive status has been strongly associated with worse 
radiographic progression
34–36
, however, to date no study has looked at whether the 
relative strength of this association has changed given the wider demographic 
changes seen in many other aspects of RA, including disease severity. It might be 
hypothesised that radiographic measures of RA will show significant changes given 
declines in disease activity, but whether previously demonstrated risk factors for 
progression continue to be influential remains unclear. 
This study therefore aims to investigate long-term radiographic progression by 
comparing data from two UK, multi-centre inception cohorts, the Early RA Study 
(ERAS), which collected patient data from 1986-2011, and the Early RA Network 
(ERAN), which collected data from 2002-2011. Specifically, this study 1) compares 
the total SvdH, erosion and JSN scores at onset and the rate of progression over the 
first 5-years between the two cohorts, and 2) estimates the association between 
seropositive status and radiographic damage at onset and progression over the first 
5-years in ERAS and ERAN. 
Patients and Methods 
The data used for this study were collected from two longitudinal inception cohorts, 
ERAS and ERAN. ERAS recruited 1,465 patients from 9 centres across the UK 
between 1986-2001, while ERAN recruited 1,236 patients from 25 centres between 
2002 and 2013. Two centres recruited to both cohorts. All patients had a confirmed 
diagnosis of RA and were recruited within 3 years of symptom onset, typically prior 
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Radiographic progression over 25-years 6
to conventional DMARD initiation. Maximum follow-up for ERAS was 25 years 
(median 10 years) and for ERAN was 11 years (median 3 years). All patients were 
treated based on standard clinical practice of the time. 
Standard clinical, laboratory and radiographic data were collected at baseline, 3 to 6 
months, 12 months, and then yearly thereafter. These included the original three 
variable 44-joint Disease Activity Score (DAS) for ERAS and the DAS28 for ERAN, the 
Health Assessment Questionnaire (HAQ), Rheumatoid Factor Positivity (seropositive 
RA) and haemoglobin level. To enable comparison of disease activity across the two 
cohorts, the original DAS in ERAS was converted to DAS28 using the formula DAS28 = 
(1.072*DAS) + 0.938
37
. 
Radiographic scoring 
Structural joint damage was assessed from plain radiographs using the SvdH scoring 
method
38
. All 32 centres collected yearly plain x-rays of hands and feet. Radiographs 
from all 9 centres recruiting from ERAS, and 7/25 (28%) centres from ERAN scored 
films using the SvdH method. 
The SvdH rates radiographic damage based on the prevalence and severity of the 
erosions in 32 joints in the hands and 12 joints in the feet, and the prevalence and 
severity of JSN in 30 joints in the hands and 12 joints in the feet. Each joint was rated 
from 0-5 (or 0-10 for erosions in the joints of the feet) giving a maximum score of 
280 for the erosion score and 168 for the JSN score. These scores were combined to 
give a total SvdH score ranging from 0 to 448. 
One person (KJ) scored the radiographs for ERAS, while another person (DMcW) 
scored the radiographs for ERAN. Each scorer rated the radiographs in chronological 
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Radiographic progression over 25-years 7
order. To assess agreement between the two, both scored a random sub-sample 
of thirty-nine radiographs from twenty patients from the ERAS cohort at two time-
points (baseline and 5 years). An Intra-class Correlation Coefficient (ICC) of 
0.95 (95% confidence intervals 0.90-0.97) was calculated for the erosion score, and 
0.98 (95% CI 0.95-0.99) calculated for both the JSN score and total SvdH score. The 
ICC is an estimate of the proportion of the total variability in ratings for the sample 
that are due to variability between x-rays, rather variability within x-rays between 
readers. The high values in our assessment of agreement confirm the risk 
of systematic bias due to two readers is low, and as such the level of agreement 
acceptable for the comparison of trends over time. 
Statistical analysis 
To assess differences in the use of first-line conventional DMARDs between the two 
cohorts, the cumulative incidence of time to first DMARD within the first 12months 
from first outpatient appointment was estimated. This was estimated for any 
DMARD use, as well as separate estimates for the two most commonly used first-line 
DMARDS, methotrexate and sulphazalasine. 
The skewed distributions of radiographic scores derived by the SvdH method renders 
linear regression inappropriate
39
. Generalised linear regression with a negative-
binomial distribution, henceforth negative binomial regression (NBR), was found to 
achieve best fit to the data, compared with linear and Poisson distributions.  
Mixed-effects NBR (MENBR) models allowed for the longitudinal structure of the 
data to be modelled appropriately, whereby random intercept and time slope 
parameters were estimated. Cohort membership (either ERAS or ERAN) was the 
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Radiographic progression over 25-years 8
main covariate of interest. Baseline scores, along with yearly measures of SvdH were 
used in the models to estimate rates at presentation and over the 5-year follow-up. 
Missing data is inherent in longitudinal studies. To probe potential selection bias 
based on the availability of radiographs, baseline characteristics of those with and 
without radiographic data were compared. Furthermore, protecting against 
confounding due to missing longitudinal data, mixed-effects models use full 
information maximum likelihood making use of all available data under the missing 
at random assumption, so that all patients with data are included. 
Time was defined as years from enrolment and was included as a continuous 
variable with a random slope to allow for the estimation of the annual rate of 
progression for each patient. Seropositive RA was the secondary covariate of interest 
and entered as a main effect, along with a three-way interaction term with cohort 
and time to allow for progression rates to be estimated separately by seropositivity 
status for each cohort. Sex, age, DAS28, HAQ, low Hb (<12/13), months from 
symptom onset to first rheumatology visit, steroid use prior to first assessment and 
DMARD use within first 12-months were all entered into the model to control for any 
potential confounding effects. 
Exponentiated regression coefficients of an NBR model are incidence rate ratios 
(IRR), which are interpreted as the relative increase in the log-count of the 
dependent variable (i.e. the SvdH score) given a one-unit increase in the respective 
covariate (e.g. age). To aid interpretation, the results from the models were also 
expressed as an absolute change in the SvdH score using the estimated mean SvdH, 
along with 95% Confidence Intervals [95% CI]. This allowed for a more direct 
interpretation of the effect that each factor had in terms of absolute difference in 
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SvdH units, the percentage of maximum possible damage, and annual progression 
greater than the minimum clinically important difference of 5 units
40
.  
 These models were estimated separately for the total SvdH score, JSN and erosion 
score. All analyses were conducted using Stata (version 14; StataCorp LP, USA). 
Results 
Of the 2,701 total patients recruited, 1,662 had SvdH data: 1,216 from ERAS and 446 
from ERAN. The demographic and baseline clinical characteristics of both ERAS and 
ERAN patients, including only those with radiographic data, are shown in Table 1. 
Reasons for missing radiographic data included loss of records, unreadable 
radiographs and loss to follow-up. Patients from ERAS were marginally younger at 
presentation and had higher DAS28, ESR, HAQ and more likely to be anaemic at 
baseline. Patient’s characteristics with recorded radiographic data were similar to 
the total number of patients in their respective cohort. 
Table 1 - Summary Statistics for each Cohort 
 
Differences in treatment strategies between the two Cohorts 
For all DMARDs, ERAS reported a 12-month cumulative incidence of 71.6% [95%CI 
69.2-73.8] and for ERAN 95.3% [95%CI 93.9-96.4] (See Figure 1). The 12-month 
cumulative incidence of sulfasalazine (SSZ) use was higher in ERAS (55% [95%CI 52.4-
57.5]) than ERAN (33.1% [95%CI 30.4-35.8]), while methotrexate (MTX) use was 
substantially lower in ERAS (1.4% [95%CI 0.9-2.1]) compared to ERAN (52.1% [95%CI 
49.2-55.0]). 
Figure 1. 12-month Cumulative Incidence of DMARD use for ERAS and ERAN 
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Radiographic progression over 25-years 10
Radiographic progression rates of ERAS and ERAN 
For the MENBR analysis a total of 1,508 patients contributing 5,430 observations 
(mean observations per patient = 3.6) were included. Overall, the ERAN cohort 
exhibited a 41% lower total SvdH score at baseline compared to ERAS (IRR 0.59 
[95%CI 0.50-0.70], p<0.001), along with a 65% slower annual rate of progression 
over the first 5-years (IRR 0.35 [95%CI 0.24-0.47], p<0.001) (See Figure 2A). The 
differences in absolute and relative scores for both cohorts are shown in Table 2. 
When expressed as a proportion of maximum possible damage, the estimated values 
indicated an increase of 1.5% [95%CI 1.4-1.7] per year for ERAS and 0.6% [95%CI 0.4-
0.7] per year for ERAN. The total proportion of patients who had annual progression 
estimated to be greater than the MCID (≥5 SvdH units) was 74% for ERAS and 27% 
for ERAN. 
 
Table 2. Mean and relative difference in baseline level and annual rate of 
progression for Total SvdH, JSN and erosion scores between ERAS and ERAN. 
Estimates based on fixing the values of the covariates to the sample means. 
Controlling covariates = age, sex, baseline DAS28, baseline HAQ, low Hb (<12/13) 
at baseline, months from symptom onset to first rheumatology visit, steroid use 
prior to first assessment and DMARD use 
 
Similar results were seen for the JSN score, with ERAN participants displaying lower 
scores at baseline (IRR 0.49 [95%CI 0.41-0.58], p<0.001) and a slower annual rate of 
progression over the first 5-years compared to ERAS (IRR 0.31 [95%CI 0.21-0.42], 
p<0.001) (See Figure 2B).  
For the erosion score, the score at baseline was similar for both cohorts (IRR 0.94 
[95%CI 0.73-1.19], p=0.593), however, ERAN exhibited a slower annual rate of 
progression over the first 5-years compared to ERAS (IRR 0.43 [95%CI 0.25-0.61], 
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Radiographic progression over 25-years 11
p<0.001) (See Figure 2C). See Table 2 for absolute and relative changes in both JSN 
and erosion scores between the two cohorts. 
Figure 2 - Progression of A) Total SvdH, B) JSN and C) Erosion score for ERAS and 
ERAN 
 
Association of seropositivity with radiographic progression in ERAS and ERAN 
The absolute and relative difference in total SvdH scores for seropositive and 
seronegative patients in both cohorts are given in Table 3 and displayed graphically 
in Figure 3. For the total SvdH score, seropositive RA was not significantly associated 
with increased radiographic damage at baseline, compared to seronegative RA, in 
either ERAS or ERAN. Seropositive RA was associated with a 70% increased annual 
rate of progression, compared to seronegative RA, in ERAS, which was statistically 
significant. The annual rate of progression for seropositive RA, compared to 
seronegative RA, in ERAN was increased by 9%, which was not significant. This 
relates to decreases in the relative impact of seropositive RA on the annual rate of 
progression of 36% for ERAN compared to ERAS, which although considerable was 
non-significant (IRR 0.64 [95%CI 0.29-1.07], p=0.224). This related to the proportion 
of seropositive patients with an annual progression greater than the MCID of 80% 
for ERAS and just 29% for ERAN.  
Investigation of the association between seropositive RA in both the cohorts for the 
separate JSN and erosion score indicated similar results to the total SvdH (See 
Supplementary Material 1). 
Figure 3 - Progression of Total SvdH score for ERAS and ERAN stratified by 
seropositivity  
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Radiographic progression over 25-years 12
Table 3. Mean and relative difference in baseline level and annual rate of 
progression for Total SvdH based on seropostive (RF+) status between ERAS and 
ERAN. Estimates based on fixing the values of the covariates to the sample means 
 
Discussion 
The findings from the present study indicate that patients with early RA with onset 
from 2002-2013 (ERAN) had significantly lower baseline and annual rates of 
radiographic progression compared to those with onset from 1986-2001 (ERAS). 
Examination of the separate erosion and JSN scores indicate that the reduction in 
the total SvdH score was largely driven by reductions in JSN. Strikingly, the strong 
association of seropositivity and increased radiographic progression in the earlier 
time period (ERAS) was markedly diminished in the later time period (ERAN). The 
reduction in the impact of seropositive RA was such that those with seropositive 
status in the ERAN cohort had markedly better radiographic outcomes at 5 years 
than those with seronegative RA in ERAN.  
Previous research has indicated that a change of 5 SvdH units indicates a minimal 
clinically important difference
40,41
, therefore a difference of 5 units per year for 
ERAN compared to ERAS on total SvdH score observed in this study demonstrates 
not only a statistically significant change in progression, but also a clinically 
meaningful reduction. Whereas 74% of patients in the earlier cohort progressed on 
average ≥5 units per year over the 5-year period of follow-up considered, just 27% of 
patients in the later cohort did.  
Our data extend previous findings of reductions in radiographic damage in RA over 
recent decades 
12,15,16
. There are two plausible explanations for these findings, both 
of which are likely to contribute to the reduction in radiographic damage over time. 
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Radiographic progression over 25-years 13
Firstly, RA may have become milder, and secondly, earlier more intensive treatment 
may have improved disease outcomes. Our models adjusted for disease severity at 
baseline, but it remains possible that lower rates of progression in the more recent 
cohort reflect milder disease. This is supported by the observation of lower SvdH 
scores in ERAN compared to ERAS at baseline, prior to DMARD initiation for the 
majority of patients. However, the dramatic reductions in radiographic progression, 
particularly the reduced impact of seropositive RA, is likely to also reflect 
improvements in the treatment of RA, given the earlier and increased use of 
methotrexate as the first line DMARD observed in ERAN in this study, which is in line 
with other reports 
12,15,16,36
. Increasing evidence from RCTs also support the 
hypothesis that early, intensive treatment has an important effect on reducing 
radiographic progression
42–46
. 
Separate investigation of the erosion and JSN components of radiographic damage 
scores showed that JSN was the primary driver for the overall reductions seen in the 
total SvdH score between the two cohorts. This finding reiterates the importance of 
reporting both the erosion and JSN score separately in clinical trials. Data from 
ASPIRE show that more patients with early RA have either erosions alone (8.5%) or 
JSN alone (4.4%), than both (3.7%) at baseline visit
30
, and that JSN may be more 
strongly associated with irreversible disability
29
. Despite this, the separate scores are 
still rarely reported
28
. If early treatment with MTX was the primary cause for the 
reduction in total SvdH in ERAN, this could indicate that the mechanism by which 
this is achieved is through the reduction of JSN and preservation of the surrounding 
cartilage. However, what is not clear is whether the JSN is directly attributable to RA 
JSN, or OA JSN. A high prevalence of radiographic OA has been documented at 
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Radiographic progression over 25-years 14
baseline in the ERAN cohort in the hands and feet, indicating that high levels of 
comorbid OA could potentially confound any radiographic assessment of RA
33
. High 
JSN scores are strongly associated with increased severity of OA osteophytosis and 
OA JSN
47
. More studies are needed to quantify the exact effect that co-morbid OA 
could be having on RA radiographic scoring. 
Seropositive RA has been consistently associated with increased radiographic 
damage
35,36
. This study also found that seropositive RA was highly associated with 
increased radiographic progression. However, when investigating the absolute 
change in radiographic score between seropositive and seronegative patients across 
the two cohorts, seropositive patients in the later cohort no longer represented a 
patient sub-group with clinically meaningful increases in radiographic progression, at 
least within the first 5-years of disease. Aletaha et al.
48
 analysed the effect of 
seropositive status on radiographic progression and found seropositive patients 
displayed higher radiographic progression, compared to seronegative patients
39,49
. 
The estimated change in median SvdH score of 0.6 units per year for seropositive 
over that of seronegative patients provides an estimate similar to this study.  
Many RCTs are restricted to seropositive patients only, and previous research has 
not focused on the effect of seropositivity in the context of reduced radiographic 
progression in more recent years. The two long-term observational cohorts 
examined in this study provide a ‘real-world’ account of patients typically seen in 
secondary care, and the high patient numbers over the full 5-year follow-up also 
provides a unique opportunity to provide precise estimates using the modelling 
techniques outlined
39
. The use of the SvdH score also provides a first look at the two 
principle components of radiographic damage, erosions and JSN, in detail. Further 
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Radiographic progression over 25-years 15
data from observational studies are needed to ascertain whether reductions in 
radiographic progression have also resulted in the diminished association with 
seropositive status, particularly in the context of anti-CCP seropositive RA, which 
could be more predictive of radiographic progression when compared to RF
36,50,51
. 
Our research is subject to a number of limitations inherent in cohort studies. 
Recruiting centres were hosted by enthusiastic clinicians within the UK and, although 
they might not necessarily reflect people with RA in other contents, or subjected to 
different treatment regimens, the multicentre recruitment for these cohorts from 
district general hospitals is likely to be representative of people with RA in the UK. 
Radiographs were not available for all participants, and it is possible that those with 
more severe disease were more likely to have x-rays, increasing the risk of selection 
bias in our study. However, baseline variables indicated minimal differences 
between the whole cohorts, and those for whom radiographic data were available. 
The impact of such a selection bias would overestimate rates of progression, 
particularly for ERAN, where data were less complete; hence our estimates should 
be treated as conservative. 
This study provides further evidence into the marked reduction in radiographic 
damage over the last 30-years, while providing accurate, quantified estimates of the 
extent of that reduction. JSN was the major driver for the overall reductions seen, 
and highlights the importance of investigating JSN and erosions separately when 
investigating radiographic damage. Advances in treatment are likely to be the main 
cause for the decline, and adequate DMARD treatment might remove the predictive 
value of seropositivity for radiographic progression in early RA. Further research 
should seek other predictors and mediators if residual radiographic progression 
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despite DMARD treatment is to be halted. The impact of these reductions on 
patients of varying disease severity, and whether these reductions have an impact 
on improved long-term functional disability will be crucial in fully realising the impact 
of these results on clinical care. 
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Tables and Figures 
 
Table 1 - Summary Statistics for each Cohort 
 
     ERAS Total    ERAN Total     ERAS+ERAN 
  
Total With SvdH 
Missing 
(%) 
Total With SvdH 
Missing 
(%) 
Total With SvdH 
Demographics   
Year of Recruitment 1986-2001 1986-2001 0 (0) 2002-2013 2002-2013 0 (0) 1986-2013 1986-2013 
Age at Onset (Mean (SD)) 55.3 (14.6) 54.9 (14.5) 0 (0) 57.1 (14) 58 (13.5) 0 (0) 56.1 (14.4) 55.7 (14.3) 
Female (%) 66 66 0 (0) 68 65 0 (0) 67 65 
Clinical Markers   
Seropositive (%) 63 64 9 (0.1) 60 61 142 (11) 62 63 
Baseline DAS (Mean (SD)) 6.32 (1.33) 6.32 (1.33) 13 (0.1) 4.53 (1.58) 4.5 (1.64) 46 (4) 5.51 (1.7) 5.84 (1.62) 
Baseline ESR (Median (IQR)) 37 (44) 38 (44) 7 (0.1) 24 (29) 21 (28) 183 (15) 30 (39) 34 (41) 
Baseline HAQ (Mean (SD)) 1.15 (0.8) 1.15 (0.8) 5 (0.1) 1.08 (0.8) 1.03 (0.8) 37 (3) 1.12 (0.8) 1.12 (0.8) 
Baseline Anaemia (%) 41 42 5 (0.1) 28 24 32 (3) 35 37 
Months from symptom 
onset to First Visit (Median 
(IQR)) 
6 (7) 6.5 (7) 0 (0) 6 (8) 6 (8) 91 (7) 6 (8) 6 (8) 
Observations 1465 1216 1216 1236 446 1216 2701 1662 
Numbers represent means (SD), medians (IQR) and proportions were used where indicated. 
SvdH = Sharp/van der Heijde, DAS=Disease Activity Score-28, ESR=Erythrocyte Sedimentation Rate, HAQ = Health Assessment Questionnaire. 
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Table 2. Mean and relative difference in baseline level and annual rate of 
progression for Total SvdH, JSN and erosion scores between ERAS and ERAN. 
Estimates based on fixing the values of the covariates to the sample means. 
Controlling covariates = age, sex, baseline DAS28, baseline HAQ, low Hb (<12/13) at 
baseline, months from symptom onset to first rheumatology visit, steroid use prior 
to first assessment and DMARD use 
 
Estimated 
means 
ERAS ERAN 
Absolute 
Difference 
Relative 
Difference (IRR) 
[95% CI] 
 
P-Value 
Total SvdH at 
baseline 
10.5 6.2 4.3  0.59 [0.50-0.70]  <0.001 
Total SvdH 
annual rate 
6.9 2.5 4.5  0.35 [0.24-0.47]  <0.001 
JSN score at 
baseline 
7.4 3.6 3.8  0.49 [0.41-0.58]  <0.001 
JSN score 
annual rate 
3.9 1.2 2.7  0.31 [0.21-0.42]  <0.001 
Erosion score 
at baseline 
1.8 1.7 0.1  0.94 [0.73-1.19]  0.593 
Erosion score 
annual rate 
1.9 0.8 1.1  0.43 [0.25-0.61]  <0.001 
 
 
Table 3. Mean and relative difference in baseline level and annual rate of 
progression for Total SvdH based on seropostive (RF+) status between ERAS and 
ERAN. Estimates based on fixing the values of the covariates to the sample means 
 
 
  RF- RF+ Difference 
Relative 
Difference (IRR) 
[95% CI] 
P-Value 
ERAS 
Total SvdH 
at baseline 
9.5 11 1.5 1.16 [1.00-1.35] 0.056 
Total SvdH 
Annual rate 
5.1 8.6 3.6 1.70 [1.42-1.97] <0.001 
ERAN 
Total SvdH 
at baseline 
6.0 6.2 0.2 1.04 [0.76-1.42] 0.811 
Total SvdH 
Annual rate 
1.9 2.0 0.2 1.09 [0.51-1.67] 0.855 
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Figure 1. 12-month Cumulative Incidence of DMARD use for ERAS and ERAN 
 
 
Figure 2 - Progression of A) Total SvdH, B) JSN and C) Erosion score for ERAS and 
ERAN 
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Figure 3 - Progression of Total SvdH score for ERAS and ERAN stratified by 
seropositivity  
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Supplementary Material 1 
 
Association of seropositivity with joint space narrowing (JSN) and erosions in ERAS and 
ERAN 
The influence of seropositive RA on the separate joint space narrowing (JSN) compared to 
seronegative rheumatoid arthritis (RA) indicated a similar pattern to the total Sharp/van der 
Heijde (SvdH) score (Supplementary Table 1 & Supplementary Figure 1A). Seropositive RA 
was not associated with increased JSN scores at baseline for either ERAS or ERAN, but was 
associated with a relative increase in the annual rate of progression. When compared to 
seronegative RA, seropositive RA indicating an increase of 58% and 19% for ERAS and ERAN 
respectively. The relative difference in the increased annual rate of progression of JSN scores 
for seropositive RA in ERAS compared to ERAN was not significantly different (IRR 0.72 [95% 
CI 0.26-1.18], p=650). 
 
Differing from the JSN score, seropositive RA was associated with a 40% increased erosion 
score at baseline, compared to seronegative RA, in ERAS.  The relative difference was 
reduced and non-significant for ERAN.  Seropositive RA was associated with relative 
increases in the annual rate of progression, compared to seronegative RA, of 107% and 21% 
for ERAS and ERAN, respectively (Supplementary Table 1 & Supplementary Figure 1B). Again, 
though the relative impact of seronegative RA was reduced in ERAN compared to ERAS the 
difference was non-significant (IRR 0.58 [95% CI 0.17-0.98], p=0.234). 
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Supplementary Table and Figure 
Supplementary Table 1 - Mean and relative difference in baseline level and annual rate of 
progression for JSN and Erosion scores based on seropostive (RF+) status between ERAS and 
ERAN. Estimates based on fixing the values of the covariates to the sample means 
 
  RF- RF+ 
Absolute 
Difference 
Relative 
Difference (IRR) 
[95% CI] 
P-Value 
ERAS 
Total JSN at 
baseline 
6.9 7.7 0.8 1.12 [0.96-1.31] 0.152 
Total JSN 
Annual rate 
2.9 4.6 1.7 1.58 [1.32-1.84] <0.001 
ERAN 
Total JSN at 
baseline 
3.8 3.5 0.3 0.92 [0.67-1.27] 0.619 
Total JSN 
Annual rate 
1.1 1.3 0.2 1.19 [0.35-2.02] 0.480 
ERAS 
Total Erosion 
at baseline 
1.5 2.0 0.6 1.40 [1.12-1.75] 0.003 
Total Erosion 
Annual rate 
1.2 2.4 1.3 2.07 [1.61-2.52] <0.001 
ERAN 
Total Erosion 
at baseline 
1.5 1.8 0.3 1.17 [0.74-1.85] 0.495 
Total Erosion 
Annual rate 
0.7 0.9 0.2 1.21 [0.28-2.14] 0.929 
 
 
Supplementary Figure 1 – Estimated sample means of A) JSN and B) Erosion score for 
seropositive and seronegative patients in both ERAS and ERAN 
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STROBE Statement—Checklist of items that should be included in reports of cohort studies  
 Item 
No Recommendation 
 Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract 
[Included in Title on page 1] 
(b) Provide in the abstract an informative and balanced summary of what was done 
and what was found [See objectives and conclusion in abstract on page 2] 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 
[Page 3 & 4] 
Objectives 3 State specific objectives, including any prespecified hypotheses [Page 2] 
Methods 
Study design 4 Present key elements of study design early in the paper [Page 4] 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, 
exposure, follow-up, and data collection [Page 4 & 5] 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of 
participants. Describe methods of follow-up [Page 4] 
(b) For matched studies, give matching criteria and number of exposed and 
unexposed [N/A] 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if applicable [Page 4 & 5] 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods if there is 
more than one group [Page 5] 
Bias 9 Describe any efforts to address potential sources of bias [Page 6] 
Study size 10 Explain how the study size was arrived at [Page 4] 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, 
describe which groupings were chosen and why [Page 5 & 6] 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 
[Page 5 & 6] 
(b) Describe any methods used to examine subgroups and interactions [Page 6] 
(c) Explain how missing data were addressed [Page 6] 
(d) If applicable, explain how loss to follow-up was addressed [Page 6] 
(e) Describe any sensitivity analyses [N\A] 
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially 
eligible, examined for eligibility, confirmed eligible, included in the study, 
completing follow-up, and analysed [Page 7] 
(b) Give reasons for non-participation at each stage [Page 7] 
(c) Consider use of a flow diagram [N/A] 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and 
information on exposures and potential confounders [Page 7] 
(b) Indicate number of participants with missing data for each variable of interest 
[Page 7] 
(c) Summarise follow-up time (eg, average and total amount) [Page 8] 
Outcome data 15* Report numbers of outcome events or summary measures over time [Page 8] 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and 
their precision (eg, 95% confidence interval). Make clear which confounders were 
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adjusted for and why they were included [Page 8 & 9 & 10] 
(b) Report category boundaries when continuous variables were categorized [N/A] 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time period [Page 8 & 9 & 10] 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and 
sensitivity analyses [N/A] 
Discussion 
Key results 18 Summarise key results with reference to study objectives [Page 9] 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias [Page 12 & 
13] 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, and other relevant evidence 
[Page 11 & 12] 
Generalisability 21 Discuss the generalisability (external validity) of the study results [Page 12] 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based [N/A] 
 
*Give information separately for exposed and unexposed groups. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and 
published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely 
available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is 
available at http://www.strobe-statement.org. 
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